(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 January 2002 (17.01.2002)

PCT

(10) International Publication Number
WO 02/03917 A2

(51) International Patent Classification[7]: A61K

(21) International Application Number: PCT/US01/21701

(22) International Filing Date: 9 July 2001 (09.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/216,995 7 July 2000 (07.07.2000) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 60/216,995 (CIP)
Filed on 7 July 2000 (07.07.2000)

(71) Applicants *(for all designated States except US)*: **ALPHAVAX, INC.** [US/US]; P.O. Box 110307, 2 Triangle Drive, Research Triangle Park, NC 27709-0307 (US). **UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL** [US/US]; 308 Bynum Hall, Campus Box 4105, Chapel Hill, NC 27599-4105 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **OLMSTED, Robert** [US/US]; 420 Bayberry Drive, Chapel Hill, NC 27514 (US). **KEITH, Paula** [US/US]; 5004 Sadelia Place, Holly Springs, NC 27540 (US). **DRYGA, Sergey** [RU/US]; 211 Bonsail Place, Chapel Hill, NC 27514 (US). **CALEY, Ian** [GB/US]; 2 Triangle Drive, P.O. Box 110307, Research Triangle Park, NC 27709-0307 (US). **MAUGHAN, Maureen** [US/US]; 2532 Wrightwood Avenue, Durham, NC 27705 (US). **JOHNSTON, Robert** [US/US]; 101 Marin Place, Chapel Hill, NC 27516 (US). **DAVIS, Nancy** [US/US]; 132 New Castle Drive, Chapel Hill, NC 27514 (US). **SWANSTROM, Ronald** [US/US]; 7021 Knotty Pine Drive, Chapel Hill, NC 27514-8659 (US).

(74) Agents: **MILLER, Mary, L.** et al.; Needle & Rosenberg, P.C., 127 Peachtree Street, N.E., Suite 1200, Atlanta, GA 30303-1811 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/03917 A2

(54) Title: ALPHAVIRUS VECTORS AND VIROSOMES WITH MODIFIED HIV GENES FOR USE AS VACCINES

(57) Abstract: The present invention provides methods and compositions comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit integrase, Rnase H and/or reverse transcriptase activity, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle.

ALPHAVIRUS VECTORS AND VIROSOMES WITH MODIFIED HIV GENES FOR USE AS VACCINES

This application claims priority to U.S. Provisional Application No. 60/216,995, filed July 7, 2000 which is hereby incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention relates to vaccines using viral antigens, and in particular, to vaccines for the treatment and prevention of human immunodeficiency virus (HIV) infection. The vaccines of this invention comprise alphavirus RNA replicon systems which contain nucleic acid sequence encoding antigens for eliciting an immune response to HIV.

Background

The successful control of the AIDS epidemic will require an effective vaccine for human immunodeficiency virus type 1 (HIV) that significantly reduces or prevents the spread of infection. Currently, several viral vector systems as well as naked DNA are at various stages of pre-clinical and clinical evaluation as candidate HIV vaccines. Recombinant poxviruses are the most widely studied virus vectors and are furthest along in clinical development (e.g., ALVAC).

The alphavirus-based replicon particle systems, such as the ones described in U.S. Patent No. 5,792,462 and herein referred to as "VRPs," have multiple distinct properties that make them attractive as an HIV vaccine delivery technology. These properties include: natural targeting to and expression in lymphoid tissues (an optimal site for induction of an immune response); high antigen expression levels, e.g., up to 20% of total cell protein; induction of balanced humoral, cellular, and mucosal immune responses; sustained efficacy over multiple simultaneous or sequential inoculations of

the vector; and a high margin of safety.

Venezuelan equine encephalitis virus (VEE) is a member of the Alphaviruses group, which also includes the prototype Sindbis virus (SIN) and Semliki Forest virus (SFV), and is comprised of enveloped viruses containing plus-stranded RNA genomes within icosahedral capsids (Strauss, 1994). Alphavirus genomes are: approximately 11.5 kb long, capped, polyadenylated, and infectious under appropriate transfection conditions. The nucleocapsid is composed of 240 molecules of the capsid protein arranged as a T=4 icosahedron, and is surrounded by a lipoprotein envelope (Paredes *et al.*, 1993). Protruding from the virion surface are 80 glycoprotein spikes, each of which is a trimer of virally encoded E1 and E2 glycoprotein heterodimers. The virions contain no host proteins.

Alphaviruses share replication strategies and genomic organization. The complete replicative cycle of alphaviruses occurs in the cytoplasm of infected cells. Expression from the alphavirus genome is segregated into two regions. The four enzymatic nonstructural proteins (nsP1-nsP4) are synthesized from the 5' two-thirds of the genome-length RNA and are required for RNA replication. Immediately following infection, the nsPs are produced by translation of parental genomes and catalyze the synthesis of a full-length negative-sense copy of the genome. This serves as a template for the synthesis of progeny plus-stranded genomes.

The negative-sense copy of the genome also serves as the template for the synthesis of subgenomic mRNA at approximately 10-fold molar excess relative to genomic RNA in infected cells (Schlesinger and Schlesinger, 1990). Synthesis of subgenomic 26S mRNA is initiated from the highly active internal 26S mRNA promoter, which is functional only on the negative-sense RNA. The subgenomic mRNA corresponds to the 3' one-third of the genome and encodes the alphavirus structural proteins.

Full-length, infectious cDNA clones of the RNA genome of VEE (Davis *et al.*, 1989) have been constructed, a panel of mutations which strongly attenuate the virus have been identified (Johnston and Smith, 1988; Davis *et al.*, 1990), and various constellations of these attenuating mutations have been inserted into the clones to generate several live attenuated VEE vaccine candidates (Davis *et al.*, 1991; 1995b; Grieder *et al.*, 1995). The resulting vaccine candidates are avirulent and provide complete protection against lethal virus challenge in rodents, horses and nonhuman primates.

The alphavirus VRPs are propagation defective, single cycle vectors that contain a self-amplifying alphavirus RNA (replicon RNA) in which the structural protein genes of the virus are replaced by a heterologous antigen gene to be expressed. Alphavirus VRPs are typically made in cultured cells, referred to as packaging cells. Following introduction into mammalian cells, the replicon RNA is packaged into VRP by supplying the structural proteins in "trans," i.e. the cells are co-transfected with both replicon RNA and one or more separate helper RNAs which together encode the full complement of alphavirus structural proteins. Importantly, only the replicon RNA is packaged into VRP, as the helper RNA(s) lack the *cis*-acting packaging sequence required for encapsidation. Thus, the VRPs are defective, in that they can only infect target cells in culture or *in vivo*, where they express the heterologous antigen gene to high level, but they lack critical portions of the VEE genome (i.e., the VEE structural protein genes) necessary to produce virus particles which could spread to other cells.

Delivery of the replicon RNA into target cells (for vaccination) is facilitated by the VRP following infection of the target cells. In the cytoplasm of the target cell, the replicon RNA is first translated to produce the viral replicase proteins necessary to initiate self-amplification and expression. The heterologous antigen gene is encoded by a subgenomic mRNA, abundantly transcribed from the replicon RNA, leading to high level expression of the heterologous antigen gene product. Since the VEE structural protein genes are not encoded by the replicon RNA delivered to the target cell, progeny

virion particles are not assembled, thus limiting the replication to a single cycle within the infected target cell. Experimental VRP vaccines have been successful in vaccinating rodents against influenza virus, Lassa fever virus and Marburg virus (Pushko *et al.*, 1997; Hevey *et al.*, 1998). In nonhuman primates, VRP vaccines have demonstrated complete efficacy against lethal Marburg virus challenge (Hevey *et al.*, 1998), shown partial but significant protection against SIV infection and disease (Davis *et al.*, 2000) and induced an anti-HA response at a level consistent with protection of humans against influenza virus infection.

The alphavirus based replicon vector systems, and in particular the VEE-based systems, present several advantages in vaccination, including safety and high immunogenicity/efficacy. VEE is unique among the alphaviruses in that a live attenuated IND VEE vaccine, TC-83, (Kinney *et al.*, 1989; Kinney *et al.*, 1993) has been inoculated into approximately 8,000 humans. This allows direct safety and efficacy comparisons between human, nonhuman primate and rodent responses to the same VEE derivative. A large body of experience strongly suggests that the animal models generally reflect the human susceptibility and disease course, except that mice are far more susceptible to lethal VEE disease than humans or nonhuman primates. Furthermore, the VEE replicon vectors express high levels of the gene of interest in cell culture, and *in vivo* expression is targeted to lymphoid tissues, reflecting the natural tropism mediated by the VEE glycoproteins. Cells in the draining lymph node of VRP-inoculated mice contain detectable amounts of the desired gene product within hours of inoculation. This expression continues for up to five days.

To date, VRP vector vaccines have been used in over 2000 rodents and in 94 macaques at doses up to 5×10^8 i.u., with no indication of any clinical manifestations.

In work reported by Pushko *et al.* (1997), individual mice were immunized sequentially with Lassa virus N-VRP and influenza virus HA-VRP. Groups of mice, which received two inoculations of 3×10^4 or 3×10^6 i.u. of Lassa N-VRP followed by

two inoculations of 2 x 10^5 i.u. of HA-VRP, all responded with serum antibodies to both antigens. The level of anti-influenza antibody induced in these sequentially inoculated mice was equivalent to a control group, which received two inoculations of buffer followed by two inoculations of 2 x 10^5 i.u. of HA-VRP. All HA-VRP immunized mice were completely protected against influenza virus challenge. Furthermore, sequential immunization of mice with two inoculations of N-VRP prior to two inoculations of HA-VRP induced an immune response to both HA and N equivalent to immunization with either VRP construct alone. Primary and booster immunization with a VRP preparation expressing an immunogen from one pathogen did not interfere with the development of a protective response to subsequent primary immunization and boosting with VRP expressing an immunogen from a second pathogen, thus showing that the VRP-based system can be used to induce immunity to a variety of pathogens in the same individual over time.

Four macaques were inoculated subcutaneously at week 0 with 10^5 i.u. each of SIV-gp160-VRP (*env*) and SIV MA/CA-VRP (*gag*), boosted by the same route at week 7 with 10^7 i.u. of each VRP vaccine, and intravenously at weeks 12 and 20 with 5 x 10^8 i.u. of each VRP. Two control animals were inoculated with equivalent doses of HA-VRP (haemagglutinin, a glycoprotein from influenza virus), and two with the vehicle only. The four SIV-VRPs immunized monkeys received subcutaneously an additional dose of 2 x 10^7 i.u. of gp140-VRP at week 41, followed by a final boost of 2 x 10^7 i.u. each of gp140-VRP and MA/CA-VRP at week 49. Four weeks after the final immunization, all eight macaques were challenged intravenously with the pathogenic virus, SIVsmE660.

After these inoculations, three of four test macaques had measurable CTL-specific killing directed against both SIV *gag* and *env*, all four had gp160 IgG antibody by ELISA, and the three animals which harbored SIV-specific CTL also showed neutralizing antibody to SIVsmH-4.

Four of four vaccinated animals were protected against disease for at least 16 months following intravenous challenge with the pathogenic SIV swarm, while the two vehicle controls required euthanasia at week 10 and week 11, post challenge. In two of the vaccinees, plasma virus levels were below the limit of detection by branched chain DNA assay. At 64 weeks post challenge, all four vaccinated animals showed no clinical signs of disease. One animal remained vDNA negative at 64 weeks.

The results of this highly pathogenic challenge demonstrated that the immune response induced by vaccination with SIV-VRP was effective in preventing early mortality and increasing the ability to suppress challenge virus replication. The ability to control SIV replication and reduce viral load to undetectable levels was closely correlated with the strongest measurable antibody and cellular immune responses.

While these results are encouraging, the level of protection obtained would not be acceptable for a human vaccine against HIV infection. Thus, there remains a need for a robust, effective and safe vaccine against HIV infection in humans. Development of a HIV vaccine comprising the complete, or immunogenic fragments of the, *gag* gene (Gag-VRP), an immunogenic portion of the *pol* gene (Pol-VRP), and the complete, or immunogenic fragments of the, *env* gene (Env-VRP), would increase the diversity of available CTL epitopes substantially and thus address this need.

SUMMARY OF THE INVENTION

The present invention provides a composition comprising two or more isolated nucleic acids selected from the group consisting of an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release

from a cell, and an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity.

Also provided is a composition comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle.

In addition, the present invention provides a composition comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse

transcriptase activity, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle, and further wherein the alphavirus replicon particles comprise a replicon RNA or at least one structural protein which comprises one or more attenuating mutations.

10. A method of making a population of alphavirus replicon particles of this invention is provided herein, comprising:

A) (a) providing a first helper cell for producing a first population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the first population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

B) (a) providing a second helper cell for producing a second population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the second population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

C) (a) providing a third helper cell for producing a third population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the third population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells; and

D) combining the first population of alphavirus particles produced from the first helper cell, the second population of alphavirus particles produced from the second

helper cell and the third population of alphavirus particles produced from the third helper cell, thereby producing the population of alphavirus replicon particles.

Also provided is a method of making a population of alphavirus replicon particles, comprising:

A) (a) providing a first helper cell for producing a first population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the first population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

B) (a) providing a second helper cell for producing a second population of infectious, replication defective alphavirus particle, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the second population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

C) (a) providing a third helper cell for producing a third population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the third population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells; and

D) combining the first population of alphavirus particles produced from the first helper cell, the second population of alphavirus particles produced from the second helper cell and the third population of alphavirus particles produced from the third helper cell, thereby producing the population of alphavirus replicon particles.

Furthermore, the present invention provides a composition comprising two or more isolated nucleic acids selected from the group consisting of an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof.

In addition, the present invention provides a composition comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an

immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle.

Also provided herein is a composition comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle, and further wherein the alphavirus replicon particles comprise a replicon RNA or at least one structural protein which comprises one or more attenuating mutations.

In these embodiments, the *gag* gene product or immunogenic fragment thereof can be modified by mutation of the second codon, whereby a glycine is changed to an alanine and the *pol* gene product or immunogenic fragment thereof can be modified by mutation of the nucleotide sequence encoding the active site motif, whereby YMDD is changed to YMAA or HMAA. In addition, the *pol* gene product or immunogenic fragment thereof is modified to produce only p51 of the *pol* gene product or immunogenic fragment thereof.

The present invention provides a method of making a population of alphavirus replicon particles, comprising:

A) (a) providing a first helper cell for producing a first population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the first population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

B) (a) providing a second helper cell for producing a second population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the second population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

C) (a) providing a third helper cell for producing a third population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA

comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the third population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells; and

D) combining the first population of alphavirus particles produced from the first helper cell, the second population of alphavirus particles produced from the second helper cell and the third population of alphavirus particles produced from the third helper cell, thereby producing the population of alphavirus replicon particles.

An additional method of making a population of alphavirus replicon particles is provided, comprising:

A) (a) providing a first helper cell for producing a first population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the first population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

B) (a) providing a second helper cell for producing a second population of

infectious, replication defective alphavirus particle, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the second population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

C) (a) providing a third helper cell for producing a third population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the third population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells; and

D) combining the first population of alphavirus particles produced from the first helper cell, the second population of alphavirus particles produced from the second helper cell and the third population of alphavirus particles produced from the third helper cell, thereby producing the population of alphavirus replicon particles.

In each of the methods above, the alphavirus replicon RNA of at least one of the first helper cell, the second helper cell and the third helper cell can comprise sequence encoding at least one alphavirus structural protein and the first helper RNA and the one or more additional helper RNA(s) in the at least one of the first helper cell, the second helper cell and the third helper cell, can encode at least one other alphavirus structural protein not encoded by the replicon RNA.

Furthermore, in the methods above which recite attenuating mutations, only at least one of the first population of alphavirus particles, the second population of alphavirus particles and the third population of alphavirus particles can comprise particles wherein at least one of the replicon RNA, the first helper RNA, and the one or more additional helper RNA(s) comprises one or more attenuating mutations.

The present invention further provides alphavirus particles produced by any of the methods of this invention.

The present invention further provides a method of inducing an immune response to human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the populations and/or compositions of this invention, in a pharmaceutically acceptable carrier.

Also provided herein is a method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an

immunogenic amount of the populations and/or compositions of this invention, in a pharmaceutically acceptable carrier.

Also provided by the present invention is an alphavirus replicon virosome comprising an alphavirus replicon RNA encapsidated by a lipid bilayer comprising alphavirus glycoproteins, E1 and E2, which in one embodiment, can be Venezuelan Equine Encephalitis glycoproteins E1 and E2.

A method of producing an alphavirus replicon virosome is further provided, comprising: a) combining alphavirus replicon RNA, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and b) gradually removing detergent, whereby alphavirus replicon virosomes are produced. Also provided is a virosome produced by this method.

Furthermore, the present invention provides a method of eliciting an immune response in a subject, comprising administering to the subject an immunogenic amount of the alphavirus replicon virosome of this invention in a pharmaceutically acceptable carrier.

The present invention additionally provides a method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the alphavirus replicon virosome of this invention, wherein the virosome comprises alphavirus replicon RNA encoding one or more HIV immunogens.

In further embodiments, the present invention provides a composition a population of alphavirus replicon virosomes comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment

thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the nucleic acids are each contained within a separate alphavirus replicon virosome.

Additionally provided herein is a composition comprising a population of alphavirus replicon virosomes comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in inactivation of reverse transcriptase activity in the *pol* gene product or immunogenic fragment thereof, and wherein the nucleic acids are each contained within a separate alphavirus replicon virosome.

A method of producing a population of alphavirus replicon virosomes is provided herein, comprising:

A) (a) producing a first population of alphavirus replicon virosomes by combining alphavirus replicon RNA comprising nucleic acid encoding and *env* gene product or immunogenic fragment thereof, alphavirus glycoproteins E1 and E2, non-

cationic lipids and detergent; and

b) gradually removing detergent, whereby alphavirus replicon virosomes are produced;

B) (a) producing a second population of alphavirus replicon virosomes by combining alphavirus replicon RNA comprising nucleic acid encoding and *gag* gene product or immunogenic fragment thereof, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and

b) gradually removing detergent, whereby alphavirus replicon virosomes are produced;

C) (a) producing a third population of alphavirus replicon virosomes by combining alphavirus replicon RNA comprising nucleic acid encoding the *pol* gene product or immunogenic fragment thereof, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and

b) gradually removing detergent, whereby alphavirus replicon virosomes are produced; and

D) combining the first population of alphavirus replicon virosomes, the second population of alphavirus replicon virosomes and the third population of alphavirus replicon virosomes to produce the population of alphavirus replicon virosomes.

In addition, a method of producing a population of alphavirus replicon virosomes is provided, comprising:

A) (a) producing a first population of alphavirus replicon virosomes by combining alphavirus replicon RNA comprising nucleic acid encoding and *env* gene product or immunogenic fragment thereof, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and

b) gradually removing detergent, whereby alphavirus replicon virosomes are produced;

B) (a) producing a second population of alphavirus replicon virosomes by combining alphavirus replicon RNA comprising nucleic acid encoding and *gag* gene product or immunogenic fragment thereof, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and

b) gradually removing detergent, whereby alphavirus replicon virosomes are produced;

C) (a) producing a third population of alphavirus replicon virosomes by combining alphavirus replicon RNA comprising nucleic acid encoding the *pol* gene product or immunogenic fragment thereof, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in inactivation of reverse transcriptase activity in the *pol* gene product or immunogenic fragment thereof, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and

b) gradually removing detergent, whereby alphavirus replicon virosomes are produced; and

D) combining the first population of alphavirus replicon virosomes, the second population of alphavirus replicon virosomes and the third population of alphavirus

replicon virosomes to produce the population of alphavirus replicon virosomes of claim 48.

Furthermore, the present invention provides a method of inducing an immune response in a subject, comprising administering to the subject an immunogenic amount of the virosomes of this invention, in a pharmaceutically acceptable carrier.

Also provided is a method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the virosomes of this invention, in a pharmaceutically acceptable carrier.

Additionally provided by this invention is a composition comprising heparin affinity-purified alphavirus replicon particles, wherein the alphavirus replicon particles comprise at least one structural protein which comprises one or more attenuating mutations, as well as a method of preparing heparin affinity-purified alphavirus particles, comprising:

a) producing alphavirus replicon particles, wherein the alphavirus replicon particles comprise a at least one structural protein which comprises one or more attenuating mutations;

b) loading the alphavirus replicon particles of step (a) in a heparin affinity chromatography column; and

c) collecting the fraction from the column which contains the heparin affinity-purified alphavirus replicon particles.

In further embodiments, the present invention provides a method of producing VRP for use in a vaccine comprising:

a) producing a plasmid encoding the nucleotide sequence of an alphavirus replicon RNA;

b) producing a plasmid encoding the nucleotide sequence of one or more

helper RNAs;

c) transcribing the plasmids of steps (a) and (b) into RNA *in vitro*;

d) electroporating the RNA of step (c) into a Vero cell line; and

e) purifying VRP from the Vero cell line of step (d) by heparin affinity chromatography. By this method, VRPs can be produced in large-scale.

In additional embodiments, the present invention provides an isolated nucleic acid encoding a *pol* gene product or immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof. This nucleic acid can be present in a composition and in a vector. Such a vector can be present in a cell. This nucleic acid can also be present in an alphavirus replicon particle.

The present invention further provides a method of making an alphavirus replicon particle comprising nucleic acid encoding a *pol* gene product or immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, comprising

a) providing a helper cell for producing an infectious, defective alphavirus particle, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or

inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cell.

In the method described above, at least one of the replicon RNA, the first helper RNA, and the one or more additional helper RNA(s) can comprises one or more attenuating mutations. The present invention additionally provides alphavirus replicon particle produced according to the above methods.

Further provided is a method of inducing an immune response in a subject, comprising administering to the subject an immunogenic amount of a composition comprising alphavirus replicon particles encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol*

gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof in a pharmaceutically acceptable carrier.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. DNA plasmid map of VEE replicon RNA expressing the HIV *gag* gene (p3-40.1.6). The plasmid is 12523 base pairs in length and encodes a single polyprotein expressing the four non-structural genes nsP1-4, the Clade C gag gene and antibiotic resistance marker, Kanamycin KN(R). The plasmid contains two promoter regions, the T7 polymerase promoter and the 26S RNA promoter. The unique NotI restriction enzyme site used to linearize prior to *in vitro* transcription is also noted.

Figure 2. DNA plasmid map of the capsid helper construct (p3-13.2.2). The plasmid is 5076 base pairs in length and encodes the VEE capsid gene (C) and antibiotic resistance marker, Kanamycin KN(R). The plasmid contains two promoter regions, the T7 polymerase promoter and the 26S RNA promoter. The unique NotI restriction enzyme site used to linearize prior to *in vitro* transcription is also noted.

Figure 3. DNA plasmid map of the glycoprotein helper construct (p3-13.4.6). The plasmid is 6989 base pairs in length and encodes the VEE glycoprotein genes (E3, E2, 6K and E1) and antibiotic resistance marker, Kanamycin KN(R). The plasmid contains two promoter regions, the T7 polymerase promoter and the 26S RNA promoter. The unique NotI restriction enzyme site used to linearize prior to *in vitro* transcription is also noted.

Figure 4. DNA plasmid map of VEE replicon RNA expressing HIV *pol* (p51) gene (p13-60.2.14). The plasmid is 12379 base pairs in length and encodes a single polyprotein expressing the four non-structural genes, nsP1-4, the Clade C pol (p51)

gene and antibiotic resistance marker, Kanamycin KN(R). The plasmid contains two promoter regions, the T7 polymerase promoter and the 26S RNA promoter. The unique NotI restriction enzyme site used to linearize prior to *in vitro* transcription is also noted.

Figure 5. DNA plasmid map of VEE replicon RNA expressing HIV *env* gene (pERK-DU151env). The plasmid is 13584 base pairs in length and encodes a single polyprotein expressing the four non-structural genes, nsP1-4, the Clade C env gene and antibiotic resistance marker, Kanamycin KN(R). The plasmid contains two promoter regions, the T7 polymerase promoter and the 26S RNA promoter. The unique NotI restriction enzyme site used to linearize prior to *in vitro* transcription is also noted.

Figure 6. Western immunoblot, demonstrating the expression of HIV proteins in baby hamster kidney (BHK) cells infected with VRPs. The outer lanes of the panel are standard molecular weight markers. Lane 1 is the expression from VRPs encoding the p51 (*pol*) gene. Lane 2 is the expression from VRPs encoding the GP-160 (*env*) gene. Lane 3 is the expression from VRPs encoding the p55 (*gag*) gene. Arrows indicate proteins migrating with the apparent molecular weight of each respective protein.

Figure 7. Western immunoblot of cells infected with the Du151*env* VRP. At 18 hr post infection, the cells were lysed and the lysate run in a denaturing polyacrylamide gel. Proteins were transferred out of the gel onto a filter and the filter was probed with serum from subject Du151 using Western immunoblot methods. Lane 1, uninfected U87.CD4-CXCR4 cells. Lane 2, uninfected U87.CD4-CCR5 cells. Lane 3, infection of a mixed culture of U87.CD4-CXCR4 cells and BHK cells (mixtures were used as a positive control in case the U87 cells were refractory to infection by the VRP, which did not turn out to be the case). Lane 4, infected U87.CD4-CXCR4 cells. Lane 5, infected BHK cells. Lane 6, infection of a mixture of BHK cells and U87.CD4-CCR5 cells. Lane 7, infected U87.CD4-CCR5 cells. The positions of

molecular weight of markers run in the same gel are shown on the right, and the inferred positions of gp160 and gp120 are shown on the left.

Figure 8. Micrographs of U87.CD4-CCR and BHK cells used to examine expression and syncytium formation of DU151 envelope expressed from the VEE replicon. U87.CD4-CCR5 cells alone (panel 1), or a mixture of U87.CD4-CCR5 and BHK cells (Panel 2), BHK cells alone (Panel 3) and U87.CD4-CXCR4 cells (panel 4) were infected with DU151 env VRP at a multiplicity of infection of 3 i.u. per cell. At 18 hours post infection, the cells were examined using light microscopy for the presence of syncytia. The U87.CD4-CCR5 in panel 1 and 2 show clear syncytia, which was absent in the control cell types in the lower panels. In addition, no syntycia were seen in uninfected control cells or VRP-GFP infected cells (data not shown).

Figures 9A-C. Antigen-specific CTL response in mice to the HIV-1 Clade C VRP-gag vaccine. Eight BALB/c mice were immunized twice, first at day 0 and again at day 28 with 10^3 i.u. (Panel A) or 10^5 i.u. (panels B and C) VRP-gag. Eight days (Panels A and B) or 49 days (Panel C) post-boost, spleen cells were isolated and stimulated *in vitro* with vaccinia virus expressing HIV Gag for 1 week. Chromium release assays were performed using vaccinia-Gag infected target cells (diamond symbols) or control vaccinia alone-infected sc11 target cells (square symbols). Clear HIV Gag-specific lysis was detected in animals vaccinated with the VRP-gag vaccine.

Figure 10. Diagrammatic representation of the HIV-1 genome. Black bars indicate relative regions of the genome sequenced to generate phylogenetic sequence comparative data for Clade C *gag*, *pol* and *env* gene isolates.

Figure 11. Phylogenetic comparison of DU422 Clade C Gag isolate with referenced Clade C strains. Consensus clade A, B, D, Mal and SA strains are also shown. DU422 the vaccine strain had 95% amino acid sequence homology to the South African consensus Clade C sequence.

Figure 12. Phylogenetic comparison of DU151 Clade C isolate Env isolate with referenced Clade C strains. DU422 the vaccine strain had 93% amino acid sequence homology to the South African consensus Clade C sequence.

Figure 13. Phylogenetic comparison of DU151 Clade C isolate Pol isolate with referenced Clade C strains. DU422 the vaccine strain had 99% amino acid sequence homology to the South African consensus Clade C sequence.

Figure 14. DU422 HIV Gag expression as detected by immunofluorescence following electroporation with Gag replicon RNA. BHK cells were electroporated and subjected to imunofluorescence staining with an anti-Gag monoclonal antibody at 24 hours post-electroporation, to demonstrate expression of the Clade C protein.

Figure 15. Immunofluorescence detection of DU422 Gag protein expression in BHK cells. BHK cells were infected with VRP-Gag particles and subjected to immunfluorescence staining with an anti-Gag monoclonal antibody at 24 hours post-infection, to demonstrate expression of the Clade C protein.

DETAILED DESCRIPTION OF THE INVENTION

As used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a pharmaceutical carrier" can mean a single pharmaceutical carrier or mixtures of two or more such carriers.

The present invention is based on the discovery of a vaccine for the treatment and/or prevention of infection by HIV, comprising novel combinations of isolated nucleic acids encoding two or more distinct antigens which elicit an immune response in a subject which is effective in treating and/or preventing infection by HIV. In a particular embodiment, the nucleic acids encoding the antigens of the vaccine are

modified to enhance the immunogenicity of the antigen, improve the safety of the vaccine, or both.

As used herein, the term "isolated nucleic acid" means a nucleic acid separated or substantially free from at least some of the other components of the naturally occurring organism, for example, the cell structural components commonly found associated with nucleic acids in a cellular environment and/or other nucleic acids. The isolation of nucleic acids can be accomplished by well known techniques such as cell lysis or disruption of virus particles, followed by phenol plus chloroform extraction, followed by ethanol precipitation of the nucleic acids (Sambrook *et al.*, latest edition). The nucleic acids of this invention can be isolated according to methods well known in the art for isolating nucleic acids. Alternatively, the nucleic acids of the present invention can be synthesized according to standard protocols well described in the literature for synthesizing nucleic acids.

HIV-VRP Vaccines

The antigens of this invention can be gene products which are complete proteins or any fragment of a protein determined to be immunogenic by methods well known in the art. Modifications are made to the antigens of this invention to enhance immunogenicity and/or improve the safety of administration of a vaccine containing the antigen. Examples of such modifications are described in the Examples section herein. Furthermore, it is understood that, where desired, other modifications and changes (e.g., substitutions, deletions, additions) may be made in the amino acid sequence of the antigen of the present invention, which may not specifically impart enhanced immunogenicity or improved safety, yet still result in a protein or fragment which retains all of the functional characteristics by which the protein or fragment is defined. Such changes may occur in natural isolates, may be introduced by synthesis of the protein or fragment, or may be introduced into the amino acid sequence of the protein or fragment using site-specific mutagenesis of nucleic acid encoding the protein or

fragment, the procedures for which, such as mis-match polymerase chain reaction (PCR), are well known in the art.

The nucleic acids of this invention can be present in a vector and the vector of this invention can be present in a cell. The vectors and cells of this invention can be in a composition comprising the cell or vector and a pharmaceutically acceptable carrier.

The vector of this invention can be an expression vector which contains all of the genetic components required for expression of the nucleic acids of this invention in cells into which the vector has been introduced, as are well known in the art. For example, the expression vector of this invention can be a vector comprising the helper RNAs of this invention. Such an expression vector can be a commercial expression vector or it can be constructed in the laboratory according to standard molecular biology protocols. The expression vector can comprise viral nucleic acid including, but not limited to, alphavirus, flavivirus, adenovirus, retrovirus and/or adeno-associated virus nucleic acid. The nucleic acid or vector of this invention can also be in a liposome or a delivery vehicle which can be taken up by a cell via receptor-mediated or other type of endocytosis.

In another embodiment, the nucleic acids of this invention can be present in a composition comprising a population of alphavirus replicon particles which comprise two or more distinct isolated nucleic acids of this invention and wherein the nucleic acids are each contained within a separate alphavirus replicon particle (herein referred to as a "VRP"). Thus, the expression vector of the present invention can be an alphavirus replicon particle comprising a nucleic acid encoding an antigen of this invention.

In a particular embodiment, the present invention provides a composition comprising two or more isolated nucleic acids selected from the group consisting of an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment

thereof of a human immunodeficiency virus, an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of particles, e.g., virus-like particles, containing the *gag* gene product or the immunogenic fragment thereof, and their release from a cell, and an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity.

In a preferred embodiment, the invention provides alphavirus replicon particles (VRPs) that can be administered as an HIV vaccine. These HIV-VRPs are propagation defective, single cycle vectors that contain a self-amplifying RNA (replicon RNA), e.g., from VEE, in which the structural protein genes of the virus are replaced by a HIV-1 Clade C *gag* gene or any other HIV antigen to be expressed. Following introduction into packaging (or helper) cells *in vitro*, the replicon RNA is packaged into VRPs by supplying the viral structural proteins in *trans* (helper RNAs).

The present invention further provides a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of particles, such as virus-like partices, containing the *gag* gene product or the immunogenic fragment thereof, from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle.

It is also contemplated that the compositions of this invention comprise alphavirus replicon particles in which either the replicon RNA or at least one structural protein comprises one or more attenuating mutations. Thus, the present invention additionally provides a population of alphavirus replicon particles comprising two or more distinct types of such particles selected from the group consisting of 1) particles expressing a nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) particles expressing a nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit release of particles, such as virus-like particles, containing the *gag* gene product or the immunogenic fragment thereof, from a cell, and 3) particles expressing a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity; and wherein the nucleic acids are each contained within a separate alphavirus replicon particle and further wherein the alphavirus replicon particles comprise a replicon RNA or at least one structural protein which comprises one or more attenuating mutations.

In a preferred embodiment, the population of alphavirus replicon particles comprises particles expressing the nucleic acids encoding *pol*, *env*, and *gag* gene products. In this embodiment, vigorous antigen-specific cellular (e.g., CTL, NK cell and T-helper) and/or humoral (e.g., antibody) responses can be obtained when such particle populations are administered to a subject.

In the compositions described above, the *gag* gene product or immunogenic fragment thereof can be modified by mutation of the second codon, whereby a glycine is changed to an alanine. Alternatively, the *gag* gene product or immunogenic fragment thereof can be modified by any other means known in the art for inhibiting the release of particles containing the *gag* gene product or immunogenic fragment thereof from a cell.

Furthermore, in the compositions of this invention, the *pol* gene product or immunogenic fragment thereof can be modified by mutation of the nucleotide sequence encoding the active site motif, whereby YMDD is changed to YMAA or HMAA (the latter providing a convenient site for cloning, see SEQ ID NO:16). The *pol* gene product or immunogenic fragment thereof can also be modified by any means known in the art for inhibiting reverse transcriptase activity.

The *pol* gene product or immunogenic fragment thereof of this invention may be further modified such that the coding sequences for integrase and RNase H are removed, inactivated and/or modified, e.g., by producing only the p51 region of the *pol* gene product. This modification has been shown in some studies to reduce the possibility of formation of replication competent alphavirus particles during production of alphavirus replicon particles comprising the *pol* gene product or immunogenic fragment thereof. This modification can be of the nucleic acid encoding the *pol* gene product or immunogenic fragment thereof according to methods known in the art. Thus, the particles and compositions of this invention can comprise nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof.

In the compositions of this invention, the *gag*, *env* or *pol* gene products or immunogenic fragments thereof can be from any HIV isolate or consensus sequence derived from HIV primary isolates now known or later identified, the isolation and characterization of which are well known in the art. Also, in the compositions of this invention, the *gag*, *env* or *pol* gene products or immunogenic fragments thereof can be produced from the same HIV isolate or HIV consensus sequence or from any combination of HIV isolates or HIV consensus sequences. In the Examples provided herein, the nucleic acid sequences encoding the *env*, *gag* and *pol* gene products of this

invention were selected based on a consensus sequence generated from primary isolates obtained from recent seroconvertors in Kwazulu/Natal in South Africa. Sequence analysis of these isolates identified them as subtype (or clade) C, and in preferred embodiments of the invention, the *env*, *gag* and *pol* genes are from Clade C isolates of HIV.

In preferred embodiments, each of the three HIV genes are derived from one or more of the South African isolates obtained from recent seroconverters in Kwazulu/Natal as described herein (see Figures 11-13 for isolate names). In a further embodiment, the *gag* gene or gene fragment is from a *gag* sequence having 95% or greater amino acid identity with the South African consensus sequence for the *gag* gene. In a specific embodiment, the *gag* gene or fragment thereof is derived from HIV Subtype Clade C isolate DU422 and the *env* and *pol* genes or fragments thereof are derived from HIV isolate DU151.

The term "alphavirus" has its conventional meaning in the art and includes the various species of the alphavirus genus, such as Eastern Equine Encephalitis virus (EEE), Venezuelan Equine Encephalitis virus (VEE), Western Equine Encephalitis virus (WEE), Everglades virus, Mucambo virus, Pixuna virus, Sindbis virus, Semliki Forest virus, South African Arbovirus No. 86, Middleburg virus, Chikungunya virus, O=nyong-nyong virus, Ross River virus, Barmah Forest virus, Getah virus, Sagiyama virus, Bebaru virus, Mayaro virus, Una virus, Aura virus, Whataroa virus, Babanki virus, Kyzylagach virus, Highlands J virus, Fort Morgan virus, Ndumu virus, Buggy Creek virus, as well as any specific strains of these alphaviruses (e.g., TR339; Girdwood) and any other virus classified by the International Committee on Taxonomy of Viruses (ICTV) as an alphavirus.

An "alphavirus replicon particle" as used herein is an infectious, replication defective, alphavirus particle which comprises alphavirus structural proteins and further comprises a replicon RNA. The replicon RNA comprises nucleic acid encoding the

alphavirus packaging segment, nucleic acid encoding alphavirus non-structural proteins and a heterologous nucleic acid sequence encoding an antigen of this invention. The non-structural proteins encoded by the replicon RNA may be such proteins as are required for replication and transcription. In a specific embodiment of this invention, the structure of the replicon RNA, starting at the 5' end, comprises the 5' untranslated region of the alphavirus RNA, the non-structural proteins (e.g., nsPs1-4) of the alphavirus, the 26S promoter (also known as the "subgenomic promoter"), the heterologous nucleic acid encoding an HIV antigen, and the 3' untranslated region of the alphavirus RNA. An example of a nucleic acid encoding alphavirus nonstructural proteins that can be inforporated into the embodiments of this invention is SEQ ID NO:2, which encodes the amino acid sequence of SEQ ID NO:3.

Although the alphavirus replicon RNA can comprise nucleic acid encoding one or two alphavirus structural proteins, the replicon RNA does not contain nucleic acid encoding all of the alphavirus structural proteins. The replicon RNA can lack nucleic acid encoding any alphavirus structural protein(s). Thus, the resulting alphavirus replicon particles of this invention are replication defective inasmuch as the replicon RNA does not encode all of the structural proteins required for encapsidation of the replicon RNA and assembly of an infectious virion.

As used herein, "alphavirus structural protein" or "structural protein" means the alphavirus proteins required for encapsidation of alphavirus replicon RNA and packaging of the encapsidated RNA into a virus particle. The alphavirus structural proteins include PE2, E2, E3, 6K and E1.

The alphavirus replicon particles of this invention can comprise replicon RNA from any of the alphaviruses of this invention. Furthermore, the alphavirus replicon particles of this invention can comprise alphavirus structural proteins from any of the alphaviruses of this invention. Thus, the replicon particles can be made up of replicon RNA and structural proteins from the same alphavirus or from different alphaviruses,

the latter of which would be chimeric alphavirus replicon particles (e.g., a particle comprising Sindbis virus replicon RNA and VEE structural proteins).

The alphavirus replicon particles of this invention can be made by employing a helper cell for expressing an infectious, replication defective, alphavirus particle in an alphavirus-permissive cell. The helper cell includes (a) a first helper RNA encoding (i) at least one alphavirus structural protein, and (ii) not encoding at least one alphavirus structural protein; and (b) a second helper RNA separate from the first helper RNA, the second helper RNA (i) not encoding the at least one alphavirus structural protein encoded by the first helper RNA, and (ii) encoding at least one alphavirus structural protein not encoded by the first helper RNA, such that all of the alphavirus structural proteins assemble together into alphavirus particles in the cell.

The alphavirus structural protein genes can be present on the helper RNAs of this invention in any combination. For example, the helper RNA of this invention can encode the alphavirus capsid and E1, capsid and E2, E1 and E2, capsid only, E1 only, E2 only, etc. It is also contemplated that the alphavirus structural proteins are provided in *trans* from genes located on three separate RNA molecules within the helper cell.

In a preferred embodiment, the helper cell also includes a replicon RNA, which encodes the alphavirus packaging segment and an inserted heterologous RNA. In the embodiment wherein the helper cell also includes a replicon RNA, the alphavirus packaging segment may be, and preferably is, deleted from both the first helper RNA and the second helper RNA. For example, in an embodiment wherein the helper cell includes a replicon RNA encoding the alphavirus packaging segment and an inserted heterologous RNA, the first helper RNA encodes the alphavirus E1 glycoprotein and the alphavirus E2 glycoprotein, and the second helper RNA encodes the alphavirus capsid protein. In a preferred embodiment, the first helper RNA encodes the E3-E2-6k-E1cassette from an alphavirus. In an alternative embodiment, the cassette encoded on the first helper RNA is referred to as the E3-E2-E1 cassette. A specific embodiment of this aspect of the invention is diagrammed in Figure 3, and an exemplary nucleotide

sequence is SEQ ID NO:11. The replicon RNA, first helper RNA, and second helper RNA are all on separate molecules and are cotransfected, e.g., by electroporation, into the helper cell, which can be any alphavirus permissive cell, as is well known in the art.

In an alternative embodiment, the helper cell includes a replicon RNA encoding the alphavirus packaging segment and an inserted heterologous RNA and also includes the alphavirus capsid protein otherwise encoded by the second helper RNA. The first helper RNA encodes the alphavirus E1 glycoprotein and the alphavirus E2 glycoprotein. Thus, the replicon RNA and the first helper RNA are on separate molecules, and the replicon RNA and the second helper RNA are on a single molecule.

The RNA encoding the structural proteins, i.e., the first helper RNA and the second helper RNA, can include one or more attenuating mutations. In a preferred embodiment, either one or both of the first helper RNA and the second helper RNA include at least one attenuating mutation. The attenuating mutations provide the advantage that in the event of RNA recombination within the cell, the coming together of the structural and non-structural genes will produce a virus of decreased virulence.

The alphavirus replicon particles of this invention can be made by a) transfecting a helper cell as given above with a replication defective replicon RNA, b) producing the alphavirus particles in the transfected cell, and c) collecting the alphavirus particles from the cell. The replicon RNA encodes the alphavirus packaging segment and a heterologous RNA. The transfected helper cell further includes the first helper RNA and second helper RNA as described above.

As described hereinabove, the structural proteins used to assemble the alphavirus replicon particles of this invention are distributed among one or more helper RNAs (i.e., a first helper RNA and a second helper RNA). As noted herein, one or more structural protein genes may be located on the replicon RNA, provided that at

least one structural protein gene is deleted from the replicon RNA such that the replicon RNA and resulting alphavirus particle are replication defective. As used herein, the terms "deleted" or "deletion" mean either total deletion of the specified nucleic acid or the deletion of a sufficient portion of the specified nucleic acid to render the nucleic acid and/or its resultant gene product inoperative or nonfunctional, in accordance with standard usage. (See, e.g., U.S. Pat. No. 4,650,764 to Temin *et al.*) The term "replication defective" as used herein means that the replicon RNA cannot replicate in the host cell (i.e., produce infectious viral particles) in the absence of the helper RNA. The replicon RNA is replication defective inasmuch as the replicon RNA does not include all of the alphavirus structural protein genes required for replication, at least one of the required structural protein genes being deleted therefrom.

In one embodiment, the packaging segment or "encapsidation sequence" is deleted from at least the first helper RNA. In a preferred embodiment, the packaging segment is deleted from both the first helper RNA and the second helper RNA. In a specific embodiment, the second helper RNA is constructed from a VEE cDNA clone, deleting all non-structural proteins (i.e., nsPs1-4), the packaging signal, and the glycoprotein cassette (E3-E2-E1). An example of a plasmid encoding such a second helper RNA is provided in Figure 2, and an exemplary nucleotide sequence for such a second helper RNA is SEQ ID NO:8.

In the preferred embodiment wherein the packaging segment is deleted from both the first helper RNA and the second helper RNA, preferably the helper cell contains a replicon RNA in addition to the first helper RNA and the second helper RNA. The replicon RNA encodes the packaging segment and an inserted heterologous RNA encoding an HIV antigen or a fragment thereof. Typically, the inserted heterologous RNA encodes a gene product which is expressed by the target cell, and includes the promoter and regulatory segments necessary for the expression of that gene product in that cell.

In another preferred embodiment, the replicon RNA, the first helper RNA and the second helper RNA are provided on separate molecules such that a first molecule, i.e., the replicon RNA, encodes the packaging segment and the inserted heterologous RNA, a second molecule, i.e., the first helper RNA, encodes at least one but not all of the required alphavirus structural proteins, and a third molecule, i.e., the second helper RNA, encodes at least one but not all of the required alphavirus structural proteins. For example, in one preferred embodiment of the present invention, the helper cell includes a set of RNAs which include (a) a replicon RNA encoding an alphavirus packaging sequence and an inserted heterologous RNA, (b) a first helper RNA encoding the alphavirus E1 glycoprotein and the alphavirus E2 glycoprotein, and (c) a second helper RNA encoding the alphavirus capsid protein, so that the alphavirus E1 glycoprotein, the alphavirus E2 glycoprotein and the capsid protein assemble together into alphavirus particles containing the replicon RNA in the helper cell.

In an alternate embodiment, the replicon RNA and the first helper RNA are on separate molecules, and the replicon RNA and the second helper RNA are on a single molecule together, thereby providing a first molecule, i.e., the first helper RNA, encoding at least one but not all of the required alphavirus structural proteins, and a second molecule, i.e., the replicon RNA and second helper RNA, encoding the packaging segment, the inserted heterologous gene product and the structural protein(s) not encoded by the first helper. Thus, one or more structural protein(s) is encoded by the second helper RNA, but the second helper RNA is located on the second molecule together with the replicon RNA. For example, in one preferred embodiment of the present invention, the helper cell includes a set of RNAs including (a) a replicon RNA encoding an alphavirus packaging sequence, an inserted heterologous RNA, and an alphavirus capsid protein, and (b) a first helper RNA encoding the alphavirus E1 glycoprotein and the alphavirus E2 glycoprotein so that the alphavirus E1 glycoprotein, the alphavirus E2 glycoprotein and the capsid protein assemble together into alphavirus particles in the helper cell.

The present invention also contemplates alphavirus replicon particles which comprise replicon RNA encoding more than one heterologous gene product. For expression of more than one heterologous nucleic acid from a single replicon RNA, a promoter can be inserted upstream of each heterologous nucleic acid on the replicon RNA, such that the promoter regulates expression of the heterologous nucleic acid, resulting in the production of more than one antigen from a single replicon RNA Another embodiment contemplates the insertion of an IRES sequence, such as the one from the picornavirus, EMC virus, between the heterologous genes downstream from a 26S promoter of the replicon, thus leading to translation of multiple antigens from a single replicon.

In one preferred embodiment of the present invention, the RNA encoding the alphavirus structural proteins, i.e., the capsid, E1 glycoprotein and/or E2 glycoprotein, contains at least one attenuating mutation. It is further contemplated that the RNA encoding the non-structural proteins can contain at least one attenuating mutation. The phrases "attenuating mutation" and "attenuating amino acid," as used herein, mean a nucleotide mutation or an amino acid coded for in view of such a mutation which result in a decreased probability of causing disease in its host (i.e., a loss of virulence), in accordance with standard terminology in the art, See, e.g., Davis *et el.* (1980). The mutation can be, for example, a substitution mutation or an in-frame deletion mutation. The phrase "attenuating mutation" excludes mutations which would be lethal to the virus. Thus, according to this embodiment, the E1 RNA and/or the E2 RNA and/or the capsid RNA can include at least one attenuating mutation. In a more preferred embodiment, the E1 RNA and/or the E2 RNA and/or the capsid RNA includes at least two, or multiple, attenuating mutations. The multiple attenuating mutations may be positioned in either the first helper RNA or in the second helper RNA, or they may be distributed randomly with one or more attenuating mutations being positioned in the first helper RNA and one or more attenuating mutations positioned in the second helper RNA. Appropriate attenuating mutations will be dependent upon the alphavirus used,

as is well known in the art.

For example, when the alphavirus is VEE, suitable attenuating mutations can be in codons at E2 amino acid position 76 which specify an attenuating amino acid, preferably lysine, arginine, or histidine as E2 amino acid 76; codons at E2 amino acid position 120 which specify an attenuating amino acid, preferably lysine as E2 amino acid 120; codons at E2 amino acid position 209 which specify an attenuating amino acid, preferably lysine, arginine, or histidine as E2 amino acid 209; codons at E1 amino acid 272 which specify an attenuating mutation, preferably threonine or serine as E1 amino acid 272; codons at E1 amino acid 81 which specify an attenuating mutation, preferably isoleucine or leucine as E1 amino acid 81; and codons at E1 amino acid 253 which specify an attenuating mutation, preferably serine or threoinine as E1 amino acid 253; and the combination mutation of the deletion of E3 codons 56-59 together with codons at E1 amino acid 253 which specify an attenuating mutation, as provided herein. Other suitable attenuating mutations within the VEE genome will be known to those skilled in the art.

In an alternate embodiment, wherein the alphavirus is the South African Arbovirus No. 86 (S.A.A.R.86), suitable attenuating mutations can be, for example, in codons at nsP1 amino acid position 538 which specify an attenuating amino acid, preferably isoleucine as nsP1 amino acid 538; codons at E2 amino acid position 304 which specify an attenuating amino acid, preferably threonine as E2 amino acid 304; codons at E2 amino acid position 314 which specify an attenuating amino acid, preferably lysine as E2 amino acid 314; codons at E2 amino acid position 376 which specify an attenuating amino acid, preferably alanine as E2 amino acid 376; codons at E2 amino acid position 372 which specify an attenuating amino acid, preferably leucine as E2 amino acid 372; codons at nsP2 amino acid position 96 which specify an attenuating amino acid, preferably glycine as nsP2 amino acid 96; codons at nsP2 amino acid position 372 which specify an attenuating amino acid, preferably valine as nsP2 amino acid 372; in combination, codons at E2 amino acid residues 304, 314, 372

and 376; codons at E2 amino acid position 378 which specify an attenuating amino acid, preferably leucine as E2 amino acid 378; codons at nsP2 amino acid residue 372 which specify an attenuating mutation, preferably valine as nsP2 amino acid 372; in combination, codons at nsP2 amino acid residues 96 and 372 attenuating substitution mutations at nsP2 amino acid residues 96 and 372; codons at nsP2 amino acid residue 529 which specify an attenuating mutation, preferably leucine, at nsP2 amino acid residue 529; codons at nsP2 amino acid residue 571 which specify an attenuating mutation, preferably asparagine, at nsP2 amino acid residue 571; codons at nsP2 amino acid residue 682 which specify an attenuating mutation, preferably arginine, at nsP2 amino acid residue 682; codons at nsP2 amino acid residue 804 which specify an attenuating mutation, preferably arginine, at nsP2 amino acid residue 804; codons at nsP3 amino acid residue 22 which specify an attenuating mutation, preferably arginine, at nsP3 amino acid residue 22; and in combination, codons at nsP2 amino acid residues 529, 571, 682 and 804, and at nsP3 amino acid residue 22, specifying attenuating amino acids at nsP2 amino acid residues 529, 571, 682 and 804 and at nsP3 amino acid residue 22. Other suitable attenuating mutations within the S.A.A.R.86 genome will be known to those skilled in the art.

The alphavirus capsid gene used to make alphavirus replicon particles can also be subjected to site-directed mutagenesis. The altered capsid protein provides additional assurance that recombination to produce the virulent virus will not occur. The altered capsid protein gene which functions in particle assembly but not in autoproteolysis provides helper function for production of replicon particles, but does not allow for production of a viable recombinant. The capsid residues required for proteolytic function are known (Strauss *et al.*, 1990).

Suitable attenuating mutations useful in embodiments wherein any of the alphaviruses of this invention are employed are known to or can be identified by those skilled in the art using routine protocols. Attenuating mutations may be introduced into the RNA by performing site-directed mutagenesis on the cDNA which encodes the

RNA, in accordance with known procedures. See Kunkel (1985), the disclosure of which is incorporated herein by reference in its entirety. Alternatively, mutations may be introduced into the RNA by replacement of homologous restriction fragments in the cDNA which encodes for the RNA, in accordance with known procedures. The identification of a particular mutation in an alphavirus as attenuating is done using routine experimentation according to methods well known in the art.

Preferably, the helper RNA of this invention includes a promoter. It is also preferred that the replicon RNA includes a promoter. Suitable promoters for inclusion in the helper RNA and replicon RNA are well known in the art. One preferred promoter is the alphavirus 26S promoter, although many suitable promoters are available, as is well known in the art.

In the system wherein a first helper RNA, a second helper RNA, and a replicon RNA are all on separate molecules, if the same promoter is used for all three RNAs, then a homologous sequence between the three molecules is provided. Thus, it is advantageous to employ different promoters on the first and second helper RNAs to provide further impediment to RNA recombination that might produce virulent virus. It is preferred that the selected promoter is operative with the non-structural proteins encoded by the replicon RNA molecule.

The infectious, replication defective, alphavirus particles of this invention are prepared according to the methods disclosed herein in combination with techniques known to those skilled in the art. The methods include, for example, transfecting an alphavirus-permissive cell with a replication defective replicon RNA including the alphavirus packaging segment and an inserted heterologous RNA, a first helper RNA encoding at least one alphavirus structural protein, and a second helper RNA encoding at least one alphavirus structural protein which is different from that encoded by the first helper RNA; producing the alphavirus particles in the transfected cell; and collecting the alphavirus particles from the cell.

Methods for transfecting the alphavirus-permissive cell with the replicon RNA and helper RNAs can be achieved, for example, by (i) treating the cells with DEAE-dextran, (ii) by lipofection, by treating the cells with, for example, LIPOFECTIN, and (iii) by electroporation, with electroporation being a preferred means of achieving RNA uptake into the alphavirus-permissive cells. Examples of these techniques are well known in the art, see e.g., U.S. Pat. No. 5,185,440 to Davis *et al.*, and PCT Publication No. WO 92/10578 to Bioption AB, the disclosures of which are incorporated herein by reference in their entirety.

The steps of producing the infectious viral particles in the cells may also be carried out using conventional techniques. See e.g., U.S. Patent No. 5,185,440 to Davis *et al.*, PCT Publication No. WO 92/10578 to Bioption AB, and U.S. Patent No. 4,650,764 to Temin *et al.* (although Temin *et al.*, relates to retroviruses rather than alphaviruses). The infectious viral particles may be produced by standard cell culture growth techniques.

The steps of collecting the infectious alphavirus particles may also be carried out using conventional techniques. For example, the infectious particles may be collected by cell lysis, or collection of the supernatant of the cell culture, as is known in the art. See e.g., U.S. Patent No. 5,185,440 to Davis *et al.*, PCT Publication No. WO 92/10578 to Bioption AB, and U.S. Patent No. 4,650,764 to Temin *et al.* (although Temin *et al.* relates to retroviruses rather than alphaviruses). Other suitable techniques will be known to those skilled in the art. Optionally, the collected infectious alphavirus particles may be purified, if desired. Purification techniques for viruses are well known to those skilled in the art, and these are suitable for the purification of small batches of infectious alphavirus particles.

Thus, the present invention provides a method of making the populations of alphavirus replicon particles of this invention comprising:

A) (a) providing a first helper cell for producing a first population of infectious,

defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the first population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

B) (a) providing a second helper cell for producing a second population of infectious, defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles

containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the second population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

C) providing a third helper cell for producing a third population of infectious, defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity or is modified to inactivate or delete integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment

thereof, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and unable to complete viral replication, and further wherein the third population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells; and

D) combining the first population of alphavirus particles produced from the first helper cell, the second population of alphavirus particles produced from the second helper cell and the third population of alphavirus particles produced from the third helper cell, thereby producing the populations of alphavirus replicon particles.

In a preferred embodiment, as noted above, the method provided also includes a mutation in the *pol* gene product or immunogenic fragment thereof resulting in inactivation or deletion of integrase and RNase H functions of the *pol* gene product or immunogenic fragment thereof. In a specific embodiment of this method, the region of the *pol* gene encoding the RNase H and integrase function of the *pol* gene product or immunogenic fragment thereof has been deleted.

A method of making the populations of alphavirus replicon particles of this invention, wherein the particles comprise at least one attenuating mutation, is also provided, comprising:

A) (a) providing a first helper cell for producing a first population of infectious, defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the first population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

B) providing a second helper cell for producing a second population of infectious,

defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit release of particles, such as virus-like particles, containing the *gag* gene product or the immunogenic fragment thereof from a cell, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the second population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

C) providing a third helper cell for producing a third population of infectious, defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity or is modified to inactivate or delete integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the third population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells; and

D) combining the first population of alphavirus particles produced from the first helper cell, the second population of alphavirus particles produced from the second

helper cell and the third population of alphavirus particles produced from the third helper cell, thereby producing the populations of alphavirus replicon particles of the present invention comprising at least one attenuating mutation.

In a preferred embodiment, as noted above, the method provided above can include a further mutation in the *pol* gene product or immunogenic fragment thereof resulting in inactivation or deletion of integrase and RNase H functions of the *pol* gene product or immunogenic fragment thereof. In a specific embodiment of this method, the region of the *pol* gene encoding the RNase H and integrase function of the *pol* gene product or immunogenic fragment thereof has been deleted.

It is also contemplated regarding the method described above, that not all of the first, second and third populations of alphavirus particles do not all have to comprise an attenuating mutation. For example, the first population may comprise attenuating mutations, but the second and third populations may not, etc.

The present invention further provides the compositions of the present invention which are produced by the methods of this invention.

The compositions and methods of this invention which incorporate attenuating mutations into the alphavirus replicon particles forming the composition and/or produced by the methods include purified compositions and methods of purification based on the presence of the attenuating mutations. In particular, certain attenuating mutations in the alphavirus structural proteins introduce heparin binding sites into these proteins which are present on the surface of the alphavirus replicon particles. As an example, the V3014 E2 glycoprotein (SEQ ID NO:12 and SEQ ID NO:13) has a mutation in which a lysine is substituted for the glutamic acid at amino acid position 209. This mutation, which creates a more positively charged glycoprotein, increases the affinity of this protein for heparin. Thus, it is possible to purify such particles using heparin affinity chromatography. Such chromatography can be performed using any of

several commercially available resins to which heparin has been bound. The source of heparin is variable; the commercially available resins currently use porcine heparin. The choice of resin will be based on its relative ease of use in a scaled-up, GMP-compliant process, e.g., price, column packing limitations, and potential for easy sanitization. The use of heparin affinity chromatography results in a substantial purification of the VRPs with very little loss of material, and it is a scalable purification step. In a preferred embodiment, a heparin affinity chromatography step results in between an 8- to 27-fold reduction in total protein per ml, or from a 300- to 1000-fold reduction in total protein per VRP. Thus, the present invention provides heparin affinity-purified alphavirus replicon particles containing attenuating mutations which are useful as clinical trial material and commercial product. The present invention also provides methods for preparing purified alphavirus replicon particles containing attenuating mutations comprising the use of heparin affinity chromatography, as described in the Examples provided herein. These particles can also be present in a composition of this invention.

The alphavirus replicon particles of this invention can also be made in a cell free system. Such replicon particles are herein referred to as virosomes. In a specific embodiment of the method, such particles are constructed from a mixture containing replicon RNA that does not encode all of the alphavirus structural proteins, purified glycoproteins E1 and E2, one or more non-cationic lipids, such as lecithin, and detergent. Detergent is slowly removed from the mixture to allow formation of lipid bilayers with incorporated RNA and glycoproteins.

In preferred embodiments of the methods of this invention, the glycoproteins E1 and E2 could be expressed in any recombinant protein expression system capable of glycosylation of mammalian proteins, such as stably transformed cell lines, for example CHO cells, or viral vector expression systems such as vaccinia, baculovirus, herpes virus, alphavirus or adenovirus. In a preferred embodiment, following expression of the proteins, the E1 and E2 glycoproteins are purified from contaminating cellular

proteins in the expression supernatant. The purification of these glycoproteins can be achieved by affinity chromatographic column purification, for example using lectin-, heparin- , or antibody-affinity columns. This affinity purification step may be preceded by selective precipitation or selective extraction from the expression system supernatant by methods including, but not limited to, ammonium sulfate precipitation or detergent extraction respectively. Final polishing steps of purification may include ion-exchange chromatography or buffer exchange, for example, and tangential flow methods to generate purified glycoproteins suitable for virosome assembly.

Thus, the present invention provides a method of producing alphavirus replicon virosomes, comprising: a) combining alphavirus replicon RNA, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and b) gradually removing detergent, whereby alphavirus replicon virosomes are produced. This method is described in more detail in the Examples section herein.

The present invention also provides alphavirus replicon virosomes comprising an alphavirus replicon RNA encapsidated by a lipid bilayer in which alphavirus glycoproteins are embedded. The replicon RNA can be from any alphavirus and the glycoproteins can be from any alphavirus. In a specific embodiment, the alphavirus glycoproteins are VEE E1 and E2. The advantage of the alphavirus replicon virosomes is the ease of preparation, their stability, and their purity, since they are devoid of any cellular components being made in a cell free system.

The helper cells, RNAs and methods of the present invention are useful in *in vitro* expression systems, wherein the inserted heterologous RNA located on the replicon RNA encodes a protein or peptide which is desirably produced *in vitro*. The helper cells, RNAs, methods, compositions and pharmaceutical formulations of the present invention are additionally useful in a method of administering a protein or peptide to a subject in need of the desired protein or peptide, as a method of treatment or otherwise.

It is contemplated that the nucleic acids, vectors and alphavirus replicon particles of this invention can be administered to a subject to impart a therapeutic or beneficial effect. Therefore, the nucleic acids, vectors and particles of this invention can be present in a pharmaceutically acceptable carrier. By "pharmaceutically acceptable" is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to a subject, along with the nucleic acid or vector of this invention, without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained. The carrier would naturally be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art (see, e.g., *Remington's Pharmaceutical Science*; latest edition).

Pharmaceutical formulations of this invention, such as vaccines, of the present invention can comprise an immunogenic amount of the alphavirus replicon particles as disclosed herein in combination with a pharmaceutically acceptable carrier. An "immunogenic amount" is an amount of the infectious alphavirus particles which is sufficient to evoke an immune response (humoral and/or cellular immune response) in the subject to which the pharmaceutical formulation is administered. An amount of from about 10^3 to about 10^7 replicon-containing particles, and preferably, about 10^4 to about 10^6 replicon-containing particles per dose is believed suitable, depending upon the age and species of the subject being treated. Exemplary pharmaceutically acceptable carriers include, but are not limited to, sterile pyrogen-free water and sterile pyrogen-free physiological saline solution.

Subjects which may be administered immunogenic amounts of the infectious, replication defective alphavirus particles of the present invention include, but are not limited to, human and animal (e.g., horse, donkey, mouse, hamster, monkey) subjects. Administration may be by any suitable means, such as intraperitoneal or intramuscular injection.

Pharmaceutical formulations for the present invention can include those suitable for parenteral (e.g., subcutaneous, intradermal, intramuscular, intravenous and intraarticular) administration. Alternatively, pharmaceutical formulations of the present invention may be suitable for administration to the mucous membranes of a subject (e.g., intranasal administration). The formulations may be conveniently prepared in unit dosage form and may be prepared by any of the methods well known in the art.

Thus, the present invention provides a method for delivering nucleic acids and vectors (e.g., alphavirus replicon particles; virosomes) encoding the antigens of this invention to a cell, comprising administering the nucleic acids or vectors to a cell under conditions whereby the nucleic acids are expressed, thereby delivering the antigens of this invention to the cell. The nucleic acids can be delivered as naked DNA or in a vector (which can be a viral vector) or other delivery vehicles and can be delivered to cells *in vivo* and/or *ex vivo* by a variety of mechanisms well known in the art (e.g., uptake of naked DNA, viral infection, liposome fusion, endocytosis and the like). The cell can be any cell which can take up and express exogenous nucleic acids.

Further provided herein is a method of inducing an immune response to an HIV antigen of this invention in a subject, comprising administering to the subject an immunogenic amount of the particles, virosomes and/or composition of this invention, in a pharmaceutically acceptable carrier.

A method of treating and/or preventing infection by HIV in a subject is also provided herein, comprising administering to the subject an effective amount of the particles, virosomes and/or compositions of this invention, in a pharmaceutically acceptable carrier.

The subject of this invention can be any animal in which an immune response can be induced or in which an infection by HIV can be treated and/or prevented. In a preferred embodiment, the subject of this invention is a mammal and most preferably is

a human.

Protocols and data regarding the testing of the compositions of this invention in animals and protocols for administration to humans are provided in the Examples herein.

In a particular embodiment, the present invention provides an isolated nucleic acid encoding a *pol* gene product or immunogenic fragment thereof of a human immunodeficiency virus, wherein the integrase, RNase H and reverse transcriptase functions of the *pol* gene product or immunogenic fragment thereof have been inactivated or deleted. Such a modification has been shown in some studies to facilitate inhibition of the formation of replication competent alphavirus particles during production of alphavirus replicon particles comprising the *pol* gene product or immunogenic fragment thereof.

Also provided herein is a composition comprising the *pol*-expressing nucleic acid described above, a vector comprising the nucleic acid and a cell comprising the vector. The *pol*-expressing nucleic acid can also be present in an alphavirus replicon particle comprising the nucleic acid.

As noted above, the nucleic acid encoding the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in the inhibition of reverse transcriptase activity. In a preferred embodiment, a mutation is introduced at the active site motif that results in inhibition of reverse transcriptase activity. Such a mutation may remove the DNA binding domain of the enzyme, for example. A mutation from YMDD to YMAA or HMAA at this motif is an example of such a mutation.

The present invention additionally provides a method of making an alphavirus replicon particle comprising nucleic acid encoding a *pol* gene product or immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or

immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions from the *pol* gene product or immunogenic fragment thereof, comprising

A) providing a helper cell for producing an infectious, defective alphavirus particle, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to delete or inactivate RNase H, integrase and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

(B) producing the alphavirus particles in the helper cell; and

(C) collecting the alphavirus particles from the helper cell.

In the method provided above, at least one of the replicon RNA, the first helper RNA, and the one or more additional helper RNA(s) can comprise one or more attenuating mutations, as described herein.

In a specific embodiment of this method, a mutation is introduced at the active site motif in the *pol* gene product or immunogenic fragment thereof that results in inhibition of reverse transcriptase activity. Such a mutation may remove the DNA binding domain of the enzyme, for example. A mutation from YMDD to YMAA or HMAA at this motif is an example of such a mutation.

Also provided herein is an alphavirus replicon particle expressing the *pol* gene product or immunogenic fragment thereof, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, produced according to any of the above methods.

In a further embodiment, the present invention provides a method of inducing an immune response in a subject, comprising administering to the subject an immunogenic amount of a composition comprising an alphavirus particle comprising nucleic acid encoding a *pol* gene product or immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, in a pharmaceutically acceptable carrier.

Furthermore, the present invention provides a method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an effective amount of a composition comprising an alphavirus particle comprising nucleic acid encoding a *pol* gene product or immunogenic fragment thereof

of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, in a pharmaceutically acceptable carrier.

In preferred embodiments of the methods of this invention, the subject is administered an effective amount of a population of alphavirus particles comprising particles expressing (1) nucleic acid encoding a *pol* gene product or immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in inactivation or deletion of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, (2) nucleic acid encoding a *gag* gene product or immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit release of *gag* gene product or the immunogenic fragment thereof from a cell, and (3) nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus in a pharmaceutically acceptable carrier.

In further preferred embodiments, the population of alphavirus particles comprises particles expressing (1) nucleic acid encoding a *gag* gene sequence that has at least 92% identity with SEQ ID NO:4; (2) nucleic acid encoding a *pol* gene sequence that has at least 99% identity with SEQ ID NO:15; and (3) nucleic acid encoding an *env* gene sequence with at least 95% identity with SEQ ID NO:18. In a specific embodiment, the population of alphavirus particles comprises particles expressing (1) nucleic acid of SEQ ID NO:4, (2) nucleic acid of SEQ ID NO:15, and (3) nucleic acid of SEQ ID NO:18.

EXAMPLES

The following examples are provided to illustrate the present invention, and

should not be construed as limiting thereof. In these examples, nm means nanometer, mL means milliliter, pfu/mL means plaque forming units/milliliter, VEE means Venezuelan Equine Encephalitis virus, EMC means encephalomyocarditis virus, BHK means baby hamster kidney cells, HA means hemagglutinin gene, N means nucleocapsid, FACS means fluorescence activated cell sorter, and IRES means internal ribosome entry site. The expression "E2 amino acid (e.g., lys, thr, etc.) number" indicates the designated amino acid at the designated residue of the E2 gene, and is also used to refer to amino acids at specific residues in the E1 protein and in the E3 protein, respectively.

EXAMPLE 1

VEE Replicon Particles as Vaccines

Replicon particles for use as a vaccine are produced using the VEE-based vector system, originally developed from a full-length, infectious cDNA clone of the RNA genome of VEE (Figure 1 in Davis *et al.*, 1989). In this Example, one or more attenuating mutations (Johnston and Smith, 1988; Davis *et al.*, 1990) have been inserted into the clone to generate attenuated VEE vaccine vectors (Davis *et al.*, 1991; 1995; Grieder *et al.*, 1995).

As described herein, these constructs are genetically modified to create an RNA replicon (i.e., an RNA that self-amplifies and expresses), and one or more helper RNAs to allow packaging. The replicon RNA expresses an HIV gene, e.g., the Clade C HIV-1 *gag* gene. The replicon RNA is packaged into virus-like particles (herein referred to as "virus replicon particles" or "VRPs") that are infectious for only one cycle. During this cycle, the characteristics of the alphavirus-based vector result in very high levels of expression of the replicon RNA in cells to which the VRP is targeted, e.g., cells of the lymph node.

In the cytoplasm of the target cell, the replicon RNA is first translated to

produce the viral replicase proteins necessary to initiate self-amplification and expression. In this Example, the HIV-1 Clade C *gag* gene is encoded by a subgenomic mRNA, abundantly transcribed from a negative-sense replicon RNA intermediate, leading to high-level expression of the HIV-1 Clade C *gag* gene product. Since the VEE structural protein genes are not encoded by the replicon RNA, progeny virion particles are not assembled, thus limiting the replication to a single cycle within the infected target cell.

Importantly, only the replicon RNA is packaged into VRPs, as the helper RNAs lack the *cis*-acting packaging sequence required for encapsidation. The "split helper" or bipartite system (see Example 4) greatly reduces the chance for an intact genome being assembled by recombination, and as a back-up safety feature, one or more highly attenuating mutations, such as those contained in the glycoprotein genes in V3014 (Grieder *et al.*, 1995), are incorporated.

Overall, the design of the VRPs incorporates several layered and redundant safety features. In addition to the above-described split helper system and attenuating mutations, over one-third of the genome of the virus has been removed, creating a defective genome which prevents spread from the initially infected target cell. Nonetheless, if a statistically rare recombination event occurs to yield replication competent virus (RCV), the resulting virus would be a highly attenuated VEE strain.

EXAMPLE 2

Construction of VEE Replicon

The VEE structural protein genes (C-PE2-6K-E1) are removed from a cDNA clone (pV4031) which contained two attenuating mutations (E2 lys 209, E1 thr 272), and a duplication of the 26S subgenomic RNA promoter sequence immediately downstream from the 3'-end of the E1 glycoprotein gene, followed by a multiple cloning site as described in U.S. Pat. No. 5,505,947 to Johnston *et al.* The pV4031

plasmid DNA is digested to completion with ApaI restriction enzyme, which cuts the VEE genomic sequence at nucleotide 7505 (numbered from the 5'-end of the genome sequence). A second recognition site for this enzyme is found in the duplicate 26S subgenomic promoter. Therefore, digestion of pV4031 with ApaI produces two DNA fragments, one containing the VEE nonstructural genes (e.g. SEQ ID NO:2) and a single copy of the 26S subgenomic RNA promoter followed by a multiple cloning site, and a second smaller fragment containing a 26S subgenomic RNA promoter followed by the VEE structural genes. The large fragment is isolated and religated to produce the replicon, pVR2. In this example, as well as in the construction of the helper plasmids (Example 3), a kanamycin resistance gene (SEQ ID NO:6, encoding amino acid sequence as in SEQ ID NO:7) is present in the plasmids to aid in the cloning manipulations.

EXAMPLE 3

Construction of Helper Plasmids

The starting materials for the helper plasmids are four full-length cDNA clones: V3000, the virulent Trinidad donkey strain of VEE, three clones with attenuating mutations, pV3014 (E2 lys 209, E1 thr 272), V3519 (E2 lys 76, E2 lys 209, E1 thr 272) and V3526 (deletion of E3 56-59, E1 ser 253), which are in the genetic background of Trinidad donkey strain VEE. Several different helper plasmids have been made by using unique or rare restriction sites in the full-length cDNA clone to delete portions of the nonstructural protein region. The full-length clone is digested with one or two restriction enzymes, the larger DNA fragment is isolated and then religated to form a functional plasmid. *In vitro* RNA transcripts from these plasmids upon transfection of tissue culture cells would not encode a functional RNA replication complex, and also would not include an encapsidation signal. The helper constructs differ in the size of the nonstructural gene deletion. The helper constructs are designated by the attenuated mutant clone used in their construction, and by the percentage of the nonstructural region deleted. The following helper constructs were generated:

V3014Δ520-7507(93%)
V3519Δ520-7507(93%)
V3526Δ520- 7505(93%)
V3014Δ520-6965(87%)
V3519Δ1687-7507(78%)
V3014Δ2311-7505(70%)
V3519Δ3958-7507(47%)
V3526Δ520-7505(93%)
V3014Δ3958-7505(47%)
V3519Δ1955-3359(19%)
V3014Δ520-3954(46%)
V3014Δ1955-3359(19%)
V3014Δ1951-3359(19%)
V3014Δ2311-3055(10%)
V3014Δ2307-3055(10%)

EXAMPLE 4

Construction of Bipartite RNA Helper Plasmids

A bipartite helper system is constructed as described herein. The V3014Δ520-7505(93%) helper is used to construct an additional deletion of the E2 and E1 glycoprotein genes by digestion with HpaI restriction enzyme and ligation, resulting in deletion of the sequence between nucleotide 8494 (in the E3 gene) and nucleotide 11,299 (near the 3'-end of the E1 gene). *In vitro* RNA transcripts of this glycoprotein helper plasmid (presented graphically in Figure 2; an exemplary nucleotide sequence for such a plasmid is SEQ ID NO:8, including the nucleotide sequence (SEQ ID NO:9 and the amino acid sequence (SEQ ID NO:10 of the VEE capsid), when electroporated into BHK cells with a replicon RNA, are replicated and transcribed to give a mRNA encoding only the capsid protein of VEE.

The second member of the bipartite helper is constructed from the same original helper plasmid 3014Δ5207505(93%) by cleavage with Tth111I restriction enzyme (at nucleotide 7544) and SpeI restriction enzyme (at nucleotide 8389), resulting in deletion of the capsid gene, followed by insertion of a synthetic double-stranded oligonucleotide with Tth111I and SpeI termini. The inserted sequence restored the downstream portion of the 26S promoter and an ATG initiation codon followed by a Ser codon, such that the first amino acid residue of E3 (Ser) is the first codon following the inserted AUG. The resulting glycoprotein helper plasmid is presented graphically in Figure 3, and an exemplary nucleic acid sequence for such a plasmid is SEQ ID NO:11, encoding the VEE glycoproteins (E3-E2-6kD-E1), SEQ ID NO:12. The *in vitro* transcript of this plasmid, when transfected into a cell with replicon RNA, will produce the VEE glycoproteins (SEQ ID NO:13). Co-electroporation of both of these helper RNAs into a cell with replicon RNA results in production of infectious particles containing only replicon RNA.

Other than the 5' and 3' ends and the 26S promoters (40 nucleotides) of these helper RNAs, the only sequence in common between the capsid and glycoprotein helpers is the sequence from 8389 to 8494 (106 nucleotides)

EXAMPLE 5

VEE REPLICON PARTICLES EXPRESSING HIV GENES

The vaccines of this invention are exemplified by the use of a propagation defective, replicon particle vector system derived from an attenuated strain of Venezuelan equine encephalitis virus (VEE) to create a mixture of VEE replicon particles individually expressing HIV-1 *gag*, *pol*, or *env* genes. The three genes used in this Example were selected based on homology to consensus sequences generated from primary isolates obtained from recent seroconverters in Kwazulu/Natal. Plasma samples from approximately 20 recent seroconverters in the Durban/Hlabisa cohort and a similar number of HIV-positive, asymptomatic individuals were collected. HIV viral

RNA was isolated from the plasma, and the sequences of the *gag*, *pol* and *env* genes were analyzed. Two regions from each gene were amplified, and the resulting PCR products were sequenced (see Figure 10 for regions analyzed). A consensus sequence was derived for each gene, and the sequences of each isolate were compared to the derived consensus. All isolates were found to be Subtype C of HIV, thus confirming the predominance of this subtype in South Africa.

A. CONSTRUCTION OF THE Gag-VRP VACCINE

Described herein is the design and manufacture of VEE replicon particles (VRPs) engineered to express the *gag* gene from a Subtype C isolate of HIV-1. The main purpose of this single antigen vaccine is to establish a safety profile for VRPs in healthy human subjects. Optimally, the HIV-Gag-VRPs will be formulated as a component of a trivalent vaccine, also containing HIV-Pol-VRP and HIV-gp160-VRP (*env*) made in analogous procedures to the one described herein for HIV-Gag-VRPs.

In this Example, the VEE particles are based on the V3014 glycoprotein helper plasmid (Figure 3, SEQ ID NO:12 and SEQ ID NO:13), which harbors two highly attenuating mutations, one in E2 and the other in E1 (Grieder *et al.*, 1995). The V3014 glycoprotein helper RNA is able to package VRPs with significantly greater efficiency than the glycoprotein helper RNA derived from V3526 (Pushko *et al.*, 1997). Nonetheless, safety of the VRP vector system has not been compromised since detailed pathogenesis studies clearly have shown V3014 to be avirulent in adult mice by subcutaneous inoculation (Grieder *et al.*, 1995). V3014 was found to be significantly impaired in its ability to reach and spread beyond the draining lymph node following subcutaneous inoculation. Unlike wild-type V3000, V3014 does not establish a viremia and does not reach the brain. In addition, on rare occasions when found, histopathological lesions in the periphery were much less severe than those induced by wild-type V3000 (Grieder *et al.*, 1995). Following inoculation with V3014, adult mice are protected against lethal wild-type VEE infection.

The attenuated phenotype of V3014 also was observed in VEE challenge studies in horses. Animals inoculated subcutaneously with V3014 showed no significant leukopenia or febrile response compared to mock-vaccinated controls. In addition, results indicated that these animals were completely protected against virulent VEE (V3000) challenge.

Taken together, these data indicate that if the rare recombination event did occur during VRP assembly to yield RCV, the worst case scenario would be the generation of a highly attenuated strain of VEE.

B. SELECTION AND CLONING OF THE HETEROLOGOUS ANTIGEN

The exemplary HIV genes used in this invention, *gag*, *pol* and *env*, are derived from Subtype C (Clade C) viruses isolated from likely Phase III clinical trial sites in South Africa. The HIV infection rate in South Africa and its long established virology and public health infrastructure make this country an attractive choice for clinical testing of HIV vaccines. Focused sequencing and phylogenetic analysis of the *gag*, *pol*, and *env* genes of these isolates has allowed the selection of genes representative of the Clade C isolates circulating in this region of Africa.

1. HIV-1 Clade C *gag* gene

Two 400 bp regions of the *gag* gene were sequenced from approximately 30 plasma samples collected from HIV seropositive individuals in South Africa. A South African consensus sequence was then determined for the *gag* gene as well as a consensus sequence from the Los Alamos database for Subtype C virus. In addition, approximately 20 comparable sequences from Malawi were used, generated as part of another study, to confirm conclusions about sequence variation. Several isolates that were close to the South African consensus sequence were compared to other isolates in distance measurements. Among these 30 isolates, one was chosen as the source for the *gag* gene (SEQ ID NO:4; corresponding to the amino acid sequence in SEQ ID NO:5)

for the following reasons.

This isolate had greater than 95% amino acid identity to the South African consensus sequence, representing the approximate middle of the sequence diversity of all isolates. This isolate, known as DU422, came from a recent seroconvertor, reflecting currently circulating strains and the transmitted phenotype. The phenotype of DU422 is NS1, CCR5(+), and CXCR4(-).

Prior to the insertion of the *gag* gene into the VEE replicon plasmid vector, the amino terminal myristylation ("myr") site of *gag* was removed to prevent the formation of Gag-containing virus-like particles. Restriction enzyme digests of the *gag* gene plasmid, the capsid helper plasmid, and the glycoprotein helper plasmid were performed to confirm the identity of the three vectors when compared to published maps of the parental plasmid pBR322, with the kanamycin resistance gene substituted for the ampicillin resistance gene. The confirmed plasmid maps of the VEE replicon plasmid containing the DU422 *gag* gene (p3-40.1.6), the capsid helper plasmid (p3-13.2.2), and the glycoprotein helper plasmid (p3-13.4.6) are presented in Figures 1, 2, and 3, respectively. The full nucleotide sequence of each of these plasmids is presented herein as SEQ ID NO:1, SEQ ID NO:8, and SEQ ID NO:11, respectively.

In Figures 6 and 15, expression of this HIV-1 Gag protein in BHK cells infected with VRPs expressing such a *gag* construct is demonstrated (Figure 6: Western blot, lane 3; Figure 15, immunofluorescence detection). The cells were infected at a multiplicity of infection (m.o.i.) of 3.5 infectious units (i.u.) per cell, and expression was measured 18 hours post-infection (p.i.). Cell lysates (from approximately 2 x 10^3 cells) were collected and fractionated either by a 4-12% gradient SDS-PAGE or by 10% SDS-PAGE. The fractionated polypeptides were transferred to PVDF membranes and probed with human HIV-1 positive serum.

2. HIV-1 Clade C *env* gene

A Clade C *env* gene (aka "gp160") from another HIV isolate, DU151, from a recent seroconverter was chosen based on its 92% amino acid identity to the South African consensus sequence for this gene, determined in an analogous method to the one described for the *gag* gene in Example 5.A.1. The phenotype of the DU151 isolate is NS1, CCR5(+), CXCR4(-). This gene was engineered into a VEE RNA replicon plasmid as shown in Figure 5, and the entire sequence of the plasmid is given at SEQ ID NO:17. The *env* gene construct used in this Example is SEQ ID NO:18.

In Figure 6, expression of this ENV protein (SEQ. ID. NO:19) in BHK cells infected with VRPs expressing this HIV *env* construct is demonstrated (Western blot, lane 2), showing that the protein expressed in the cells is of the correct size and is immunoreactive. In Figure 7, expression of this ENV protein in U87.CD4.CCR5 cells is shown. These cells process the ENV protein into two components, GP120 and GP41. In these cells, the expressed GP160 is fusogenic (see Figure 8).

3. HIV-1 Clade C *pol* gene

A Clade C *pol* gene from isolate DU151 was chosen based on its 99% amino acid identity with the South African consensus sequence. This gene was modified at the active site of the reverse transcriptase encoding sequence to inhibit its activity, and the p51 fragment of this modified gene (SEQ ID NO:15) was engineered into a VEE RNA replicon plasmid. The map of this *pol* plasmid is shown in Figure 4, and the nucleotide sequence of the plasmid is provided as SEQ ID NO:14. In Figure 6, expression of this POL p51 fragment (SEQ ID NO:16) in BHK cells is demonstrated (Western blot, lane 1), showing that the protein expressed in these cells is both the correct size and immunoreactive.

C. IMMUNOLOGICAL RESPONSE TO VRP-GAG VACCINE

Mice were injected subcutaneously in two doses, with 8-9 mice in each group. The mice were immunized once, then immunized a second time, with the same dose, 28 days later. Serum was collected the day prior to the first immunization, then at day 27 ("after 1st immunization) and at day 35 (after 2nd immunization).

The vigorous, antigen-specific humoral response of mice to the HIV-1 Clade C VRP-gag vaccine described in Example 5.A.1. is presented in Table 1. Details of this assay are described in Example 7A.1.

TABLE 1. Humoral Response to VRP-gag Vaccine

Dose:	Total Ab Titer (log_{10})
10^3 i.u. dose:	
after 1st immunization	1.3 +/- 0.1
after 2nd immunization	2.8 +/- 1.1
10^5 i.u. dose	
after 1st immunization	2.1 +/- 0.5
after 2nd immunization	4.1 +/- 0.6

The vigorous, antigen-specific CTL response in mice to the HIV-1 Clade C VRP-gag vaccine (Example 5.A.1) is presented in Figure 9. Details of this assay are described in Example 7A.3.

EXAMPLE 6

MANUFACTURING PROCESS FOR HIV VRP VACCINES

A. Manufacturing Process

Disclosed herein is a manufacturing process for VRP vaccines that is suitable for large-scale preparation of GMP-compliant (GMP = Good Manufacturing Practices) material for use in human clinical trials or for commercial manufacture. The process includes several steps and after each step (as appropriate), a set of "in process control" (IPC) assays or Release Tests (RT) is performed to confirm the successful completion of the step. The process steps and the accompanying IPC assay(s) or RTs (described in more detail in Example 6D.1 and 6D.2) are as follows:

Process Step	IPC/RT
Linearize 3 DNA plasmids	IPC: Check for linearity
In vitro RNA transcription	IPC: Size, integrity and concentration
Electroporation of certified Vero cell line	
Harvest culture fluids	IPC: Titration/Identity Test for replication-competent virus (RCV)
Pool the culture fluid	RT: Mycoplasma Adventitious virus PERT assay
Purification of bulk VRP by heparin affinity chromatography	IPCs: Heparin residual assay BSA assay Bovine IgG assay

Filtration of bulk VRP	RT: Test for RCV Titration/Identity Contaminating protein/DNA Sterility Endotoxin
Formulate, Fill, Release	RT: Titration/Identity Sterility General Safety

B. Preparation of plasmid DNAs

Stock solutions of replicon plasmid DNA, capsid helper plasmid DNA and glycoprotein helper plasmid DNA are produced in *Eschericia coli* XL2 Blue cells (Stratagene, cat# 200150). All plasmids harbor the kanamycin resistance gene marker. The three plasmid DNAs were manufactured and purified by PureSyn, Inc. (Malvern, PA) under appropriate GLP/GMP procedures, with a complete Batch Record with full traceability. Following fermentation and cell harvest, cell paste was lysed with base and plasmid DNAs were purified by ion pair chromatography on PolyFlo^{TM} separation media.

Prior to release by appropriate quality assurance/quality control oversight, each lot of each plasmid DNA is analyzed to confirm identity, purity and quality (Table 2). An approved certificate of analysis for each DNA is then established for each plasmid DNA lot.

Table 2. Plasmid DNA Release Tests

Test	Method	Specification
DNA homogeneity	Agarose gel electrophoresis	>90% supercoiled
E. coli genomic DNA	Southern Blot	<50 μg/mg plasmid
E. coli RNA	Agarose gel electrophoresis	No detectable bands
Endotoxin	Limulus Amoebocyte Lysate (LAL)	< 0.1 EU/mg
Total protein	Abs 260/280	1.8-1.9
Sterility	Bioburden assay, USP23	< 1 CFU
Identity	Restriction enzyme analysis	Matches map

To produce HIV-VRP vaccine for clinical use, both replicon and helper plasmids are linearized by digestion at the unique Not I site and used as templates for synthesis of run-off transcripts. The quality of the transcription products (i.e., the replicon and the two helper RNAs) is evaluated by agarose gel electrophoresis.

C. Characterization of the Vero cells

Vero cells are used in the production of HIV-VRPs (WHO Vero MCB P139, BioReliance Inc., Rockville, MD). Vials contained approximately 1 x 10^7 cells/mL in a cryoprotectant solution of 90% fetal bovine serum and 10% dimethyl sulfoxide. A Cell Certification Summary is provided with each lot. BioReliance Inc. has filed a Master File with the FDA regarding the WHO Vero MCB P139.

Vials of WHO Vero MCB P139 cells are expanded into flasks. Each of the flasks is then expanded again in order to prepare the Master Cell Bank (MCB). The Working Cell Bank (WCB) is prepared from the MCB. The MCB is tested for purity and identity. The WCB is tested for adventitious agents (detection of mycoplasma and viruses). Viability tests are performed on both the MCB and the WCB.

Tumorigenicity tests are performed once at the end of the production period.

D. Electroporation

Vero cells are cotransfected by electroporation with RNA mixtures comprising replicon RNA transcripts encoding HIV-gag, VEE capsid helper RNA transcripts, and VEE glycoprotein helper RNA transcripts. The transfected cells are transferred to tissue culture vessels and incubated in well-defined culture medium. Following harvest, the HIV-Gag-VRP is purified from pooled culture fluid supernatants by affinity column chromatography. Prior to formulation and filling, purified, bulk HIV-Gag-VRP is tested for the presence of RCV.

E. Final formulated product

The HIV-Gag-VRP vaccine is vialed at four different doses. The material is filtered (0.22 μm) and added to vials at the appropriate concentration and volume, stoppered, quick-frozen and stored at –20° C.

F. Control tests of the Gag-VRP vaccine

1. In-Process Controls

Table 3 below summarizes the In-Process Controls performed during the manufacturing process of the HIV-Gag-VRP Vaccine.

Table 3. IPCs during the manufacture of HIV-Gag-VRP Vaccine

Test	Method	Target
Check for linearity	Agarose Gel electrophoresis	Report
Size, integrity and concentration of RNAs	Agarose Gel electrophoresis	Report
Titration/Identity	Indirect immunofluorescence assay(IFA), using standardized Gag-specific antibody preparation	Report
Test for RCV	CPE Assay	Report
Heparin Residual	Chromogenic Inhibitory Assay	Report
BSA residual	ELISA	Report
Bovine IgG Residual	ELISA	Report

2. Release tests

Tables 4 and 5 below summarize the release tests performed on the HIV-Gag-VRP Vaccine.

Table 4. Pool of the Culture Fluids

Test	Method	Target
Adventitious Virus (*in vivo*)	European guidelines	Negative
Adventitious Virus (*in vitro*)	5 cell lines	No growth
Mycoplasma	21CFR 610.30	No Growth
Reverse Transcriptase	PERT Assay	Negative

Table 5. Bulk VRP and Final Vial testing

Test	Method	Target Result
Replication competent virus (RCV)	Cytopathic effect (CPE) assay	Absence (in BHK cells, sensitivity is 1-10 pfu V3014)
VRP identity/ potency	Indirect immunofluorescence assay (IFA)	10^6 to 10^8 i.u. per mL
Cellular Protein Contaminant	Bio-Rad® DC protein assay	Total protein content per dose
Cellular DNA Contaminant	Southern Blot or PCR	< 10 ng per dose
Sterility	21 CFR § 610.12	Pass

Endotoxin	LAL	< 5 EU/dose
General Safety	21 CFR § 610.11	Pass
Particulates	USP	Pass
Stability	IFA	10^6 to 10^8 i.u. per mL

EXAMPLE 7

PRECLINICAL STUDIES

Pilot lots are manufactured following written procedures (SOPs and STMs) and according to the manufacturing scheme described in Example 6. These pilot lots are prepared and used for two major tasks. The first one is a preclinical immunogenicity evaluation, which includes studies to assess the immune response and the cell-mediated immune response in vaccinated animals. The second major task is a preclinical safety evaluation, which includes evaluations of system toxicity, hematopoietic and immune system toxicity, and local reactogenicity.

Finally, an *in situ* hydridization study is performed in mice in order to verify the *in vivo* expression of HIV-Gag-VRP gene product in lymphoid tissue.

A. Immunogenicity Studies

A.1 Humoral Immune Response in Mice

Three groups of five female BALB/c mice (4-6 weeks of age) are inoculated subcutaneously with 10^5, 10^6, or 10^7 i.u. of the HIV-Gag-VRP at three time points: on day 0, and at weeks 4 and 8. The fourth group, Control Group, receives the vehicle only. Immediately prior to inoculation, and at weeks 3, 5, 8 and 10 post-inoculation,

blood samples are collected for humoral immune response evaluations. Gag protein-specific serum antibody titers and seroconversion rates are measured by ELISA (Caley *et al.*, 1997) against purified, recombinant Gag protein. The source of the antigen is the homologous Clade C *gag* gene expressed in insect or mammalian cells. Antigen specificity also is confirmed by immunoblot analysis. Anti-VEE responses are monitored by ELISA (Johnston and Smith, 1988).

A.2 Humoral Immune Response in Rabbits

Three groups of five female New Zealand white rabbits are inoculated subcutaneously with 10^5, 10^6, or 10^7 i.u. of the HIV-Gag-VRP. The fourth group, Control Group, receives the vehicle only. Immediately prior to inoculation, and at weeks 3, 5,8 and 10 post-inoculation, blood samples are collected for humoral immune response evaluations.

Humoral immune responses are evaluated as described in Section A.1.

A.3 Cell-Mediated Immune Response in Mice

Three groups of five female BALB/c mice are inoculated subcutaneously with 10^5, 10^6, or 10^7 i.u. of the HIV-Gag-VRP at day 0 and day 28. The fourth group, Control Group, receives the vehicle only. Blood samples are collected at week 3 post-inoculation. Spleens are harvested for splenocyte collection on day 7 following the second inoculation for evaluation of cell-mediated immune responses.

The cell-mediated immune response is evaluated by determining the ability of splenic T cells from immunized mice to proliferate *ex vivo* in the presence of either Gag protein or Gag peptide(s). The ability of splenic T and CD4+ T cells to produce interferon-γ and interleukin-4 respectively, is determined. Finally, the ability of cytotoxic T lymphocytes to lyse target cells that present murine major

histocompatibility complex class-I restricted epitopes for HIV-1 Clade C Gag protein is measured (see Betts *et al.*, 1997 for methods)

B. Safety Study

Three groups of six male and six female New Zealand white rabbits are inoculated subcutaneously with 10^4, 10^6, or 3 x 10^7 i.u. of the HIV-Gag-VRP. The fourth group, Control Group, receives the vehicle only. Animals receive four injections at week 0, week 3, week 6 and Week 9. Half of the animals are sacrificed two days after the last injection (week 9) and the other half at three weeks after the last injection (week 12). Similar studies are performed in mice with a high dose at 10^8 i.u. This level is 100 times the likely primate dose, based on efficacy studies in rhesus macaques.

In addition to system toxicity (record of mortality/morbidity, body temperature, body weight, food consumption and ophthalmic examinations), hematopoietic toxicity is evaluated by quantitating cellular components of peripheral blood, and immune system toxicity is assessed by histopathologic evaluation of the lymphoid organs. Local reactogenicity is evaluated by examining the injection sites grossly and microscopically to determine irritation potential. Serum samples are also tested for the presence of replication competent virus by blind passage in cell culture.

C. In *Situ* Hybridization Study in Mice

Three groups of five female BALB/c mice are inoculated subcutaneously with 10^5, 10^6, or 10^7 i.u. of the HIV-Gag-VRP. The fourth group, Control Group, receives the vehicle only. A single injection is performed in each group.

To verify expression of HIV-GAG-VRP in lymphoid tissue, the draining lymph nodes, spleen, and thymus of the mice are examined by *in situ* hybridization at 24 hours and 48 hours after the single inoculation.

EXAMPLE 8

Heparin Affinity Chromatography of VRPs

Generally, the majority of contaminating protein is non-VEE protein from the conditioned media. Heparin column capacity requirements for GMP manufacturing runs are therefore based on the volume of conditioned media, rather than the concentration of VRPs. Column parameters are optimized at room temperature, but variations in temperature do not greatly affect performance. The expected yields of VRPs can range from 50% to > 90%.

While only minimal leaching of heparin from the columns has been detected, GMP requirements stipulate that a residual heparin assay be performed as an IPC test following the chromatography step.

A. Pharmacia HiTrap® Heparin

Five mL columns of Pharmacia HiTrap® Heparin (cat no. 17-0407-01, Amersham Pharmacia Biotech), pre-equilibrated with 25 mM HEPES/0.25 M NaCl, pH 7.5, were loaded with HIV-Gag-VRPs produced in Vero cells. After column washing with the equilibration buffer, VRPs were eluted with a 15 column volume gradient from 0.25 – 1.0 M NaCl gradient in 25 mM HEPES, pH 7.5. The HIV-Gag-VRPs eluted at a conductivity of approximately 48 mS/cm. The wash step was optimized (based on the A_{280} peak) at a NaCl concentration between 0.25 M and 0.3 M.

B. Heparin Sepharose 6 Fast Flow® resin

Heparin Sepharose 6 Fast Flow® resin (catalog no. 90-1000-2; Amersham Pharmacia Biotech) is supplied as a bulk resin which allows various size columns to be packed as needed. Fast Flow® resins have the advantages of excellent flow

characteristics and ability to be sanitized with sodium hydroxide solutions, which are particularly useful in a GMP manufacturing process. A 6 mL column was prepared by packing the Heparin Sepharose 6 Fast Flow® bulk resin in a BioRad® Econo-Column chromatography column, which was then pre-equilibrated with 25 mM HEPES/0.12 M NaCl, pH 7.5. VRPs were loaded onto the column, which was then washed with the equilibration buffer. Initial experiments indicated that the VRPs eluted at a lower conductivity (36 mS/cm) with this resin as compared to the HiTrap® Heparin, so the wash conditions were modified accordingly. The VRPs were eluted from the Fast Flow® resin with a 15 column volume gradient from 0.12 M to 1 M NaCl in 25 mM HEPES, pH 7.5.

EXAMPLE 9

Virosome Formation

The feasibility of virosome formation is demonstrated in a series of experiments in which replicon RNA and RNA encoding the glycoprotein E1 and E2 genes (glycoprotein helper) were first transfected into BHK cells by electroporation. After 18-24 hours, cell supernatants were harvested and tested for the presence of virosomes as described briefly below.

Cell Culture

BHK cells were used as a cell substrate and were maintained in growth medium (alpha-MEM (Life Technologies), supplemented with 10% Fetal Bovine Serum (HyClone), 1x Glutamine (Life-Technologies)), in an atmosphere of 5% CO_2 at 37°C. Prior to electroporation, cells were detached from the cell culture vessel using 0.05% trypsin-0.53 mM EDTA solution (Life Technologies). Trypsin was neutralized with growth medium, and cells were washed twice with cold Phosphate-Buffered Saline (PBS, BioWhittaker) and resuspended at a concentration of 1.5×10^7 cells/ml.

RNA Transcription, Electroporation and Virosome Harvest

Plasmid DNA pVR-GFP (green fluorescent protein) was linearized using restriction endonuclease NotI (New England Biolabs) as recommended by the manufacturer. DNA was extracted with phenol:chloroform:iso-amyl alcohol (25:24:1, Gibco BRL) and precipitated with ethanol, following the addition of NH_4Ac to 2.5 M final concentration. RNA was synthesized in an *in vitro* transcription reaction using an mMessage mMachine® kit (Ambion) as recommended by the manufacturer. This RNA, without further purification, was used to transfect BHK cells. Helper RNA was prepared in a similar fashion. A BHK cell suspension in PBS (0.8 mL, 1.2×10^7 cells) was mixed with 10 µg of each RNA, and the mixture was electroporated. Electroporation settings for Gene-Pulser® (Bio-Rad Laboratories) were: 850 V, 25 µF, 3 pulses. Culture supernatant was collected at 18-24 hr post-electroporation and clarified by centrifugation for 10 min at 1000 rpm.

Titration of Virosomes

The presence of infectious virosome particles was demonstrated using an immunofluorescence assay to titer the virosomes by detecting the fluorescence of the GFP encoded by the replicon RNA in the virosomes. Serial dilutions of the cell culture supernatant were added to 12-well plates of BHK cells. Following an 18-24 hour incubation in an atmosphere of 5% CO_2 at 37°C, the medium was removed from each plate. Virosome infectious titer was then determined by counting the number of green-fluorescent single cells at a particular dilution, followed by a back-calculation to determine total infectious units (i.u.) per mL. A final titer of 440 i.u./mL was collected.

Confirmation of virosome identity

Three independent experimental methods were used to determine that the infectious particles were in fact virosomes, rather than replication competent viral

particles or naked RNA being carried over from the electroporated cells.

i) The virosome-containing supernatant was passaged a second time by removing the cell supernatant from the 12-well plate used for titration and placing this supernatant onto a fresh monolayer of BHK cells. At 18-24 hours post-passage, the monolayer was examined under U/V fluorescence and found to contain 0 (zero) GFP-positive cells, indicating the infectious particles produced using this method can undergo only a single round of replication, a critical characteristic of a virosome.

ii) To establish that the infectious titer detected following virosome packaging was not due to carry-over of RNA used in the electroporation, the supernatant was treated with RNase A (Invitrogen) at a concentration of 100 μg/μL for 15 minutes at 37°C. The treated and untreated control supernatants were titered according to the methods outlined above. The RNase-treated sample contained 400 i.u./mL and the control group had 440 i.u./mL, indicating that the RNAse treatment had no significant effect on virosome titer.

iii) To establish that the infectious particles were enveloped in the E1 and E2 glycoproteins, anti-VEE mouse serum was used to treat the cell supernatant in a neutralization assay. As a control, normal mouse serum was used to treat the virosome supernatant. In addition, VEE replicon particles expressing GFP were used in the assay, the infectivity of which is known to be inhibited by this serum.

	Particle Titer (i.u./mL)		
	Anti-VEE serum	Normal Mouse Serum	No ser
Virosome Supernatant	20	440	530
VRP-GFP	0	530	890

The infectivity of the virosomes was inhibited similar to that of VRP-GFP,

indicating that the virosome particles were enveloped by the E1 and E2 glycoproteins.

These examples clearly demonstrate the ability to produce infectious virosome particles comprising replicon RNA enveloped with only the alphavirus E1 and E2 glycoproteins. Testing confirmed that these virosomes are infectious agents, but that they undergo only a single round of replication, as indicated by the inability to passage the agent. In addition, the agents contained the E1 and E2 glycoproteins, as evidenced by the ability to block infection with only VEE specific serum. Finally, the infectious RNA is protected from RNase enzymatic digestion, indicating an enveloped particle.

The natural lipid content in BHK cells is primarily non-cationic. Virosomes made in a completely cell free system can be made by using one or more non-cationic lipids, such as lecithin (phosphatidycholine).

EXAMPLE 10

PHASE I CLINICAL PROTOCOL

Phase I Safety and Immunogenicity Trial of an HIV Subtype C Gag-VEE Replicon Particle Vaccine in HIV-1 Seronegative Human Subjects

A Phase I trial is conducted to evaluate the safety and immunogenicity of the HIV Gag-VRP prototype vaccine component in healthy seronegative adult volunteers. The doses are selected based on preclinical studies in rodents and nonhuman primates. The schedule mimics previous preclinical efficacy studies with the SIV model that demonstrated the capacity of SIV-VRP to induce SIV specific neutralizing antibodies and CTL.

Purpose: To evaluate the candidate vaccine component in an open-labeled, placebo-controlled study.

Subjects: Healthy adult volunteers without a history of identifiable high-risk behavior for HIV-1 infection as determined by a comprehensive screening questionnaire.

No. Subjects: **40**

Route: Subcutaneous injection

Scheme: The volunteers are arranged in four groups, ten subjects per group. In each group, two subjects receive a placebo, while the other eight subjects receive either 10^4, 10^6, 10^7, or 10^8 i.u. of HIV-Gag-VRPs. Subjects are vaccinated on day 0, day 30, and day 120.

Estimated Duration: Forty weeks

A. SELECTION of SUBJECTS

Subjects are healthy HIV-1 seronegative adults who fully comprehend the purpose and details of the study as described in the informed consent. Subjects whom either themselves or whose sexual partners have identifiable higher risk behavior for HIV-1 infection are not eligible. Higher risk behavior is determined by a prescreen series of questions designed to identify risk factors for HIV-1 infection. An assessment of absolute exclusion criteria using the self-administered and interview questions is conducted. Subsequently, investigators proceed with phlebotomy, history and physical examination, and final questions regarding sexual behavior and other practices. Eligibility determinations for the trial depend on results of laboratory tests and answers to these self-administered and interview questions.

The criteria used to define low risk behavior are as follows:

EITHER ALL OF THE FOLLOWING:

1. No newly acquired higher risk associated STD in the last six months
2. No possibly safe or unsafe sex with a known HIV+ individual or an active

injection drug user in the past six months

3. No unsafe sexual activity

4. Possibly safe sexual activity with two or fewer partners within the last six months

5. No injection drug use

OR BOTH OF THE FOLLOWING:

1. Mutually monogamous relationship with a known or presumed HIV seronegative partner for the last six months

2. No injection drug use

A.1 Inclusion Criteria

Age: 18-60

Sex: Male or Female *[For females, negative pregnancy test at time of entry and assurance that adequate birth control measures will be used for one month prior to immunization and the duration of the study]*

Normal history and physical examination

Lower risk sexual behavior as defined above.

Normal complete blood count and differential defined as:

- Hematocrit 34% for women; 38% for men
- White count 3500 cells/mm^3 with normal differential
- Total lymphocyte count 800 cells/mm^3
- Absolute CD4 count 400 cells/mm^3
- Platelets (150,000-550,000)

Normal ALT (~ 1.5 x institutional upper normal limit) and creatinine (1.6 mg/dl)

Normal urine dipstick with esterase and nitrite

Negative for hepatitis B surface antigen

Negative ELISA for HIV within eight weeks of immunization

Availability for follow-up for planned duration of the study (68 weeks)

A viable EBV transformed autologous B cell line

A.2 Exclusion Criteria

History of immunodeficiency, chronic illness, malignancy, autoimmune disease, or use of immunosuppressive medications

Medical or psychiatric condition or occupational responsibilities which preclude subject compliance with the protocol

Subjects with identifiable higher risk behavior for HIV infection as determined by screening questionnaire designed to identify risk factors for HIV infection; specific exclusions include:

History of injection drug use within the last 12 months prior to enrollment.

Higher risk sexual behavior defined as one or more of the following behaviors:

1. A newly acquired higher risk associated STD within the past six months
2. Possibly safe or unsafe sex with a known HIV+ individual in the past six months
3. Possibly safe sexual activity with twelve or more partners in the past six months
4. Unsafe sexual activity with four or more partners within the past six months.

Live attenuated vaccines within 60 days of study [NOTE: Medically indicated subunit or killed vaccines (e.g., influenza, pneumococcal) are not exclusionary, but should be given at least two weeks away from test article immunizations.]

Use of experimental agents within 30 days prior to study

Receipt of blood products or immunoglobulin in the past six months

Active syphilis [NOTE: If the serology is documented to be a false positive or

due to a remote (>six months) treated infection, the volunteer is eligible]

Active tuberculosis [NOTE: Volunteers with a positive PPD and a normal chest X-ray showing no evidence of TB and not requiring INH therapy are eligible.]

History of anaphylaxis or other serious adverse reactions to vaccines

Prior receipt of HIV vaccines or a placebo recipient in an HIV vaccine trial

Pregnant or lactating women

B. SAFETY and IMMUNOGENICITY MONITORING

Safety is evaluated by monitoring volunteers for adverse reactions during the course of the trial. Volunteers are followed for a total of 26 weeks post-final inoculation. The main toxicity associated with the subcutaneous injection in this study is that associated with subcutaneous injection of any immunogen, i.e., pain, redness and swelling at the injection site, as well as the possibility of fever, chills, aches and pains and perhaps fatigue.

Safety monitoring includes periodic review of data from the trial with particular emphasis on monitoring for adverse reactions including the following evaluations:

Hematologic: CBC, differential, platelets

Hepatic/renal: ALT, creatinine, urinalysis

Neurologic: headache, paralysis, anxiety, confusion, weakness, tremors.

Systemic symptoms: fever, gastrointestinal complaints, myalgia, malaise, fatigue, headache, anaphylaxis, immune complex disease, and other hypersensitivity reactions

Local toxicity at the site of injection: e.g., pain, tenderness, erythema, regional lymphadenopathy, limitation of limb movement

The immunogenicity monitoring includes the following immunological assays, all utilizing HIV Subtype C based reagents:

Humoral responses:

HIV Subtype C Gag-specific ELISA

Anti-VEE ELISA

Cellular immune responses:

Standard cell-killing assay (i.e., chromium release) to measure CD8+ Gag-specific CTL activity

ELISPOT assay to measure IFN-?

Mucosal immune responses:

Standardized assay for assessment of Gag-specific IgA

Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

REFERENCES

Barany F. 1985. Single-stranded hexameric linkers: a system for in-phase insertion mutagenesis and protein engineering. *Gene* 37(1-3):111-23.

Betts, M. R., J. Krowka, C. Santamaria, K. Balsamo, F. Gao, G. Mulundu, C. Luo, N. N'Gandu, H. Sheppard, B. H. Hahn, S. Allen and J. A. Frelinger. 1997. Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians. *J. Virol.* 71:8908-8911.

Caley, I. J., M.R. Betts, D.M. Irlbeck, N. L. Davis, R. Swanstrom, J.A. Frelinger and R. E. Johnston. 1997. Humoral, mucosal and cellular immunity in response to an HIV-1 vaccine candidate. *J. Virol.* 71:3031-3038.

Davis *et al.* 1980. In: Microbiology, 3d ed., p. 132.

Davis, N.L., L.V. Willis, J.F. Smith and R.E. Johnston. 1989. *In vitro* synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: Analysis of a viable deletion mutant. *Virology* **171**:189-204.

Davis, N. L., L. V. Willis, J. F. Smith, G. Greenwald and R. E. Johnston. 1990. *In vitro* synthesis of infectious VEE virus RNA from a cDNA clone: Analysis of a viable deletion mutant and mutations affecting virulence. In: Vaccines 90, Cold Spring Harbor Press, Cold Spring Harbor, NY. pp. 109-113.

Davis, N. L., N. Powell, G. F. Greenwald, L. V. Willis, B. J. Johnson, J. F. Smith and R. E. Johnston. 1991. Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: Construction of single and multiple mutants in a full-length cDNA clone. *Virology* **183**:20-31.

Davis, N. L., K. W. Brown, G. F. Greenwald, A. J. Zajac, V. L. Zacny, J. F. Smith and R. E. Johnston. 1995. Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1. *Virology* **212**:102-110.

Davis, N. L., K. W. Brown and R. E. Johnston. 1996a. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. *J. Virol.* **70**:3781-3787.

Davis, N. L., P. Pushko, K. W. Brown, P. C. Charles, I. J. Caley, M. Parker, G. Ludwig, J. F. Smith and R. E. Johnston. 1996b. Immunization against influenza with attenuated Venezuelan equine encephalitis virus vectors. In: Options for the Control of Influenza, III, L. E. Brown and A. W. Hampson, eds. Elsevier, Amsterdam. pp.803-809.

Davis, N. L., I. J. Caley , K. W. Brown, M.R. Betts, D.L. Irlbeck, K.M. McGrath, M.J. Connell, D.C. Montefiori, J.A. Frelinger, R. Swanstrom, P.R. Johnson and R. E. Johnston. 2000. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. *J. Virol.* 74:371-378

Grieder, F. B., N. L. Davis, J. F. Aronson, P. C. Charles, D. C. Sellon, K. Suzuki and R. E. Johnston. 1995. Specific restrictions in the progression of Venezuelan equine encephalitis virus induced disease resulting from single amino acid changes in the glycoproteins. *Virology* **206**:994-1006.

Hevey, M., D. Negley, P. Pushko, J. Smith and A. Schmaljohn. 1998. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. *Virology* **251**:28-37.

Hirsch, V., T.R. Fuerst, G. Sutter, M.W. Carroll, L. C. Yang, S. Goldstein *et al.* 1996. Patterns of viral replication correlate with outcome in SIV-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. *J. Virol.* **70**:3741-3752.

Johnston, Robert E. and Jonathan F. Smith. 1988. Selection for accelerated penetration in cell culture co-selects for attenuated mutants of Venezuelan equine encephalitis virus. *Virology* **162**:437-443.

Johnston, R. E. and C. J. Peters. 1996. *Alphaviruses*. In: Virology, Third Edition, B. N. Fields, D. M. Knipe and P. M. Howley, eds., Raven Press, New York. pp. 843-898.

Kinney, R.M., B.J.B. Johnson, J.B. Welch, K.R. Tsuchiya and D.W. Trent. 1989. The full-length nucleotide sequences of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and its attenuated vaccine derivative, strain TC-83. *Virology* **170**:19-30.

Kinney, R.M., G-J. Chang, K. R. Tsuchiya, J. M. Sneider, J. T. Roehrig, T. M. Woodward and D. W. Trent. 1993. Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5'-noncoding region and the E2 envelope glycoprotein. *J. Virol.* 67:1269-1277.

Kunkel. 1985. *Proc. Natl. Acad. Sci.* USA 82:488.

Paredes, A.M., D.T. Brown, R. Rothnagel, W. Chiu, R.J. Schoepp, R.E. Johnston and B.V.Prasad. 1993. Three-dimensional structure of a membrane-containing virus. *Proc. Natl. Acad. Sci.*, USA **90**:9095-9099.

Pushko, P., M. Parker, G. V. Ludwig, N. L. Davis, R. E. Johnston and J. F. Smith. 1997. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes *in vitro* and immunization against heterologous pathogens *in vivo*. *Virology* **239**:389-401.

Rosenberg, A.H., *et al.* 1987. Vectors for selective expression of cloned DNAs by T7 RNA polymerase. *Gene.* **56**(1): p. 125-35.

Schlesinger, S. and M.J. Schlesinger. 1990. *Replication of Togaviridae and Flaviviridae*. In: Virology, Fields, B.N. and Knipe, D.M. (eds.) Raven Press. pp. 697-711.

Strauss *et al.* 1990. *Seminars in Virology* 1:347.

Strauss, J.H. and E.G. Strauss. 1994. The alphaviruses: Gene expression, replication, and evolution. *Micro. Rev.* **58**:491-562.

Studier, F.W., *et al.* 1990. Use of T7 RNA polymerase to direct expression of cloned genes. 1990. *Methods Enzymol.* **185**:60-89.

What is claimed is:

1. A composition comprising two or more isolated nucleic acids selected from the group consisting of an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity.

2. A composition comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle.

3. A composition comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag*

gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle, and further wherein the alphavirus replicon particles comprise a replicon RNA or at least one structural protein which comprises one or more attenuating mutations.

4. A method of making the population of alphavirus replicon particles of claim 2 comprising:

A) (a) providing a first helper cell for producing a first population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the first population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

B) (a) providing a second helper cell for producing a second population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the

helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the second population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

C) (a) providing a third helper cell for producing a third population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the third population contains

no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells; and

D) combining the first population of alphavirus particles produced from the first helper cell, the second population of alphavirus particles produced from the second helper cell and the third population of alphavirus particles produced from the third helper cell, thereby producing the population of alphavirus replicon particles of claim 2.

5. The method of claim 4, wherein the alphavirus replicon RNA of at least one of the first helper cell, the second helper cell and the third helper cell comprises sequence encoding at least one alphavirus structural protein and wherein the first helper RNA and the one or more additional helper RNA(s) in the at least one of the first helper cell, the second helper cell and the third helper cell, encodes at least one other alphavirus structural protein not encoded by said replicon RNA.

6. A method of making the population of alphavirus replicon particles of claim 3, comprising:

A) (a) providing a first helper cell for producing a first population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein;

and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the first population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

B) (a) providing a second helper cell for producing a second population of infectious, replication defective alphavirus particle, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and

furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the second population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

C) (a) providing a third helper cell for producing a third population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and

furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the third population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells; and

D) combining the first population of alphavirus particles produced from the first helper cell, the second population of alphavirus particles produced from the second helper cell and the third population of alphavirus particles produced from the third helper cell, thereby producing the population of alphavirus replicon particles of claim 3.

7. The method of claim 6, wherein the alphavirus replicon RNA of at least one of the first helper cell, the second helper cell and the third helper cell comprises sequence encoding at least one alphavirus structural protein and wherein the first helper RNA and the one or more additional helper RNA(s) in the at least one of the first helper cell, the second helper cell and the third helper cell, encodes at least one other alphavirus structural protein not encoded by said replicon RNA.

8. The method of claim 6, wherein only at least one of the first population of alphavirus particles, the second population of alphavirus particles and the third population of alphavirus particles comprises particles wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations.

9. A population of alphavirus replicon particles produced by the method of claim 4.

10. A population of alphavirus replicon particles produced by the method of claim 6.

11. A method of inducing an immune response to human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 1 in a pharmaceutically acceptable carrier.

12. A method of inducing an immune response to human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 2 in a pharmaceutically acceptable carrier.

13. A method of inducing an immune response to human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 3 in a pharmaceutically acceptable carrier.

14. A method of inducing an immune response to human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the population of claim 9 in a pharmaceutically acceptable carrier.

15. A method of inducing an immune response to human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the

population of claim 10 in a pharmaceutically acceptable carrier.

16. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 1 in a pharmaceutically acceptable carrier.

17. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 2 in a pharmaceutically acceptable carrier.

18. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 3 in a pharmaceutically acceptable carrier.

19. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the population of claim 9 in a pharmaceutically acceptable carrier.

20. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the population of claim 10 in a pharmaceutically acceptable carrier.

21. A composition comprising two or more isolated nucleic acids selected from the group consisting of an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof

of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof.

22. A composition comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle.

23. A composition comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a

modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle, and further wherein the alphavirus replicon particles comprise a replicon RNA or at least one structural protein which comprises one or more attenuating mutations.

24. A method of making the population of alphavirus replicon particles of claim 22, comprising:

A) (a) providing a first helper cell for producing a first population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the first population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

B) (a) providing a second helper cell for producing a second population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the second population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

C) (a) providing a third helper cell for producing a third population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the third population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells; and

D) combining the first population of alphavirus particles produced from the first helper cell, the second population of alphavirus particles produced from the second helper cell and the third population of alphavirus particles produced from the third helper cell, thereby producing the population of alphavirus replicon particles of claim 22.

25. The method of claim 24, wherein the alphavirus replicon RNA of at least one of the first helper cell, the second helper cell and the third helper cell comprises sequence encoding at least one alphavirus structural protein and wherein the first helper RNA and the one or more additional helper RNA(s) in the at least one of the first helper cell, the second helper cell and the third helper cell, encodes at least one other alphavirus structural protein not encoded by said replicon RNA.

26. A method of making the population of alphavirus replicon particles of claim 23, comprising:

A) (a) providing a first helper cell for producing a first population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the first population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

B) (a) providing a second helper cell for producing a second population of infectious, replication defective alphavirus particle, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein

not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the second population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

C) (a) providing a third helper cell for producing a third population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional

helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the third population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells; and

D) combining the first population of alphavirus particles produced from the first helper cell, the second population of alphavirus particles produced from the second helper cell and the third population of alphavirus particles produced from the third helper cell, thereby producing the population of alphavirus replicon particles of claim 23.

27. The method of claim 26, wherein the alphavirus replicon RNA of at least one of the first helper cell, the second helper cell and the third helper cell comprises sequence encoding at least one alphavirus structural protein and wherein the first helper RNA and the one or more additional helper RNA(s) in the at least one of the first helper cell, the second helper cell and the third helper cell, encodes at least one other alphavirus structural protein not encoded by said replicon RNA.

28. The method of claim 26, wherein only at least one of the first population of alphavirus particles, the second population of alphavirus particles and the third population of alphavirus particles comprises particles wherein at least one of said

replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations.

29. A population of alphavirus replicon particles produced by the method of claim 24.

30. A population of alphavirus replicon particles produced by the method of claim 26.

31. A method of inducing an immune response to human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 21 in a pharmaceutically acceptable carrier.

32. A method of inducing an immune response to human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 22 in a pharmaceutically acceptable carrier.

33. A method of inducing an immune response to human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 23 in a pharmaceutically acceptable carrier.

34. A method of inducing an immune response to human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the population of claim 29 in a pharmaceutically acceptable carrier.

35. A method of inducing an immune response to human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the population of claim 30 in a pharmaceutically acceptable carrier.

36. A method of treating or preventing infection by human immunodeficiency

virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 21 in a pharmaceutically acceptable carrier.

37. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 22 in a pharmaceutically acceptable carrier.

38. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 23 in a pharmaceutically acceptable carrier.

39. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the population of claim 29 in a pharmaceutically acceptable carrier.

40. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the population of claim 30 in a pharmaceutically acceptable carrier.

41. An alphavirus replicon virosome comprising an alphavirus replicon RNA encapsidated by a lipid bilayer comprising alphavirus glycoproteins, E1 and E2.

42. The virosome of claim 41, wherein the alphavirus glycoproteins are Venezuelan Equine Encephalitis glycoproteins E1 and E2.

43. A method of producing the alphavirus replicon virosome of claim 41, comprising:

a) combining alphavirus replicon RNA, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and

b) gradually removing detergent, whereby alphavirus replicon virosomes are produced.

44. An alphavirus replicon virosome produced from the method of claim 43.

45. A method of eliciting an immune response in a subject, comprising administering to the subject an immunogenic amount of the alphavirus replicon virosome of claim 41 in a pharmaceutically acceptable carrier.

46. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the alphavirus replicon virosome of claim 41, wherein the virosome comprises alphavirus replicon RNA encoding one or more HIV immunogens.

47. A composition comprising a population of alphavirus replicon virosomes comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the nucleic acids are each contained within a separate alphavirus replicon virosome.

48. A composition comprising a population of alphavirus replicon virosomes

comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in inactivation of reverse transcriptase activity in the *pol* gene product or immunogenic fragment thereof, and wherein the nucleic acids are each contained within a separate alphavirus replicon virosome.

49. A method of producing the population of alphavirus replicon virosomes of claim 47, comprising:

A) (a) producing a first population of alphavirus replicon virosomes by combining alphavirus replicon RNA comprising nucleic acid encoding and *env* gene product or immunogenic fragment thereof, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and

b) gradually removing detergent, whereby alphavirus replicon virosomes are produced;

B) (a) producing a second population of alphavirus replicon virosomes by combining alphavirus replicon RNA comprising nucleic acid encoding and *gag* gene product or immunogenic fragment thereof, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and

b) gradually removing detergent, whereby alphavirus replicon virosomes

are produced;

C) (a) producing a third population of alphavirus replicon virosomes by combining alphavirus replicon RNA comprising nucleic acid encoding the *pol* gene product or immunogenic fragment thereof, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and

b) gradually removing detergent, whereby alphavirus replicon virosomes are produced; and

D) combining the first population of alphavirus replicon virosomes, the second population of alphavirus replicon virosomes and the third population of alphavirus replicon virosomes to produce the population of alphavirus replicon virosomes of claim 47.

50. A method of producing the population of alphavirus replicon virosomes of claim 48, comprising:

A) (a) producing a first population of alphavirus replicon virosomes by combining alphavirus replicon RNA comprising nucleic acid encoding and *env* gene product or immunogenic fragment thereof, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and

b) gradually removing detergent, whereby alphavirus replicon virosomes are produced;

B) (a) producing a second population of alphavirus replicon virosomes by combining alphavirus replicon RNA comprising nucleic acid encoding and *gag* gene product or immunogenic fragment thereof, wherein the *gag* gene product or

immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and

b) gradually removing detergent, whereby alphavirus replicon virosomes are produced;

C) (a) producing a third population of alphavirus replicon virosomes by combining alphavirus replicon RNA comprising nucleic acid encoding the *pol* gene product or immunogenic fragment thereof, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in inactivation of reverse transcriptase activity in the *pol* gene product or immunogenic fragment thereof, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and

b) gradually removing detergent, whereby alphavirus replicon virosomes are produced; and

D) combining the first population of alphavirus replicon virosomes, the second population of alphavirus replicon virosomes and the third population of alphavirus replicon virosomes to produce the population of alphavirus replicon virosomes of claim 48.

51. A method of eliciting an immune response in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 47, in a pharmaceutically acceptable carrier.

52. A method of eliciting an immune response in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 48, in a pharmaceutically acceptable carrier.

53. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 47, in a pharmaceutically acceptable carrier.

54. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 47, in a pharmaceutically acceptable carrier.

55. A composition comprising heparin affinity-purified alphavirus replicon particles, wherein the alphavirus replicon particles comprise at least one structural protein which comprises one or more attenuating mutations.

56. A method of preparing the heparin affinity-purified alphavirus particles of claim 55, comprising:

a) producing alphavirus replicon particles, wherein the alphavirus replicon particles comprise a at least one structural protein which comprises one or more attenuating mutations;

b) loading the alphavirus replicon particles of step (a) in a heparin affinity chromatography column; and

c) collecting the fraction from the column which contains the heparin affinity-purified alphavirus replicon particles.

57. A composition produced by the method of claim 56.

58. A method of producing VRP for use in a vaccine comprising:

a) producing a plasmid encoding the nucleotide sequence of an alphavirus replicon RNA;

b) producing a plasmid encoding the nucleotide sequence of one or more helper RNAs;

c) transcribing the plasmids of steps (a) and (b) into RNA *in vitro*;

d) electroporating the RNA of step (c) into a Vero cell line; and

e) purifying VRP from the Vero cell line of step (d) by heparin affinity chromatography.

59. The method of claim 58, wherein the VRP is produced in large-scale.

60. VRP produced by the method of claim 59.

61. An isolated nucleic acid encoding a *pol* gene product or immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof.

62. A composition comprising the nucleic acid of claim 61.

63. A vector comprising the nucleic acid of claim 61.

64. A cell comprising the vector of claim 63.

65. An alphavirus replicon particle comprising the nucleic acid of claim 61.

66. A method of making the alphavirus replicon particle of claim 65, comprising

a) providing a helper cell for producing an infectious, defective alphavirus particle, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cell.

67. The method of claim 66, wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations.

68. An alphavirus replicon particle produced according to the method of claim 66.

69. An alphavirus replicon particle produced according to the method of claim 67.

70. A method of inducing an immune response in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 62 in a pharmaceutically acceptable carrier.

71. A method of inducing an immune response in a subject, comprising administering to the subject an immunogenic amount of the alphavirus replicon particle of claim 65 in a pharmaceutically acceptable carrier.

72. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 62 in a pharmaceutically acceptable carrier.

73. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the alphavirus replicon particle of claim 65 in a pharmaceutically acceptable carrier.

74. A method of inducing an immune response in a subject, comprising administering to the subject an immunogenic amount of a composition comprising the alphavirus replicon particles of claim 65 in a pharmaceutically acceptable carrier.

75. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of a composition comprising the alphavirus replicon particles of claim 65 in a pharmaceutically acceptable carrier.


Xba I (12497)
EcoR I (12354)
T7 P
KN(R)
nsP1
COLE1 ORI
EcoR I (2137)
nsP2
p3-40.1.6
12523 bp
Not I (9232)
gag
26S promoter
Apa I (7506)
nsP3
nsP4

FIG. 1


Xba I (5047)
T7 P
Eco R I (4904)
KN(R)
26S promoter
C
p3-13.2.2
5076 bp
COLE1 ORI
Not I (1782)

FIG. 2


Xba I (6960)
Eco R I (6817)
T7 P
KN(R)
26S promoter
E3
E2
p3-13.4.6
6989 bp
COLE1 ORI
Xba I (1930)
6KD
E1
Not I (3695)

FIG. 3


T7 P
KN(R)
nsP1
COLE1 ORI
nsP2
13-60.2.14
12379 bp
Not I (9085)
p51
26S promoter
nsP3
nsP4

FIG. 4


XbaI (13549)
EcoRI (13406)
KN(R)
COLE1 ORI
nsP1
EcoRI (2131)
nsP2
pERK-DU151env
13584 bp
NotI (10284)
nsP3
DU151 env
XbaI (8642)
26S promoter
ApaI (7500)
nsP4

FIG. 5



FIG. 6



FIG. 7



FIG. 8



FIG. 9A



FIG. 9B



FIG. 9C


HIV-1 genes
LTR
gag
pro/pol
vif
vpr
vpu
tat
rev
env
nef
Regions sequenced for selection

FIG. 10


Gag
Agagcon
Dgagcon
Bgagcon
CTSC1 gag
DU204 gag
DU174 gag
RB21gag
DU172 gag
DU258 gag
DU179 gag
GG10gag
DU123 gag
RB12gag
DU156gag
GG5gag
RB13gag
DU467 gag
GG3gag
RB14gag
RB18gag
CTSC2 gag
GG6gag
DU368 gag
DU115 gag
RB22gag
DU457 gag
DU281 gag
RB15gag
RB28gag
GG1gag
GG4gag
RB27gag
SAgagcon
ES2gag
DU422 gag
Malgagcon
Cgagcon
consensus
vaccine candidate
gag clone

FIG. 11


Env
b_us.jrfl
b_fr.hxb2r
d_ug.94ug114
a_se.sose7253
a_ke.q2317
d_zr.84zr085
GG3env
RB27env
du115env
GG4env
RB28env
du156env
du174env
GG10env
du281env
du422env
RB22env
GG5env
du368env
RB13env
du258env
RB12env
du467env
du172env
du204env
du457env
GG6env
RB21env
RB14env
RB18env
DU151ENV25
du151env
DU123ENV17
du123env
*Cenvcon
*SAenvcon
* consensus
vaccine candidate
env clone

FIG. 12


Pol
b_us.jrfl
b_fr.hxb2r
a_se.sose7253
a_ke.q2317
d_zr.84zr085
d_ug.94ug114
RB14pol
RB22pol
du368
du115
du172
du258
RB15pol
GG6pol
RB13pol
GG4pol
ctsc1
GG10pol
du422
du457
*SApolcon
du151
du204
du179
GG3pol
DU151POL8
RB21pol
du156
ctsc2
RB27pol
RB18pol
RB28pol
Cpolcon *
GG5pol
du174
* consensus
vaccine candidate
pol clone

FIG. 13



FIG. 14

BEST AVAILABLE COPY



FIG. 15

BEST AVAILABLE COPY

SEQUENCE LISTING

<110> AlphaVax, Inc. and University of North Carolina

Olmsted, Robert
Keith, Paula
Drygan, Sergey
Daley, Ian
Maughan, Maureen
Johnston, Robert
Davis, Nancy
Swanstrom, Ronald

<120> ALPHAVIRUS VECTORS AND VIROSOMES WITH MODIFIED HIV GENES FOR USE AS VACCINES

<130> 01113.0001P1

<150> 60/216,995
<151> 2000-07-07

<160> 19

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 12523
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence; Note = synthetic construct

<400> 1
atgggcggcg catgagagaa gcccagacca attacctacc caaaatggag aaagttcacg 60
ttgacatcga ggaagacagc ccattcctca gagctttgca gcggagcttc ccgcagtttg 120
aggtagaagc caagcaggtc actgataatg accatgctaa tgccagagcg ttttcgcatc 180
tggcttcaaa actgatcgaa acggaggtgg acccatccga cacgatcctt gacattggaa 240
gtgcgcccgc ccgcagaatg tattctaagc acaagtatca ttgtatctgt ccgatgagat 300
gtgcggaaga tccggacaga ttgtataagt atgcaactaa gctgaagaaa aactgtaagg 360
aaataactga taaggaattg gacaagaaaa tgaaggagct cgccgccgtc atgagcgacc 420
ctgacctgga aactgagact atgtgcctcc acgacgacga gtcgtgtcgc tacgaagggc 480
aagtcgctgt ttaccaggat gtatacgcgg ttgacggacc gacaagtctc tatcaccaag 540
ccaataaggg agttagagtc gcctactgga taggctttga caccacccct tttatgttta 600
agaacttggc tggagcatat ccatcatact ctaccaactg ggccgacgaa accgtgttaa 660
cggctcgtaa cataggccta tgcagctctg acgttatgga gcggtcacgt agagggatgt 720
ccattcttag aaagaagtat ttgaaaccat ccaacaatgt tctattctct gttggctcga 780
ccatctacca cgagaagagg gacttactga ggagctggca cctgccgtct gtatttcact 840
tacgtggcaa gcaaaattac acatgtcggt gtgagactat agttagttgc gacgggtacg 900
tcgttaaaag aatagctatc agtccaggcc tgtatgggaa gccttcaggc tatgctgcta 960
cgatgcaccg cgagggattc ttgtgctgca aagtgacaga cacattaaac ggggagaggg 1020
tctcttttcc cgtgtgcacg tatgtgccag ctacattgtg tgaccaaatg actggcatac 1080
tggcaacaga tgtcagtgcg gacgacgcgc aaaaactgct ggttgggctc aaccagcgta 1140

tagtcgtcaa cggtcgcacc cagagaaaca ccaataccat gaaaaattac cttttgcccg 1200
tagtggccca ggcatttgct aggtgggcaa aggaatataa ggaagatcaa gaagatgaaa 1260
ggccactagg actacgagat agacagttag tcatggggtg ttgttgggct tttagaaggc 1320
acaagataac atctatttat aagcgcccgg atacccaaac catcatcaaa gtgaacagcg 1380
atttccactc attcgtgctg cccaggatag gcagtaacac attggagatc gggctgagaa 1440
caagaatcag gaaaatgtta gaggagcaca aggagccgtc acctctcatt accgccgagg 1500
acgtacaaga agctaagtgc gcagccgatg aggctaagga ggtgcgtgaa gccgaggagt 1560
tgcgcgcagc tctaccacct ttggcagctg atgttgagga gcccactctg gaagccgatg 1620
tcgacttgat gttacaagag gctggggccg gctcagtgga gacacctcgt ggcttgataa 1680
aggttaccag ctacgctggc gaggacaaga tcggctctta cgctgtgctt tctccgcagg 1740
ctgtactcaa gagtgaaaaa ttatcttgca tccaccctct cgctgaacaa gtcatagtga 1800
taacacactc tggccgaaaa gggcgttatg ccgtggaacc ataccatggt aaagtagtgg 1860
tgccagaggg acatgcaata cccgtccagg actttcaagc tctgagtgaa agtgccacca 1920
ttgtgtacaa cgaacgtgag ttcgtaaaca ggtacctgca ccatattgcc acacatggag 1980
gagcgctgaa cactgatgaa gaatattaca aaactgtcaa gcccagcgag cacgacggcg 2040
aatacctgta cgacatcgac aggaaacagt gcgtcaagaa agaactagtc actgggctag 2100
ggctcacagg cgagctggtg gatcctccct tccatgaatt cgcctacgag agtctgagaa 2160
cacgaccagc cgctccttac caagtaccaa ccataggggt gtatggcgtg ccaggatcag 2220
gcaagtctgg catcattaaa agcgcagtca ccaaaaaaga tctagtggtg agcgccaaga 2280
aagaaaactg tgcagaaatt ataagggacg tcaagaaaat gaaagggctg gacgtcaatg 2340
ccagaactgt ggactcagtg ctcttgaatg gatgcaaaca ccccgtagag accctgtata 2400
ttgacgaagc ttttgcttgt catgcaggta ctctcagagc gctcatagcc attataagac 2460
ctaaaaaggc agtgctctgc ggggatccca aacagtgcgg ttttttaac atgatgtgcc 2520
tgaaagtgca ttttaaccac gagatttgca cacaagtctt ccacaaaagc atctctcgcc 2580
gttgcactaa atctgtgact tcggtcgtct caaccttgtt ttacgacaaa aaaatgagaa 2640
cgacgaatcc gaaagagact aagattgtga ttgacactac cggcagtacc aaacctaagc 2700
aggacgatct cattctcact tgtttcagag ggtgggtgaa gcagttgcaa atagattaca 2760
aaggcaacga aataatgacg gcagctgcct ctcaagggct gacccgtaaa ggtgtgtatg 2820
ccgttcggta caaggtgaat gaaaatcctc tgtacgcacc cacctcagaa catgtgaacg 2880
tcctactgac ccgcacggag gaccgcatcg tgtggaaaac actagccggc gacccatgga 2940
taaaaacact gactgccaag taccctggga atttcactgc cacgatagag gagtggcaag 3000
cagagcatga tgccatcatg aggcacatct tggagagacc ggaccctacc gacgtcttcc 3060
agaataaggc aaacgtgtgt tgggccaagg ctttagtgcc ggtgctgaag accgctggca 3120
tagacatgac cactgaacaa tggaacactg tggattattt tgaaacggac aaagctcact 3180
cagcagagat agtattgaac caactatgcg tgaggttctt tggactcgat ctggactccg 3240
gtctattttc tgcacccact gttccgttat ccattaggaa taatcactgg gataactccc 3300
cgtcgcctaa catgtacggg ctgaataaag aagtggtccg tcagctctct cgcaggtacc 3360
cacaactgcc tcgggcagtt gccactggaa gagtctatga catgaacact ggtacactgc 3420
gcaattatga tccgcgcata aacctagtac ctgtaaacag aagactgcct catgctttag 3480
tcctccacca taatgaacac ccacagagtg acttttcttc attcgtcagc aaattgaagg 3540
gcagaactgt cctggtggtc ggggaaaagt tgtccgtccc aggcaaaatg gttgactggt 3600
tgtcagaccg gcctgaggct accttcagag ctcggctgga tttaggcatc ccaggtgatg 3660
tgcccaaata tgacataata tttgttaatg tgaggacccc atataaatac catcactatc 3720
agcagtgtga agaccatgcc attaagctta gcatgttgac caagaaagct tgtctgcatc 3780
tgaatcccgg cggaacctgt gtcagcatag gttatggtta cgctgacagg gccagcgaaa 3840
gcatcattgg tgctatagcg cggcagttca agttttcccg ggtatgcaaa ccgaaatcct 3900
cacttgaaga gacggaagtt ctgtttgtat tcattgggta cgatcgcaag gcccgtacgc 3960
acaatcctta caagctttca tcaaccttga ccaacattta tacaggttcc agactccacg 4020
aagccggatg tgcaccctca tatcatgtgg tgcgagggga tattgccacg gccaccgaag 4080
gagtgattat aaatgctgct aacagcaaag gacaacctgg cggaggggtg tgcggagcgc 4140
tgtataagaa gttcccggaa agcttcgatt tacagccgat cgaagtagga aaagcgcgac 4200
tggtcaaagg tgcagctaaa catatcattc atgccgtagg accaaacttc aacaaagttt 4260
cggaggttga aggtgacaaa cagttggcag aggcttatga gtccatcgct aagattgtca 4320
acgataacaa ttacaagtca gtagcgattc cactgttgtc caccggcatc ttttccggga 4380
acaaagatcg actaacccaa tcattgaacc atttgctgac agctttagac accactgatg 4440

cagatgtagc catatactgc agggacaaga aatgggaaat gactctcaag gaagcagtgg 4500
ctaggagaga agcagtggag gagatatgca tatccgacga ctcttcagtg acagaacctg 4560
atgcagagct ggtgagggtg catccgaaga gttctttggc tggaaggaag ggctacagca 4620
caagcgatgg caaaactttc tcatatttgg aagggaccaa gtttcaccag gcggccaagg 4680
atatagcaga aattaatgcc atgtggcccg ttgcaacgga ggccaatgag caggtatgca 4740
tgtatatcct cggagaaagc atgagcagta ttaggtcgaa atgccccgtc gaagagtcgg 4800
aagcctccac accacctagc acgctgcctt gcttgtgcat ccatgccatg actccagaaa 4860
gagtacagcg cctaaaagcc tcacgtccag aacaaattac tgtgtgctca tcctttccat 4920
tgccgaagta tagaatcact ggtgtgcaga agatccaatg ctcccagcct atattgttct 4980
caccgaaagt gcctgcgtat attcatccaa ggaagtatct cgtggaaaca ccaccggtag 5040
acgagactcc ggagccatcg gcagagaacc aatccacaga ggggacacct gaacaaccac 5100
cacttataac cgaggatgag accaggacta gaacgcctga gccgatcatc atcgaagagg 5160
aagaagagga tagcataagt ttgctgtcag atggcccgac ccaccaggtg ctgcaagtcg 5220
aggcagacat tcacgggccg ccctctgtat ctagctcatc ctggtccatt cctcatgcat 5280
ccgactttga tgtggacagt ttatccatac ttgacaccct ggagggagct agcgtgacca 5340
gcggggcaac gtcagccgag actaactctt acttcgcaaa gagtatggag tttctggcgc 5400
gaccggtgcc tgcgcctcga acagtattca ggaaccctcc acatcccgct ccgcgcacaa 5460
gaacaccgtc acttgcaccc agcagggcct gctcgagaac cagcctagtt tccacccccgc 5520
caggcgtgaa tagggtgatc actagagagg agctcgaggc gcttaccccg tcacgcactc 5580
ctagcaggtc ggtctcgaga accagcctgg tctccaaccc gccaggcgta aatagggtga 5640
ttacaagaga ggagtttgag gcgttcgtag cacaacaaca atgacggttt gatgcgggtg 5700
catacatctt ttcctccgac accggtcaag ggcatttaca acaaaaatca gtaaggcaaa 5760
cggtgctatc cgaagtggtg ttggagagga ccgaattgga gatttcgtat gccccgcgcc 5820
tcgaccaaga aaaagaagaa ttactacgca agaaattaca gttaaatccc acacctgcta 5880
acagaagcag ataccagtcc aggaaggtgg agaacatgaa agccataaca gctagacgta 5940
ttctgcaagg cctagggcat tatttgaagg cagaaggaaa agtggagtgc taccgaaccc 6000
tgcatcctgt tcctttgtat tcatctagtg tgaaccgtgc cttttcaagc cccaaggtcg 6060
cagtggaagc ctgtaacgcc atgttgaaag agaactttcc gactgtggct tcttactgta 6120
ttattccaga gtacgatgcc tatttggaca tggttgacgg agcttcatgc tgcttagaca 6180
ctgccagttt ttgccctgca aagctgcgca gctttccaaa gaaacactcc tatttggaac 6240
ccacaatacg atcggcagtg ccttcagcga tccagaacac gctccagaac gtcctggcag 6300
ctgccacaaa aagaaattgc aatgtcacgc aaatgagaga attgcccgta ttggattcgg 6360
cggcctttaa tgtggaatgc ttcaagaaat atgcgtgtaa taatgaatat tgggaaacgt 6420
ttaaagaaaa ccccatcagg cttactgaag aaaacgtggt aaattacatt accaaattaa 6480
aaggaccaaa agctgctgct ctttttgcga agacacataa tttgaatatg ttgcaggaca 6540
taccaatgga caggtttgta atggacttaa agagagacgt gaaagtgact ccaggaacaa 6600
aacatactga agaacggccc aaggtacagg tgatccaggc tgccgatccg ctagcaacag 6660
cgtatctgtg cggaatccac cgagagctgg ttaggagatt aaatgcggtc ctgcttccga 6720
acattcatac actgtttgat atgtcggctg aagactttga cgctattata gccgagcact 6780
tccagcctgg ggattgtgtt ctggaaactg acatcgcgtc gtttgataaa agtgaggacg 6840
acgccatggc tctgaccgcg ttaatgattc tggaagactt aggtgtggac gcagagctgt 6900
tgacgctgat tgaggcggct ttcggcgaaa tttcatcaat acatttgccc actaaaacta 6960
aatttaaatt cggagccatg atgaaatctg gaatgttcct cacactgttt gtgaacacag 7020
tcattaacat tgtaatcgca agcagagtgt tgagagaacg gctaaccgga tcaccatgtg 7080
cagcattcat tggagatgac aatatcgtga aaggagtcaa atcggacaaa ttaatggcag 7140
acaggtgcgc cacctggttg aatatggaag tcaagattat agatgctgtg gtgggcgaga 7200
aagcgcccta tttctgtgga gggtttattt tgtgtgactc cgtgaccggc acagcgtgcc 7260
gtgtggcaga ccccctaaaa aggctgttta agcttggcaa acctctggca gcagacgatg 7320
aacatgatga tgacaggaga agggcattgc atgaagagtc aacacgctgg aaccgagtgg 7380
gtattctttc agagctgtgc aaggcagtag aatcaaggta tgaaaccgta ggaacttcca 7440
tcatagttat ggccatgact actctagcta gcagtgttaa atcattcagc tacctgagag 7500
gggcccctat aactctctac ggctaacctg aatggactac gacatagtct agtccgccaa 7560
gatggctgcg agagcgtcaa tattaagagg ggaaaaatta gataaatggg aaaagattag 7620
gttaaggcca gggggaaaga aacattatat gttaaaacac atagtatggg cgagcaggga 7680
gctggaaaga tttgcactta accctggcct tttagaaaca tcagaaggat gtaaacaaat 7740

aatgaaacag ctacaaccag ctctccagac aggaacagag gaacttaaat cattatacaa 7800
cacagtagca actctctatt gtgtacatga aaagatagaa gtacgagaca ccaaggaagc 7860
cttagataag atagaggaag aacaaaacaa atgtcagcaa aaaacgcagc aggcaaaagc 7920
ggctgacggg aaagtcagtc aaaattatcc tatagtgcag aatctccaag ggcaaatggt 7980
acatcaagcc atatcaccta gaaccttgaa tgcatgggta aaagtaatag aagaaaaggc 8040
ttttagccca gaggtaatac ccatgtttac agcattatca gaaggagcca ccccacaaga 8100
tttaaacacc atgttaaata cagtgggggg acaccaagca gccatgcaaa tgttaaaaga 8160
tactattaat gaagaggctg cagaatggga tagattacat ccagtccatg cggggcctat 8220
tgcaccaggc cagatgagag aaccaagggg aagtgacata gcaggaacta ctagtaccct 8280
tcaggaacaa atagcatgga tgacaagtaa cccacctatt ccagtgggag acatctataa 8340
aagatggata attctggggt taaataaaat agtgagaatg tatagcccgg tcagcatttt 8400
ggacataaga caagggccaa aggaaccctt tcgagactat gtagatcggt tctttaaaac 8460
tttaagagct gaacaagcta cacaagaagt aaaaaattgg atgacagaca ccttgttagt 8520
ccaaaatgcg aacccagatt gtaagaccat tttgagagca ttaggaccag gggctacatt 8580
agaagaaatg atgacagcat gtcaaggggt gggaggacct ggccacaaag caagagtatt 8640
ggctgaggca atgagtcaaa caaacagtgg aaacataatg atgcagagaa gcaattttaa 8700
aggccctaga agaattgtta aatgttttaa ctgtggcaag gaagggcaca tagccagaaa 8760
ttgcagagcc cctaggaaaa aaggctgttg gaaatgtgga aaagaaggac accaaatgaa 8820
agactgcact gagaggcagg ctaatttttt agggaaaatt tggccttccc acaaggggag 8880
gccagggaat ttccttcaga acagaccaga gccaacagcc ccaccagcag agagcttcag 8940
gttcgaagag acaacccccg ctccgaaaca ggagccgata gaaagggaac ccttaacttc 9000
cctcaaatca ctctttggca gcgacccctt gtctcaataa gagtttaatt aagtaacgat 9060
acagcagcaa ttggcaagct gcttacatag aactcgcggc gattggcatg ccgctttaaa 9120
atttttattt tatttttctt ttcttttccg aatcggattt tgtttttaat atttcaaaaa 9180
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa gggaagagcg cggccgcgcg 9240
ctgggctacg ttttgctggc gttcgcgacg cgaggctgga tggccttccc cattatgatt 9300
cttctcgctt ccggcggcat cgggatgccc gcgttgcagg ccatgctgtc caggcaggta 9360
gatgacgacc atcagggaca gcttcaagga tcgctcgcgg ctcttaccag cctaacttcg 9420
atcattggac cgctgatcgt cacggcgatt tatgccgcct cggcgagcac atggaacggg 9480
ttggcatgga ttgtaggcgc cgccctatac cttgtctgcc tccccgcgtt gcgtcgcggt 9540
gcatggagcc gggccacctc gacctgaatg gaagccggcg gcacctcgct aacggattca 9600
ccactccaag aattggagcc aatcaattct tgcggagaac tgtgaatgcg caaaccaacc 9660
cttggcagaa catatccatc gcgtccgcca tctccagcag ccgcacgcgg cgcatctcgg 9720
gcagcgttgg gtcctggcca cgggtgcgca tgatcgtgct cctgtcgttg aggacccggc 9780
taggctggcg gggttgcctt actggttagc agaatgaatc accgatacgc gagcgaacgt 9840
gaagcgactg ctgctgcaaa acgtctgcga cctgagcaac aacatgaatg gtcttcggtt 9900
tccgtgtttc gtaaagtctg gaaacgcgga agtcagcgcc ctgcaccatt atgttccgga 9960
tctgcatcgc aggatgctgc tggctaccct gtggaacacc tacatctgta ttaacgaagc 10020
gctggcattg accctgagtg attttttctt ggtcccgccg catccatacc gccagttgtt 10080
taccctcaca acgttccagt aaccgggcat gttcatcatc agtaacccgt atcgtgagca 10140
tcctctctcg tttcatcggt atcattaccc ccatgaacag aaatcccccc tacacggagg 10200
catcagtgac caaacaggaa aaaaccgccc ttaacatggc ccgctttatc agaagccaga 10260
cattaacgct tctggagaaa ctcaacgagc tggacgcgga tgaacaggca gacatctgtg 10320
aatcgcttca cgaccacgct gatgagcttt accgcagctg cctcgcgcgt ttcggtgatg 10380
acggtgaaaa cctctgacac atgcagctcc cggagacggt cacagcttgt ctgtaagcgg 10440
atgccgggag cagacaagcc cgtcagggcg cgtcagcggg tgttggcggg tgtcggggcg 10500
cagccatgac ccagtcacgt agcgatagcg gagtgtatac tggcttaact atgcggcatc 10560
agagcagatt gtactgagag tgcaccattg cggtgtgaaa taccgcacag atgcgtaagg 10620
agaaaatacc gcatcaggcg ctcttccgct tcctcgctca ctgactcgct gcgctcggtc 10680
gttcggctgc ggcgagcggt atcagctcac tcaaaggcgg taatacggtt atccacagaa 10740
tcaggggata acgcaggaaa gaacatgtga gcaaaaggcc agcaaaaggc caggaaccgt 10800
aaaaaggccg cgttgctggc gtttttccat aggctccgcc cccctgacga gcatcacaaa 10860
aatcgacgct caagtcagag gtggcgaaac ccgacaggac tataaagata ccaggcgttt 10920
cccctggaa gctccctcgt gcgctctcct gttccgaccc tgccgcttac cggatacctg 10980
tccgcctttc tcccttcggg aagcgtggcg ctttctcata gctcacgctg taggtatctc 11040

```
agttcggtgt aggtcgttcg ctccaagctg ggctgtgtgc acgaaccccc cgttcagccc   11100
gaccgctgcg ccttatccgg taactatcgt cttgagtcca acccggtaag acacgactta   11160
tcgccactgg cagcagccac tggtaacagg attagcagag cgaggtatgt aggcggtgct   11220
acagagttct tgaagtggtg gcctaactac ggctacacta gaaggacagt atttggtatc   11280
tgcgctctgc tgaagccagt taccttcgga aaaagagttg gtagctcttg atccggcaaa   11340
caaaccaccg ctggtagcgg tggttttttt gtttgcaagc agcagattac gcgcagaaaa   11400
aaaggatctc aagaagatcc tttgatcttt tctacggggt ctgacgctca gtggaacgaa   11460
aactcacgtt aagggatttt ggtcatgaac aataaaactg tctgcttaca taaacagtaa   11520
tacaaggggt gttatgagcc atattcaacg ggaaacgtct tgctcgaggc cgcgattaaa   11580
ttccaacatg gatgctgatt tatatgggta taaatgggct cgcgataatg tcgggcaatc   11640
aggtgcgaca atctatcgat tgtatgggaa gcccgatgcg ccagagttgt ttctgaaaca   11700
tggcaaaggt agcgttgcca atgatgttac agatgagatg gtcagactaa actggctgac   11760
ggaatttatg cctcttccga ccatcaagca ttttatccgt actcctgatg atgcatggtt   11820
actcaccact gcgatccccg ggaaaacagc attccaggta ttagaagaat atcctgattc   11880
aggtgaaaat attgttgatg cgctggcagt gttcctgcgc cggttgcatt cgattcctgt   11940
ttgtaattgt ccttttaaca gcgatcgcgt atttcgtctc gctcaggcgc aatcacgaat   12000
gaataacggt ttggttgatg cgagtgattt tgatgacgag cgtaatggct ggcctgttga   12060
acaagtctgg aaagaaatgc ataagctttt gccattctca ccggattcag tcgtcactca   12120
tggtgatttc tcacttgata accttatttt tgacgagggg aaattaatag gttgtattga   12180
tgttggacga gtcggaatcg cagaccgata ccaggatctt gccatcctat ggaactgcct   12240
cggtgagttt tctccttcat tacagaaacg gctttttcaa aaatatggta ttgataatcc   12300
tgatatgaat aaattgcagt ttcatttgat gctcgatgag tttttctaag aattctcatg   12360
tttgacagct tatcatcgat aagctttaat gcggtagttt atcacagtta aattgctaac   12420
gcagtcaggc accgtgtatg aaatctaaca atgcgctcat cgtcatcctc ggcaccgtca   12480
ccctggatgc tgtctagagg atcccctaata cgactcacta tag                    12523
```

<210> 2
<211> 7479
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence; Note =
synthetic construct

<221> CDS
<222> (1)...(7479)

<400> 2

```
atg gag aaa gtt cac gtt gac atc gag gaa gac agc cca ttc ctc aga       48
Met Glu Lys Val His Val Asp Ile Glu Glu Asp Ser Pro Phe Leu Arg
 1               5                  10                  15

gct ttg cag cgg agc ttc ccg cag ttt gag gta gaa gcc aag cag gtc       96
Ala Leu Gln Arg Ser Phe Pro Gln Phe Glu Val Glu Ala Lys Gln Val
            20                  25                  30

act gat aat gac cat gct aat gcc aga gcg ttt tcg cat ctg gct tca      144
Thr Asp Asn Asp His Ala Asn Ala Arg Ala Phe Ser His Leu Ala Ser
         35                  40                  45
aaa ctg atc gaa acg gag gtg gac cca tcc gac acg atc ctt gac att      192
Lys Leu Ile Glu Thr Glu Val Asp Pro Ser Asp Thr Ile Leu Asp Ile
     50                  55                  60
```

```
gga agt gcg ccc gcc cgc aga atg tat tct aag cac aag tat cat tgt      240
Gly Ser Ala Pro Ala Arg Arg Met Tyr Ser Lys His Lys Tyr His Cys
 65                  70                  75                  80

atc tgt ccg atg aga tgt gcg gaa gat ccg gac aga ttg tat aag tat      288
Ile Cys Pro Met Arg Cys Ala Glu Asp Pro Asp Arg Leu Tyr Lys Tyr
                85                  90                  95

gca act aag ctg aag aaa aac tgt aag gaa ata act gat aag gaa ttg      336
Ala Thr Lys Leu Lys Lys Asn Cys Lys Glu Ile Thr Asp Lys Glu Leu
            100                 105                 110

gac aag aaa atg aag gag ctc gcc gcc gtc atg agc gac cct gac ctg      384
Asp Lys Lys Met Lys Glu Leu Ala Ala Val Met Ser Asp Pro Asp Leu
        115                 120                 125

gaa act gag act atg tgc ctc cac gac gac gag tcg tgt cgc tac gaa      432
Glu Thr Glu Thr Met Cys Leu His Asp Asp Glu Ser Cys Arg Tyr Glu
    130                 135                 140

ggg caa gtc gct gtt tac cag gat gta tac gcg gtt gac gga ccg aca      480
Gly Gln Val Ala Val Tyr Gln Asp Val Tyr Ala Val Asp Gly Pro Thr
145                 150                 155                 160

agt ctc tat cac caa gcc aat aag gga gtt aga gtc gcc tac tgg ata      528
Ser Leu Tyr His Gln Ala Asn Lys Gly Val Arg Val Ala Tyr Trp Ile
                165                 170                 175

ggc ttt gac acc acc cct ttt atg ttt aag aac ttg gct gga gca tat      576
Gly Phe Asp Thr Thr Pro Phe Met Phe Lys Asn Leu Ala Gly Ala Tyr
            180                 185                 190

cca tca tac tct acc aac tgg gcc gac gaa acc gtg tta acg gct cgt      624
Pro Ser Tyr Ser Thr Asn Trp Ala Asp Glu Thr Val Leu Thr Ala Arg
        195                 200                 205

aac ata ggc cta tgc agc tct gac gtt atg gag cgg tca cgt aga ggg      672
Asn Ile Gly Leu Cys Ser Ser Asp Val Met Glu Arg Ser Arg Arg Gly
    210                 215                 220

atg tcc att ctt aga aag aag tat ttg aaa cca tcc aac aat gtt cta      720
Met Ser Ile Leu Arg Lys Lys Tyr Leu Lys Pro Ser Asn Asn Val Leu
225                 230                 235                 240

ttc tct gtt ggc tcg acc atc tac cac gag aag agg gac tta ctg agg      768
Phe Ser Val Gly Ser Thr Ile Tyr His Glu Lys Arg Asp Leu Leu Arg
                245                 250                 255

agc tgg cac ctg ccg tct gta ttt cac tta cgt ggc aag caa aat tac      816
Ser Trp His Leu Pro Ser Val Phe His Leu Arg Gly Lys Gln Asn Tyr
            260                 265                 270
aca tgt cgg tgt gag act ata gtt agt tgc gac ggg tac gtc gtt aaa      864
Thr Cys Arg Cys Glu Thr Ile Val Ser Cys Asp Gly Tyr Val Val Lys
        275                 280                 285
```

```
aga ata gct atc agt cca ggc ctg tat ggg aag cct tca ggc tat gct      912
Arg Ile Ala Ile Ser Pro Gly Leu Tyr Gly Lys Pro Ser Gly Tyr Ala
    290                 295                 300

gct acg atg cac cgc gag gga ttc ttg tgc tgc aaa gtg aca gac aca      960
Ala Thr Met His Arg Glu Gly Phe Leu Cys Cys Lys Val Thr Asp Thr
305                 310                 315                 320

tta aac ggg gag agg gtc tct ttt ccc gtg tgc acg tat gtg cca gct     1008
Leu Asn Gly Glu Arg Val Ser Phe Pro Val Cys Thr Tyr Val Pro Ala
                325                 330                 335

aca ttg tgt gac caa atg act ggc ata ctg gca aca gat gtc agt gcg     1056
Thr Leu Cys Asp Gln Met Thr Gly Ile Leu Ala Thr Asp Val Ser Ala
            340                 345                 350

gac gac gcg caa aaa ctg ctg gtt ggg ctc aac cag cgt ata gtc gtc     1104
Asp Asp Ala Gln Lys Leu Leu Val Gly Leu Asn Gln Arg Ile Val Val
        355                 360                 365

aac ggt cgc acc cag aga aac acc aat acc atg aaa aat tac ctt ttg     1152
Asn Gly Arg Thr Gln Arg Asn Thr Asn Thr Met Lys Asn Tyr Leu Leu
    370                 375                 380

ccc gta gtg gcc cag gca ttt gct agg tgg gca aag gaa tat aag gaa     1200
Pro Val Val Ala Gln Ala Phe Ala Arg Trp Ala Lys Glu Tyr Lys Glu
385                 390                 395                 400

gat caa gaa gat gaa agg cca cta gga cta cga gat aga cag tta gtc     1248
Asp Gln Glu Asp Glu Arg Pro Leu Gly Leu Arg Asp Arg Gln Leu Val
                405                 410                 415

atg ggg tgt tgt tgg gct ttt aga agg cac aag ata aca tct att tat     1296
Met Gly Cys Cys Trp Ala Phe Arg Arg His Lys Ile Thr Ser Ile Tyr
            420                 425                 430

aag cgc ccg gat acc caa acc atc atc aaa gtg aac agc gat ttc cac     1344
Lys Arg Pro Asp Thr Gln Thr Ile Ile Lys Val Asn Ser Asp Phe His
        435                 440                 445

tca ttc gtg ctg ccc agg ata ggc agt aac aca ttg gag atc ggg ctg     1392
Ser Phe Val Leu Pro Arg Ile Gly Ser Asn Thr Leu Glu Ile Gly Leu
    450                 455                 460

aga aca aga atc agg aaa atg tta gag gag cac aag gag ccg tca cct     1440
Arg Thr Arg Ile Arg Lys Met Leu Glu Glu His Lys Glu Pro Ser Pro
465                 470                 475                 480

ctc att acc gcc gag gac gta caa gaa gct aag tgc gca gcc gat gag     1488
Leu Ile Thr Ala Glu Asp Val Gln Glu Ala Lys Cys Ala Ala Asp Glu
                485                 490                 495
gct aag gag gtg cgt gaa gcc gag gag ttg cgc gca gct cta cca cct     1536
Ala Lys Glu Val Arg Glu Ala Glu Glu Leu Arg Ala Ala Leu Pro Pro
            500                 505                 510
```

```
ttg gca gct gat gtt gag gag ccc act ctg gaa gcc gat gtc gac ttg     1584
Leu Ala Ala Asp Val Glu Glu Pro Thr Leu Glu Ala Asp Val Asp Leu
        515                 520                 525

atg tta caa gag gct ggg gcc ggc tca gtg gag aca cct cgt ggc ttg     1632
Met Leu Gln Glu Ala Gly Ala Gly Ser Val Glu Thr Pro Arg Gly Leu
    530                 535                 540

ata aag gtt acc agc tac gct ggc gag gac aag atc ggc tct tac gct     1680
Ile Lys Val Thr Ser Tyr Ala Gly Glu Asp Lys Ile Gly Ser Tyr Ala
545                 550                 555                 560

gtg ctt tct ccg cag gct gta ctc aag agt gaa aaa tta tct tgc atc     1728
Val Leu Ser Pro Gln Ala Val Leu Lys Ser Glu Lys Leu Ser Cys Ile
                565                 570                 575

cac cct ctc gct gaa caa gtc ata gtg ata aca cac tct ggc cga aaa     1776
His Pro Leu Ala Glu Gln Val Ile Val Ile Thr His Ser Gly Arg Lys
            580                 585                 590

ggg cgt tat gcc gtg gaa cca tac cat ggt aaa gta gtg gtg cca gag     1824
Gly Arg Tyr Ala Val Glu Pro Tyr His Gly Lys Val Val Val Pro Glu
        595                 600                 605

gga cat gca ata ccc gtc cag gac ttt caa gct ctg agt gaa agt gcc     1872
Gly His Ala Ile Pro Val Gln Asp Phe Gln Ala Leu Ser Glu Ser Ala
    610                 615                 620

acc att gtg tac aac gaa cgt gag ttc gta aac agg tac ctg cac cat     1920
Thr Ile Val Tyr Asn Glu Arg Glu Phe Val Asn Arg Tyr Leu His His
625                 630                 635                 640

att gcc aca cat gga gga gcg ctg aac act gat gaa gaa tat tac aaa     1968
Ile Ala Thr His Gly Gly Ala Leu Asn Thr Asp Glu Glu Tyr Tyr Lys
                645                 650                 655

act gtc aag ccc agc gag cac gac ggc gaa tac ctg tac gac atc gac     2016
Thr Val Lys Pro Ser Glu His Asp Gly Glu Tyr Leu Tyr Asp Ile Asp
            660                 665                 670

agg aaa cag tgc gtc aag aaa gaa cta gtc act ggg cta ggg ctc aca     2064
Arg Lys Gln Cys Val Lys Lys Glu Leu Val Thr Gly Leu Gly Leu Thr
        675                 680                 685

ggc gag ctg gtg gat cct ccc ttc cat gaa ttc gcc tac gag agt ctg     2112
Gly Glu Leu Val Asp Pro Pro Phe His Glu Phe Ala Tyr Glu Ser Leu
    690                 695                 700

aga aca cga cca gcc gct cct tac caa gta cca acc ata ggg gtg tat     2160
Arg Thr Arg Pro Ala Ala Pro Tyr Gln Val Pro Thr Ile Gly Val Tyr
705                 710                 715                 720
ggc gtg cca gga tca ggc aag tct ggc atc att aaa agc gca gtc acc     2208
Gly Val Pro Gly Ser Gly Lys Ser Gly Ile Ile Lys Ser Ala Val Thr
                725                 730                 735
```

```
aaa aaa gat cta gtg gtg agc gcc aag aaa gaa aac tgt gca gaa att     2256
Lys Lys Asp Leu Val Val Ser Ala Lys Lys Glu Asn Cys Ala Glu Ile
            740                 745                 750

ata agg gac gtc aag aaa atg aaa ggg ctg gac gtc aat gcc aga act     2304
Ile Arg Asp Val Lys Lys Met Lys Gly Leu Asp Val Asn Ala Arg Thr
        755                 760                 765

gtg gac tca gtg ctc ttg aat gga tgc aaa cac ccc gta gag acc ctg     2352
Val Asp Ser Val Leu Leu Asn Gly Cys Lys His Pro Val Glu Thr Leu
    770                 775                 780

tat att gac gaa gct ttt gct tgt cat gca ggt act ctc aga gcg ctc     2400
Tyr Ile Asp Glu Ala Phe Ala Cys His Ala Gly Thr Leu Arg Ala Leu
785                 790                 795                 800

ata gcc att ata aga cct aaa aag gca gtg ctc tgc ggg gat ccc aaa     2448
Ile Ala Ile Ile Arg Pro Lys Lys Ala Val Leu Cys Gly Asp Pro Lys
                805                 810                 815

cag tgc ggt ttt ttt aac atg atg tgc ctg aaa gtg cat ttt aac cac     2496
Gln Cys Gly Phe Phe Asn Met Met Cys Leu Lys Val His Phe Asn His
            820                 825                 830

gag att tgc aca caa gtc ttc cac aaa agc atc tct cgc cgt tgc act     2544
Glu Ile Cys Thr Gln Val Phe His Lys Ser Ile Ser Arg Arg Cys Thr
        835                 840                 845

aaa tct gtg act tcg gtc gtc tca acc ttg ttt tac gac aaa aaa atg     2592
Lys Ser Val Thr Ser Val Val Ser Thr Leu Phe Tyr Asp Lys Lys Met
    850                 855                 860

aga acg acg aat ccg aaa gag act aag att gtg att gac act acc ggc     2640
Arg Thr Thr Asn Pro Lys Glu Thr Lys Ile Val Ile Asp Thr Thr Gly
865                 870                 875                 880

agt acc aaa cct aag cag gac gat ctc att ctc act tgt ttc aga ggg     2688
Ser Thr Lys Pro Lys Gln Asp Asp Leu Ile Leu Thr Cys Phe Arg Gly
                885                 890                 895

tgg gtg aag cag ttg caa ata gat tac aaa ggc aac gaa ata atg acg     2736
Trp Val Lys Gln Leu Gln Ile Asp Tyr Lys Gly Asn Glu Ile Met Thr
            900                 905                 910

gca gct gcc tct caa ggg ctg acc cgt aaa ggt gtg tat gcc gtt cgg     2784
Ala Ala Ala Ser Gln Gly Leu Thr Arg Lys Gly Val Tyr Ala Val Arg
        915                 920                 925

tac aag gtg aat gaa aat cct ctg tac gca ccc acc tca gaa cat gtg     2832
Tyr Lys Val Asn Glu Asn Pro Leu Tyr Ala Pro Thr Ser Glu His Val
    930                 935                 940
aac gtc cta ctg acc cgc acg gag gac cgc atc gtg tgg aaa aca cta     2880
Asn Val Leu Leu Thr Arg Thr Glu Asp Arg Ile Val Trp Lys Thr Leu
945                 950                 955                 960
```

```
gcc ggc gac cca tgg ata aaa aca ctg act gcc aag tac cct ggg aat     2928
Ala Gly Asp Pro Trp Ile Lys Thr Leu Thr Ala Lys Tyr Pro Gly Asn
                965                 970                 975

ttc act gcc acg ata gag gag tgg caa gca gag cat gat gcc atc atg     2976
Phe Thr Ala Thr Ile Glu Glu Trp Gln Ala Glu His Asp Ala Ile Met
            980                 985                 990

agg cac atc ttg gag aga ccg gac cct acc gac gtc ttc cag aat aag     3024
Arg His Ile Leu Glu Arg Pro Asp Pro Thr Asp Val Phe Gln Asn Lys
        995                 1000                1005

gca aac gtg tgt tgg gcc aag gct tta gtg ccg gtg ctg aag acc gct     3072
Ala Asn Val Cys Trp Ala Lys Ala Leu Val Pro Val Leu Lys Thr Ala
    1010                1015                1020

ggc ata gac atg acc act gaa caa tgg aac act gtg gat tat ttt gaa     3120
Gly Ile Asp Met Thr Thr Glu Gln Trp Asn Thr Val Asp Tyr Phe Glu
1025                1030                1035                1040

acg gac aaa gct cac tca gca gag ata gta ttg aac caa cta tgc gtg     3168
Thr Asp Lys Ala His Ser Ala Glu Ile Val Leu Asn Gln Leu Cys Val
                1045                1050                1055

agg ttc ttt gga ctc gat ctg gac tcc ggt cta ttt tct gca ccc act     3216
Arg Phe Phe Gly Leu Asp Leu Asp Ser Gly Leu Phe Ser Ala Pro Thr
            1060                1065                1070

gtt ccg tta tcc att agg aat aat cac tgg gat aac tcc ccg tcg cct     3264
Val Pro Leu Ser Ile Arg Asn Asn His Trp Asp Asn Ser Pro Ser Pro
        1075                1080                1085

aac atg tac ggg ctg aat aaa gaa gtg gtc cgt cag ctc tct cgc agg     3312
Asn Met Tyr Gly Leu Asn Lys Glu Val Val Arg Gln Leu Ser Arg Arg
    1090                1095                1100

tac cca caa ctg cct cgg gca gtt gcc act gga aga gtc tat gac atg     3360
Tyr Pro Gln Leu Pro Arg Ala Val Ala Thr Gly Arg Val Tyr Asp Met
1105                1110                1115                1120

aac act ggt aca ctg cgc aat tat gat ccg cgc ata aac cta gta cct     3408
Asn Thr Gly Thr Leu Arg Asn Tyr Asp Pro Arg Ile Asn Leu Val Pro
                1125                1130                1135

gta aac aga aga ctg cct cat gct tta gtc ctc cac cat aat gaa cac     3456
Val Asn Arg Arg Leu Pro His Ala Leu Val Leu His His Asn Glu His
            1140                1145                1150

cca cag agt gac ttt tct tca ttc gtc agc aaa ttg aag ggc aga act     3504
Pro Gln Ser Asp Phe Ser Ser Phe Val Ser Lys Leu Lys Gly Arg Thr
        1155                1160                1165
gtc ctg gtg gtc ggg gaa aag ttg tcc gtc cca ggc aaa atg gtt gac     3552
Val Leu Val Val Gly Glu Lys Leu Ser Val Pro Gly Lys Met Val Asp
    1170                1175                1180
```

```
tgg ttg tca gac cgg cct gag gct acc ttc aga gct cgg ctg gat tta     3600
Trp Leu Ser Asp Arg Pro Glu Ala Thr Phe Arg Ala Arg Leu Asp Leu
1185                1190                1195                1200

ggc atc cca ggt gat gtg ccc aaa tat gac ata ata ttt gtt aat gtg     3648
Gly Ile Pro Gly Asp Val Pro Lys Tyr Asp Ile Ile Phe Val Asn Val
                1205                1210                1215

agg acc cca tat aaa tac cat cac tat cag cag tgt gaa gac cat gcc     3696
Arg Thr Pro Tyr Lys Tyr His His Tyr Gln Gln Cys Glu Asp His Ala
            1220                1225                1230

att aag ctt agc atg ttg acc aag aaa gct tgt ctg cat ctg aat ccc     3744
Ile Lys Leu Ser Met Leu Thr Lys Lys Ala Cys Leu His Leu Asn Pro
        1235                1240                1245

ggc gga acc tgt gtc agc ata ggt tat ggt tac gct gac agg gcc agc     3792
Gly Gly Thr Cys Val Ser Ile Gly Tyr Gly Tyr Ala Asp Arg Ala Ser
    1250                1255                1260

gaa agc atc att ggt gct ata gcg cgg cag ttc aag ttt tcc cgg gta     3840
Glu Ser Ile Ile Gly Ala Ile Ala Arg Gln Phe Lys Phe Ser Arg Val
1265                1270                1275                1280

tgc aaa ccg aaa tcc tca ctt gaa gag acg gaa gtt ctg ttt gta ttc     3888
Cys Lys Pro Lys Ser Ser Leu Glu Glu Thr Glu Val Leu Phe Val Phe
                1285                1290                1295

att ggg tac gat cgc aag gcc cgt acg cac aat cct tac aag ctt tca     3936
Ile Gly Tyr Asp Arg Lys Ala Arg Thr His Asn Pro Tyr Lys Leu Ser
            1300                1305                1310

tca acc ttg acc aac att tat aca ggt tcc aga ctc cac gaa gcc gga     3984
Ser Thr Leu Thr Asn Ile Tyr Thr Gly Ser Arg Leu His Glu Ala Gly
        1315                1320                1325

tgt gca ccc tca tat cat gtg gtg cga ggg gat att gcc acg gcc acc     4032
Cys Ala Pro Ser Tyr His Val Val Arg Gly Asp Ile Ala Thr Ala Thr
    1330                1335                1340

gaa gga gtg att ata aat gct gct aac agc aaa gga caa cct ggc gga     4080
Glu Gly Val Ile Ile Asn Ala Ala Asn Ser Lys Gly Gln Pro Gly Gly
1345                1350                1355                1360

ggg gtg tgc gga gcg ctg tat aag aag ttc ccg gaa agc ttc gat tta     4128
Gly Val Cys Gly Ala Leu Tyr Lys Lys Phe Pro Glu Ser Phe Asp Leu
                1365                1370                1375

cag ccg atc gaa gta gga aaa gcg cga ctg gtc aaa ggt gca gct aaa     4176
Gln Pro Ile Glu Val Gly Lys Ala Arg Leu Val Lys Gly Ala Ala Lys
            1380                1385                1390
cat atc att cat gcc gta gga cca aac ttc aac aaa gtt tcg gag gtt     4224
His Ile Ile His Ala Val Gly Pro Asn Phe Asn Lys Val Ser Glu Val
        1395                1400                1405
```

```
gaa ggt gac aaa cag ttg gca gag gct tat gag tcc atc gct aag att     4272
Glu Gly Asp Lys Gln Leu Ala Glu Ala Tyr Glu Ser Ile Ala Lys Ile
    1410                1415                1420

gtc aac gat aac aat tac aag tca gta gcg att cca ctg ttg tcc acc     4320
Val Asn Asp Asn Asn Tyr Lys Ser Val Ala Ile Pro Leu Leu Ser Thr
1425                1430                1435                1440

ggc atc ttt tcc ggg aac aaa gat cga cta acc caa tca ttg aac cat     4368
Gly Ile Phe Ser Gly Asn Lys Asp Arg Leu Thr Gln Ser Leu Asn His
                1445                1450                1455

ttg ctg aca gct tta gac acc act gat gca gat gta gcc ata tac tgc     4416
Leu Leu Thr Ala Leu Asp Thr Thr Asp Ala Asp Val Ala Ile Tyr Cys
            1460                1465                1470

agg gac aag aaa tgg gaa atg act ctc aag gaa gca gtg gct agg aga     4464
Arg Asp Lys Lys Trp Glu Met Thr Leu Lys Glu Ala Val Ala Arg Arg
        1475                1480                1485

gaa gca gtg gag gag ata tgc ata tcc gac gac tct tca gtg aca gaa     4512
Glu Ala Val Glu Glu Ile Cys Ile Ser Asp Asp Ser Ser Val Thr Glu
    1490                1495                1500

cct gat gca gag ctg gtg agg gtg cat ccg aag agt tct ttg gct gga     4560
Pro Asp Ala Glu Leu Val Arg Val His Pro Lys Ser Ser Leu Ala Gly
1505                1510                1515                1520

agg aag ggc tac agc aca agc gat ggc aaa act ttc tca tat ttg gaa     4608
Arg Lys Gly Tyr Ser Thr Ser Asp Gly Lys Thr Phe Ser Tyr Leu Glu
                1525                1530                1535

ggg acc aag ttt cac cag gcg gcc aag gat ata gca gaa att aat gcc     4656
Gly Thr Lys Phe His Gln Ala Ala Lys Asp Ile Ala Glu Ile Asn Ala
            1540                1545                1550

atg tgg ccc gtt gca acg gag gcc aat gag cag gta tgc atg tat atc     4704
Met Trp Pro Val Ala Thr Glu Ala Asn Glu Gln Val Cys Met Tyr Ile
        1555                1560                1565

ctc gga gaa agc atg agc agt att agg tcg aaa tgc ccc gtc gaa gag     4752
Leu Gly Glu Ser Met Ser Ser Ile Arg Ser Lys Cys Pro Val Glu Glu
    1570                1575                1580

tcg gaa gcc tcc aca cca cct agc acg ctg cct tgc ttg tgc atc cat     4800
Ser Glu Ala Ser Thr Pro Pro Ser Thr Leu Pro Cys Leu Cys Ile His
1585                1590                1595                1600

gcc atg act cca gaa aga gta cag cgc cta aaa gcc tca cgt cca gaa     4848
Ala Met Thr Pro Glu Arg Val Gln Arg Leu Lys Ala Ser Arg Pro Glu
                1605                1610                1615
caa att act gtg tgc tca tcc ttt cca ttg ccg aag tat aga atc act     4896
Gln Ile Thr Val Cys Ser Ser Phe Pro Leu Pro Lys Tyr Arg Ile Thr
            1620                1625                1630
```

```
ggt gtg cag aag atc caa tgc tcc cag cct ata ttg ttc tca ccg aaa     4944
Gly Val Gln Lys Ile Gln Cys Ser Gln Pro Ile Leu Phe Ser Pro Lys
        1635                1640                1645

gtg cct gcg tat att cat cca agg aag tat ctc gtg gaa aca cca ccg     4992
Val Pro Ala Tyr Ile His Pro Arg Lys Tyr Leu Val Glu Thr Pro Pro
    1650                1655                1660

gta gac gag act ccg gag cca tcg gca gag aac caa tcc aca gag ggg     5040
Val Asp Glu Thr Pro Glu Pro Ser Ala Glu Asn Gln Ser Thr Glu Gly
1665                1670                1675                1680

aca cct gaa caa cca cca ctt ata acc gag gat gag acc agg act aga     5088
Thr Pro Glu Gln Pro Pro Leu Ile Thr Glu Asp Glu Thr Arg Thr Arg
                1685                1690                1695

acg cct gag ccg atc atc atc gaa gag gaa gaa gag gat agc ata agt     5136
Thr Pro Glu Pro Ile Ile Ile Glu Glu Glu Glu Glu Asp Ser Ile Ser
            1700                1705                1710

ttg ctg tca gat ggc ccg acc cac cag gtg ctg caa gtc gag gca gac     5184
Leu Leu Ser Asp Gly Pro Thr His Gln Val Leu Gln Val Glu Ala Asp
        1715                1720                1725

att cac ggg ccg ccc tct gta tct agc tca tcc tgg tcc att cct cat     5232
Ile His Gly Pro Pro Ser Val Ser Ser Ser Ser Trp Ser Ile Pro His
    1730                1735                1740

gca tcc gac ttt gat gtg gac agt tta tcc ata ctt gac acc ctg gag     5280
Ala Ser Asp Phe Asp Val Asp Ser Leu Ser Ile Leu Asp Thr Leu Glu
1745                1750                1755                1760

gga gct agc gtg acc agc ggg gca acg tca gcc gag act aac tct tac     5328
Gly Ala Ser Val Thr Ser Gly Ala Thr Ser Ala Glu Thr Asn Ser Tyr
                1765                1770                1775

ttc gca aag agt atg gag ttt ctg gcg cga ccg gtg cct gcg cct cga     5376
Phe Ala Lys Ser Met Glu Phe Leu Ala Arg Pro Val Pro Ala Pro Arg
            1780                1785                1790

aca gta ttc agg aac cct cca cat ccc gct ccg cgc aca aga aca ccg     5424
Thr Val Phe Arg Asn Pro Pro His Pro Ala Pro Arg Thr Arg Thr Pro
        1795                1800                1805

tca ctt gca ccc agc agg gcc tgc tcg aga acc agc cta gtt tcc acc     5472
Ser Leu Ala Pro Ser Arg Ala Cys Ser Arg Thr Ser Leu Val Ser Thr
    1810                1815                1820

ccg cca ggc gtg aat agg gtg atc act aga gag gag ctc gag gcg ctt     5520
Pro Pro Gly Val Asn Arg Val Ile Thr Arg Glu Glu Leu Glu Ala Leu
1825                1830                1835                1840
acc ccg tca cgc act cct agc agg tcg gtc tcg aga acc agc ctg gtc     5568
Thr Pro Ser Arg Thr Pro Ser Arg Ser Val Ser Arg Thr Ser Leu Val
                1845                1850                1855
```

```
tcc aac ccg cca ggc gta aat agg gtg att aca aga gag gag ttt gag     5616
Ser Asn Pro Pro Gly Val Asn Arg Val Ile Thr Arg Glu Glu Phe Glu
            1860                1865                1870

gcg ttc gta gca caa caa caa tga cgg ttt gat gcg ggt gca tac atc     5664
Ala Phe Val Ala Gln Gln Gln  *  Arg Phe Asp Ala Gly Ala Tyr Ile
        1875                    1880                1885

ttt tcc tcc gac acc ggt caa ggg cat tta caa caa aaa tca gta agg     5712
Phe Ser Ser Asp Thr Gly Gln Gly His Leu Gln Gln Lys Ser Val Arg
        1890                1895                1900

caa acg gtg cta tcc gaa gtg gtg ttg gag agg acc gaa ttg gag att     5760
Gln Thr Val Leu Ser Glu Val Val Leu Glu Arg Thr Glu Leu Glu Ile
    1905                1910                1915

tcg tat gcc ccg cgc ctc gac caa gaa aaa gaa gaa tta cta cgc aag     5808
Ser Tyr Ala Pro Arg Leu Asp Gln Glu Lys Glu Glu Leu Leu Arg Lys
1920                1925                1930                1935

aaa tta cag tta aat ccc aca cct gct aac aga agc aga tac cag tcc     5856
Lys Leu Gln Leu Asn Pro Thr Pro Ala Asn Arg Ser Arg Tyr Gln Ser
                1940                1945                1950

agg aag gtg gag aac atg aaa gcc ata aca gct aga cgt att ctg caa     5904
Arg Lys Val Glu Asn Met Lys Ala Ile Thr Ala Arg Arg Ile Leu Gln
            1955                1960                1965

ggc cta ggg cat tat ttg aag gca gaa gga aaa gtg gag tgc tac cga     5952
Gly Leu Gly His Tyr Leu Lys Ala Glu Gly Lys Val Glu Cys Tyr Arg
        1970                1975                1980

acc ctg cat cct gtt cct ttg tat tca tct agt gtg aac cgt gcc ttt     6000
Thr Leu His Pro Val Pro Leu Tyr Ser Ser Ser Val Asn Arg Ala Phe
    1985                1990                1995

tca agc ccc aag gtc gca gtg gaa gcc tgt aac gcc atg ttg aaa gag     6048
Ser Ser Pro Lys Val Ala Val Glu Ala Cys Asn Ala Met Leu Lys Glu
2000                2005                2010                2015

aac ttt ccg act gtg gct tct tac tgt att att cca gag tac gat gcc     6096
Asn Phe Pro Thr Val Ala Ser Tyr Cys Ile Ile Pro Glu Tyr Asp Ala
                2020                2025                2030

tat ttg gac atg gtt gac gga gct tca tgc tgc tta gac act gcc agt     6144
Tyr Leu Asp Met Val Asp Gly Ala Ser Cys Cys Leu Asp Thr Ala Ser
            2035                2040                2045

ttt tgc cct gca aag ctg cgc agc ttt cca aag aaa cac tcc tat ttg     6192
Phe Cys Pro Ala Lys Leu Arg Ser Phe Pro Lys Lys His Ser Tyr Leu
        2050                2055                2060
gaa ccc aca ata cga tcg gca gtg cct tca gcg atc cag aac acg ctc     6240
Glu Pro Thr Ile Arg Ser Ala Val Pro Ser Ala Ile Gln Asn Thr Leu
    2065                2070                2075
```

```
cag aac gtc ctg gca gct gcc aca aaa aga aat tgc aat gtc acg caa     6288
Gln Asn Val Leu Ala Ala Ala Thr Lys Arg Asn Cys Asn Val Thr Gln
2080                2085                2090                2095

atg aga gaa ttg ccc gta ttg gat tcg gcg gcc ttt aat gtg gaa tgc     6336
Met Arg Glu Leu Pro Val Leu Asp Ser Ala Ala Phe Asn Val Glu Cys
                2100                2105                2110

ttc aag aaa tat gcg tgt aat aat gaa tat tgg gaa acg ttt aaa gaa     6384
Phe Lys Lys Tyr Ala Cys Asn Asn Glu Tyr Trp Glu Thr Phe Lys Glu
            2115                2120                2125

aac ccc atc agg ctt act gaa gaa aac gtg gta aat tac att acc aaa     6432
Asn Pro Ile Arg Leu Thr Glu Glu Asn Val Val Asn Tyr Ile Thr Lys
        2130                2135                2140

tta aaa gga cca aaa gct gct gct ctt ttt gcg aag aca cat aat ttg     6480
Leu Lys Gly Pro Lys Ala Ala Ala Leu Phe Ala Lys Thr His Asn Leu
    2145                2150                2155

aat atg ttg cag gac ata cca atg gac agg ttt gta atg gac tta aag     6528
Asn Met Leu Gln Asp Ile Pro Met Asp Arg Phe Val Met Asp Leu Lys
2160                2165                2170                2175

aga gac gtg aaa gtg act cca gga aca aaa cat act gaa gaa cgg ccc     6576
Arg Asp Val Lys Val Thr Pro Gly Thr Lys His Thr Glu Glu Arg Pro
                2180                2185                2190

aag gta cag gtg atc cag gct gcc gat ccg cta gca aca gcg tat ctg     6624
Lys Val Gln Val Ile Gln Ala Ala Asp Pro Leu Ala Thr Ala Tyr Leu
            2195                2200                2205

tgc gga atc cac cga gag ctg gtt agg aga tta aat gcg gtc ctg ctt     6672
Cys Gly Ile His Arg Glu Leu Val Arg Arg Leu Asn Ala Val Leu Leu
        2210                2215                2220

ccg aac att cat aca ctg ttt gat atg tcg gct gaa gac ttt gac gct     6720
Pro Asn Ile His Thr Leu Phe Asp Met Ser Ala Glu Asp Phe Asp Ala
    2225                2230                2235

att ata gcc gag cac ttc cag cct ggg gat tgt gtt ctg gaa act gac     6768
Ile Ile Ala Glu His Phe Gln Pro Gly Asp Cys Val Leu Glu Thr Asp
2240                2245                2250                2255

atc gcg tcg ttt gat aaa agt gag gac gac gcc atg gct ctg acc gcg     6816
Ile Ala Ser Phe Asp Lys Ser Glu Asp Asp Ala Met Ala Leu Thr Ala
                2260                2265                2270

tta atg att ctg gaa gac tta ggt gtg gac gca gag ctg ttg acg ctg     6864
Leu Met Ile Leu Glu Asp Leu Gly Val Asp Ala Glu Leu Leu Thr Leu
            2275                2280                2285
att gag gcg gct ttc ggc gaa att tca tca ata cat ttg ccc act aaa     6912
Ile Glu Ala Ala Phe Gly Glu Ile Ser Ser Ile His Leu Pro Thr Lys
        2290                2295                2300
```

```
act aaa ttt aaa ttc gga gcc atg atg aaa tct gga atg ttc ctc aca     6960
Thr Lys Phe Lys Phe Gly Ala Met Met Lys Ser Gly Met Phe Leu Thr
    2305                2310                2315

ctg ttt gtg aac aca gtc att aac att gta atc gca agc aga gtg ttg     7008
Leu Phe Val Asn Thr Val Ile Asn Ile Val Ile Ala Ser Arg Val Leu
2320                2325                2330                2335

aga gaa cgg cta acc gga tca cca tgt gca gca ttc att gga gat gac     7056
Arg Glu Arg Leu Thr Gly Ser Pro Cys Ala Ala Phe Ile Gly Asp Asp
                2340                2345                2350

aat atc gtg aaa gga gtc aaa tcg gac aaa tta atg gca gac agg tgc     7104
Asn Ile Val Lys Gly Val Lys Ser Asp Lys Leu Met Ala Asp Arg Cys
            2355                2360                2365

gcc acc tgg ttg aat atg gaa gtc aag att ata gat gct gtg gtg ggc     7152
Ala Thr Trp Leu Asn Met Glu Val Lys Ile Ile Asp Ala Val Val Gly
        2370                2375                2380

gag aaa gcg ccc tat ttc tgt gga ggg ttt att ttg tgt gac tcc gtg     7200
Glu Lys Ala Pro Tyr Phe Cys Gly Gly Phe Ile Leu Cys Asp Ser Val
    2385                2390                2395

acc ggc aca gcg tgc cgt gtg gca gac ccc cta aaa agg ctg ttt aag     7248
Thr Gly Thr Ala Cys Arg Val Ala Asp Pro Leu Lys Arg Leu Phe Lys
2400                2405                2410                2415

ctt ggc aaa cct ctg gca gca gac gat gaa cat gat gat gac agg aga     7296
Leu Gly Lys Pro Leu Ala Ala Asp Asp Glu His Asp Asp Asp Arg Arg
                2420                2425                2430

agg gca ttg cat gaa gag tca aca cgc tgg aac cga gtg ggt att ctt     7344
Arg Ala Leu His Glu Glu Ser Thr Arg Trp Asn Arg Val Gly Ile Leu
            2435                2440                2445

tca gag ctg tgc aag gca gta gaa tca agg tat gaa acc gta gga act     7392
Ser Glu Leu Cys Lys Ala Val Glu Ser Arg Tyr Glu Thr Val Gly Thr
        2450                2455                2460

tcc atc ata gtt atg gcc atg act act cta gct agc agt gtt aaa tca     7440
Ser Ile Ile Val Met Ala Met Thr Thr Leu Ala Ser Ser Val Lys Ser
    2465                2470                2475

ttc agc tac ctg aga ggg gcc cct ata act ctc tac ggc                 7479
Phe Ser Tyr Leu Arg Gly Ala Pro Ile Thr Leu Tyr Gly
2480                2485                2490
```

<210> 3
<211> 2492
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence; Note = synthetic construct

<400> 3

```
Met Glu Lys Val His Val Asp Ile Glu Glu Asp Ser Pro Phe Leu Arg
 1               5                  10                  15
Ala Leu Gln Arg Ser Phe Pro Gln Phe Glu Val Glu Ala Lys Gln Val
            20                  25                  30
Thr Asp Asn Asp His Ala Asn Ala Arg Ala Phe Ser His Leu Ala Ser
        35                  40                  45
Lys Leu Ile Glu Thr Glu Val Asp Pro Ser Asp Thr Ile Leu Asp Ile
    50                  55                  60
Gly Ser Ala Pro Ala Arg Arg Met Tyr Ser Lys His Lys Tyr His Cys
65                  70                  75                  80
Ile Cys Pro Met Arg Cys Ala Glu Asp Pro Asp Arg Leu Tyr Lys Tyr
                85                  90                  95
Ala Thr Lys Leu Lys Lys Asn Cys Lys Glu Ile Thr Asp Lys Glu Leu
            100                 105                 110
Asp Lys Lys Met Lys Glu Leu Ala Ala Val Met Ser Asp Pro Asp Leu
        115                 120                 125
Glu Thr Glu Thr Met Cys Leu His Asp Asp Glu Ser Cys Arg Tyr Glu
    130                 135                 140
Gly Gln Val Ala Val Tyr Gln Asp Val Tyr Ala Val Asp Gly Pro Thr
145                 150                 155                 160
Ser Leu Tyr His Gln Ala Asn Lys Gly Val Arg Val Ala Tyr Trp Ile
                165                 170                 175
Gly Phe Asp Thr Thr Pro Phe Met Phe Lys Asn Leu Ala Gly Ala Tyr
            180                 185                 190
Pro Ser Tyr Ser Thr Asn Trp Ala Asp Glu Thr Val Leu Thr Ala Arg
        195                 200                 205
Asn Ile Gly Leu Cys Ser Ser Asp Val Met Glu Arg Ser Arg Arg Gly
    210                 215                 220
Met Ser Ile Leu Arg Lys Lys Tyr Leu Lys Pro Ser Asn Asn Val Leu
225                 230                 235                 240
Phe Ser Val Gly Ser Thr Ile Tyr His Glu Lys Arg Asp Leu Leu Arg
                245                 250                 255
Ser Trp His Leu Pro Ser Val Phe His Leu Arg Gly Lys Gln Asn Tyr
            260                 265                 270
Thr Cys Arg Cys Glu Thr Ile Val Ser Cys Asp Gly Tyr Val Val Lys
        275                 280                 285
Arg Ile Ala Ile Ser Pro Gly Leu Tyr Gly Lys Pro Ser Gly Tyr Ala
    290                 295                 300
Ala Thr Met His Arg Glu Gly Phe Leu Cys Cys Lys Val Thr Asp Thr
305                 310                 315                 320
Leu Asn Gly Glu Arg Val Ser Phe Pro Val Cys Thr Tyr Val Pro Ala
                325                 330                 335
Thr Leu Cys Asp Gln Met Thr Gly Ile Leu Ala Thr Asp Val Ser Ala
            340                 345                 350
Asp Asp Ala Gln Lys Leu Leu Val Gly Leu Asn Gln Arg Ile Val Val
        355                 360                 365
Asn Gly Arg Thr Gln Arg Asn Thr Asn Thr Met Lys Asn Tyr Leu Leu
    370                 375                 380
Pro Val Val Ala Gln Ala Phe Ala Arg Trp Ala Lys Glu Tyr Lys Glu
385                 390                 395                 400
```

```
Asp Gln Glu Asp Glu Arg Pro Leu Gly Leu Arg Asp Arg Gln Leu Val
                405                 410                 415
Met Gly Cys Cys Trp Ala Phe Arg Arg His Lys Ile Thr Ser Ile Tyr
            420                 425                 430
Lys Arg Pro Asp Thr Gln Thr Ile Ile Lys Val Asn Ser Asp Phe His
        435                 440                 445
Ser Phe Val Leu Pro Arg Ile Gly Ser Asn Thr Leu Glu Ile Gly Leu
    450                 455                 460
Arg Thr Arg Ile Arg Lys Met Leu Glu Glu His Lys Glu Pro Ser Pro
465                 470                 475                 480
Leu Ile Thr Ala Glu Asp Val Gln Glu Ala Lys Cys Ala Ala Asp Glu
                485                 490                 495
Ala Lys Glu Val Arg Glu Ala Glu Glu Leu Arg Ala Ala Leu Pro Pro
            500                 505                 510
Leu Ala Ala Asp Val Glu Glu Pro Thr Leu Glu Ala Asp Val Asp Leu
        515                 520                 525
Met Leu Gln Glu Ala Gly Ala Gly Ser Val Glu Thr Pro Arg Gly Leu
    530                 535                 540
Ile Lys Val Thr Ser Tyr Ala Gly Glu Asp Lys Ile Gly Ser Tyr Ala
545                 550                 555                 560
Val Leu Ser Pro Gln Ala Val Leu Lys Ser Glu Lys Leu Ser Cys Ile
                565                 570                 575
His Pro Leu Ala Glu Gln Val Ile Val Ile Thr His Ser Gly Arg Lys
            580                 585                 590
Gly Arg Tyr Ala Val Glu Pro Tyr His Gly Lys Val Val Val Pro Glu
        595                 600                 605
Gly His Ala Ile Pro Val Gln Asp Phe Gln Ala Leu Ser Glu Ser Ala
    610                 615                 620
Thr Ile Val Tyr Asn Glu Arg Glu Phe Val Asn Arg Tyr Leu His His
625                 630                 635                 640
Ile Ala Thr His Gly Gly Ala Leu Asn Thr Asp Glu Glu Tyr Tyr Lys
                645                 650                 655
Thr Val Lys Pro Ser Glu His Asp Gly Glu Tyr Leu Tyr Asp Ile Asp
            660                 665                 670
Arg Lys Gln Cys Val Lys Lys Glu Leu Val Thr Gly Leu Gly Leu Thr
        675                 680                 685
Gly Glu Leu Val Asp Pro Pro Phe His Glu Phe Ala Tyr Glu Ser Leu
    690                 695                 700
Arg Thr Arg Pro Ala Ala Pro Tyr Gln Val Pro Thr Ile Gly Val Tyr
705                 710                 715                 720
Gly Val Pro Gly Ser Gly Lys Ser Gly Ile Ile Lys Ser Ala Val Thr
                725                 730                 735
Lys Lys Asp Leu Val Val Ser Ala Lys Lys Glu Asn Cys Ala Glu Ile
            740                 745                 750
Ile Arg Asp Val Lys Lys Met Lys Gly Leu Asp Val Asn Ala Arg Thr
        755                 760                 765
Val Asp Ser Val Leu Leu Asn Gly Cys Lys His Pro Val Glu Thr Leu
    770                 775                 780
Tyr Ile Asp Glu Ala Phe Ala Cys His Ala Gly Thr Leu Arg Ala Leu
785                 790                 795                 800
Ile Ala Ile Ile Arg Pro Lys Lys Ala Val Leu Cys Gly Asp Pro Lys
                805                 810                 815
Gln Cys Gly Phe Phe Asn Met Met Cys Leu Lys Val His Phe Asn His
            820                 825                 830
```

```
Glu Ile Cys Thr Gln Val Phe His Lys Ser Ile Ser Arg Arg Cys Thr
        835                 840                 845
Lys Ser Val Thr Ser Val Val Ser Thr Leu Phe Tyr Asp Lys Lys Met
    850                 855                 860
Arg Thr Thr Asn Pro Lys Glu Thr Lys Ile Val Ile Asp Thr Thr Gly
865                 870                 875                 880
Ser Thr Lys Pro Lys Gln Asp Asp Leu Ile Leu Thr Cys Phe Arg Gly
                885                 890                 895
Trp Val Lys Gln Leu Gln Ile Asp Tyr Lys Gly Asn Glu Ile Met Thr
            900                 905                 910
Ala Ala Ala Ser Gln Gly Leu Thr Arg Lys Gly Val Tyr Ala Val Arg
        915                 920                 925
Tyr Lys Val Asn Glu Asn Pro Leu Tyr Ala Pro Thr Ser Glu His Val
    930                 935                 940
Asn Val Leu Leu Thr Arg Thr Glu Asp Arg Ile Val Trp Lys Thr Leu
945                 950                 955                 960
Ala Gly Asp Pro Trp Ile Lys Thr Leu Thr Ala Lys Tyr Pro Gly Asn
                965                 970                 975
Phe Thr Ala Thr Ile Glu Glu Trp Gln Ala Glu His Asp Ala Ile Met
            980                 985                 990
Arg His Ile Leu Glu Arg Pro Asp Pro Thr Asp Val Phe Gln Asn Lys
        995                 1000                1005
Ala Asn Val Cys Trp Ala Lys Ala Leu Val Pro Val Leu Lys Thr Ala
    1010                1015                1020
Gly Ile Asp Met Thr Thr Glu Gln Trp Asn Thr Val Asp Tyr Phe Glu
1025                1030                1035                1040
Thr Asp Lys Ala His Ser Ala Glu Ile Val Leu Asn Gln Leu Cys Val
                1045                1050                1055
Arg Phe Phe Gly Leu Asp Leu Asp Ser Gly Leu Phe Ser Ala Pro Thr
            1060                1065                1070
Val Pro Leu Ser Ile Arg Asn Asn His Trp Asp Asn Ser Pro Ser Pro
        1075                1080                1085
Asn Met Tyr Gly Leu Asn Lys Glu Val Val Arg Gln Leu Ser Arg Arg
    1090                1095                1100
Tyr Pro Gln Leu Pro Arg Ala Val Ala Thr Gly Arg Val Tyr Asp Met
1105                1110                1115                1120
Asn Thr Gly Thr Leu Arg Asn Tyr Asp Pro Arg Ile Asn Leu Val Pro
                1125                1130                1135
Val Asn Arg Arg Leu Pro His Ala Leu Val Leu His His Asn Glu His
            1140                1145                1150
Pro Gln Ser Asp Phe Ser Ser Phe Val Ser Lys Leu Lys Gly Arg Thr
        1155                1160                1165
Val Leu Val Val Gly Glu Lys Leu Ser Val Pro Gly Lys Met Val Asp
    1170                1175                1180
Trp Leu Ser Asp Arg Pro Glu Ala Thr Phe Arg Ala Arg Leu Asp Leu
1185                1190                1195                1200
Gly Ile Pro Gly Asp Val Pro Lys Tyr Asp Ile Ile Phe Val Asn Val
                1205                1210                1215
Arg Thr Pro Tyr Lys Tyr His His Tyr Gln Gln Cys Glu Asp His Ala
            1220                1225                1230
Ile Lys Leu Ser Met Leu Thr Lys Lys Ala Cys Leu His Leu Asn Pro
        1235                1240                1245
Gly Gly Thr Cys Val Ser Ile Gly Tyr Gly Tyr Ala Asp Arg Ala Ser
    1250                1255                1260
```

```
Glu Ser Ile Ile Gly Ala Ile Ala Arg Gln Phe Lys Phe Ser Arg Val
1265                1270                1275                1280
Cys Lys Pro Lys Ser Ser Leu Glu Glu Thr Glu Val Leu Phe Val Phe
                1285                1290                1295
Ile Gly Tyr Asp Arg Lys Ala Arg Thr His Asn Pro Tyr Lys Leu Ser
            1300                1305                1310
Ser Thr Leu Thr Asn Ile Tyr Thr Gly Ser Arg Leu His Glu Ala Gly
        1315                1320                1325
Cys Ala Pro Ser Tyr His Val Val Arg Gly Asp Ile Ala Thr Ala Thr
    1330                1335                1340
Glu Gly Val Ile Ile Asn Ala Ala Asn Ser Lys Gly Gln Pro Gly Gly
1345                1350                1355                1360
Gly Val Cys Gly Ala Leu Tyr Lys Lys Phe Pro Glu Ser Phe Asp Leu
                1365                1370                1375
Gln Pro Ile Glu Val Gly Lys Ala Arg Leu Val Lys Gly Ala Ala Lys
            1380                1385                1390
His Ile Ile His Ala Val Gly Pro Asn Phe Asn Lys Val Ser Glu Val
        1395                1400                1405
Glu Gly Asp Lys Gln Leu Ala Glu Ala Tyr Glu Ser Ile Ala Lys Ile
    1410                1415                1420
Val Asn Asp Asn Asn Tyr Lys Ser Val Ala Ile Pro Leu Leu Ser Thr
1425                1430                1435                1440
Gly Ile Phe Ser Gly Asn Lys Asp Arg Leu Thr Gln Ser Leu Asn His
                1445                1450                1455
Leu Leu Thr Ala Leu Asp Thr Thr Asp Ala Asp Val Ala Ile Tyr Cys
            1460                1465                1470
Arg Asp Lys Lys Trp Glu Met Thr Leu Lys Glu Ala Val Ala Arg Arg
        1475                1480                1485
Glu Ala Val Glu Glu Ile Cys Ile Ser Asp Asp Ser Ser Val Thr Glu
    1490                1495                1500
Pro Asp Ala Glu Leu Val Arg Val His Pro Lys Ser Ser Leu Ala Gly
1505                1510                1515                1520
Arg Lys Gly Tyr Ser Thr Ser Asp Gly Lys Thr Phe Ser Tyr Leu Glu
                1525                1530                1535
Gly Thr Lys Phe His Gln Ala Ala Lys Asp Ile Ala Glu Ile Asn Ala
            1540                1545                1550
Met Trp Pro Val Ala Thr Glu Ala Asn Glu Gln Val Cys Met Tyr Ile
        1555                1560                1565
Leu Gly Glu Ser Met Ser Ser Ile Arg Ser Lys Cys Pro Val Glu Glu
    1570                1575                1580
Ser Glu Ala Ser Thr Pro Pro Ser Thr Leu Pro Cys Leu Cys Ile His
1585                1590                1595                1600
Ala Met Thr Pro Glu Arg Val Gln Arg Leu Lys Ala Ser Arg Pro Glu
                1605                1610                1615
Gln Ile Thr Val Cys Ser Ser Phe Pro Leu Pro Lys Tyr Arg Ile Thr
            1620                1625                1630
Gly Val Gln Lys Ile Gln Cys Ser Gln Pro Ile Leu Phe Ser Pro Lys
        1635                1640                1645
Val Pro Ala Tyr Ile His Pro Arg Lys Tyr Leu Val Glu Thr Pro Pro
    1650                1655                1660
Val Asp Glu Thr Pro Glu Pro Ser Ala Glu Asn Gln Ser Thr Glu Gly
1665                1670                1675                1680
Thr Pro Glu Gln Pro Pro Leu Ile Thr Glu Asp Glu Thr Arg Thr Arg
                1685                1690                1695
```

Thr Pro Glu Pro Ile Ile Ile Glu Glu Glu Glu Glu Asp Ser Ile Ser
1700 1705 1710
Leu Leu Ser Asp Gly Pro Thr His Gln Val Leu Gln Val Glu Ala Asp
1715 1720 1725
Ile His Gly Pro Pro Ser Val Ser Ser Ser Ser Trp Ser Ile Pro His
1730 1735 1740
Ala Ser Asp Phe Asp Val Asp Ser Leu Ser Ile Leu Asp Thr Leu Glu
1745 1750 1755 1760
Gly Ala Ser Val Thr Ser Gly Ala Thr Ser Ala Glu Thr Asn Ser Tyr
1765 1770 1775
Phe Ala Lys Ser Met Glu Phe Leu Ala Arg Pro Val Pro Ala Pro Arg
1780 1785 1790
Thr Val Phe Arg Asn Pro Pro His Pro Ala Pro Arg Thr Arg Thr Pro
1795 1800 1805
Ser Leu Ala Pro Ser Arg Ala Cys Ser Arg Thr Ser Leu Val Ser Thr
1810 1815 1820
Pro Pro Gly Val Asn Arg Val Ile Thr Arg Glu Glu Leu Glu Ala Leu
1825 1830 1835 1840
Thr Pro Ser Arg Thr Pro Ser Arg Ser Val Ser Arg Thr Ser Leu Val
1845 1850 1855
Ser Asn Pro Pro Gly Val Asn Arg Val Ile Thr Arg Glu Glu Phe Glu
1860 1865 1870
Ala Phe Val Ala Gln Gln Gln Arg Phe Asp Ala Gly Ala Tyr Ile Phe
1875 1880 1885
Ser Ser Asp Thr Gly Gln Gly His Leu Gln Gln Lys Ser Val Arg Gln
1890 1895 1900
Thr Val Leu Ser Glu Val Val Leu Glu Arg Thr Glu Leu Glu Ile Ser
1905 1910 1915 1920
Tyr Ala Pro Arg Leu Asp Gln Glu Lys Glu Glu Leu Leu Arg Lys Lys
1925 1930 1935
Leu Gln Leu Asn Pro Thr Pro Ala Asn Arg Ser Arg Tyr Gln Ser Arg
1940 1945 1950
Lys Val Glu Asn Met Lys Ala Ile Thr Ala Arg Arg Ile Leu Gln Gly
1955 1960 1965
Leu Gly His Tyr Leu Lys Ala Glu Gly Lys Val Glu Cys Tyr Arg Thr
1970 1975 1980
Leu His Pro Val Pro Leu Tyr Ser Ser Ser Val Asn Arg Ala Phe Ser
1985 1990 1995 2000
Ser Pro Lys Val Ala Val Glu Ala Cys Asn Ala Met Leu Lys Glu Asn
2005 2010 2015
Phe Pro Thr Val Ala Ser Tyr Cys Ile Ile Pro Glu Tyr Asp Ala Tyr
2020 2025 2030
Leu Asp Met Val Asp Gly Ala Ser Cys Cys Leu Asp Thr Ala Ser Phe
2035 2040 2045
Cys Pro Ala Lys Leu Arg Ser Phe Pro Lys Lys His Ser Tyr Leu Glu
2050 2055 2060
Pro Thr Ile Arg Ser Ala Val Pro Ser Ala Ile Gln Asn Thr Leu Gln
2065 2070 2075 2080
Asn Val Leu Ala Ala Ala Thr Lys Arg Asn Cys Asn Val Thr Gln Met
2085 2090 2095
Arg Glu Leu Pro Val Leu Asp Ser Ala Ala Phe Asn Val Glu Cys Phe
2100 2105 2110
Lys Lys Tyr Ala Cys Asn Asn Glu Tyr Trp Glu Thr Phe Lys Glu Asn
2115 2120 2125

```
Pro Ile Arg Leu Thr Glu Glu Asn Val Val Asn Tyr Ile Thr Lys Leu
    2130                2135                2140
Lys Gly Pro Lys Ala Ala Ala Leu Phe Ala Lys Thr His Asn Leu Asn
2145                2150                2155                2160
Met Leu Gln Asp Ile Pro Met Asp Arg Phe Val Met Asp Leu Lys Arg
                2165                2170                2175
Asp Val Lys Val Thr Pro Gly Thr Lys His Thr Glu Glu Arg Pro Lys
            2180                2185                2190
Val Gln Val Ile Gln Ala Ala Asp Pro Leu Ala Thr Ala Tyr Leu Cys
        2195                2200                2205
Gly Ile His Arg Glu Leu Val Arg Arg Leu Asn Ala Val Leu Leu Pro
    2210                2215                2220
Asn Ile His Thr Leu Phe Asp Met Ser Ala Glu Asp Phe Asp Ala Ile
2225                2230                2235                2240
Ile Ala Glu His Phe Gln Pro Gly Asp Cys Val Leu Glu Thr Asp Ile
                2245                2250                2255
Ala Ser Phe Asp Lys Ser Glu Asp Asp Ala Met Ala Leu Thr Ala Leu
            2260                2265                2270
Met Ile Leu Glu Asp Leu Gly Val Asp Ala Glu Leu Leu Thr Leu Ile
        2275                2280                2285
Glu Ala Ala Phe Gly Glu Ile Ser Ser Ile His Leu Pro Thr Lys Thr
    2290                2295                2300
Lys Phe Lys Phe Gly Ala Met Met Lys Ser Gly Met Phe Leu Thr Leu
2305                2310                2315                2320
Phe Val Asn Thr Val Ile Asn Ile Val Ile Ala Ser Arg Val Leu Arg
                2325                2330                2335
Glu Arg Leu Thr Gly Ser Pro Cys Ala Ala Phe Ile Gly Asp Asp Asn
            2340                2345                2350
Ile Val Lys Gly Val Lys Ser Asp Lys Leu Met Ala Asp Arg Cys Ala
        2355                2360                2365
Thr Trp Leu Asn Met Glu Val Lys Ile Ile Asp Ala Val Val Gly Glu
    2370                2375                2380
Lys Ala Pro Tyr Phe Cys Gly Gly Phe Ile Leu Cys Asp Ser Val Thr
2385                2390                2395                2400
Gly Thr Ala Cys Arg Val Ala Asp Pro Leu Lys Arg Leu Phe Lys Leu
                2405                2410                2415
Gly Lys Pro Leu Ala Ala Asp Asp Glu His Asp Asp Asp Arg Arg Arg
            2420                2425                2430
Ala Leu His Glu Glu Ser Thr Arg Trp Asn Arg Val Gly Ile Leu Ser
        2435                2440                2445
Glu Leu Cys Lys Ala Val Glu Ser Arg Tyr Glu Thr Val Gly Thr Ser
    2450                2455                2460
Ile Ile Val Met Ala Met Thr Thr Leu Ala Ser Ser Val Lys Ser Phe
2465                2470                2475                2480
Ser Tyr Leu Arg Gly Ala Pro Ile Thr Leu Tyr Gly
                2485                2490
```

<210> 4
<211> 1476
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence; Note =
synthetic construct

<221> CDS
<222> (1)...(1476)

<400> 4

```
atg gct gcg aga gcg tca ata tta aga ggg gaa aaa tta gat aaa tgg       48
Met Ala Ala Arg Ala Ser Ile Leu Arg Gly Glu Lys Leu Asp Lys Trp
 1               5                  10                  15

gaa aag att agg tta agg cca ggg gga aag aaa cat tat atg tta aaa       96
Glu Lys Ile Arg Leu Arg Pro Gly Gly Lys Lys His Tyr Met Leu Lys
            20                  25                  30

cac ata gta tgg gcg agc agg gag ctg gaa aga ttt gca ctt aac cct      144
His Ile Val Trp Ala Ser Arg Glu Leu Glu Arg Phe Ala Leu Asn Pro
        35                  40                  45

ggc ctt tta gaa aca tca gaa gga tgt aaa caa ata atg aaa cag cta      192
Gly Leu Leu Glu Thr Ser Glu Gly Cys Lys Gln Ile Met Lys Gln Leu
    50                  55                  60

caa cca gct ctc cag aca gga aca gag gaa ctt aaa tca tta tac aac      240
Gln Pro Ala Leu Gln Thr Gly Thr Glu Glu Leu Lys Ser Leu Tyr Asn
65                  70                  75                  80

aca gta gca act ctc tat tgt gta cat gaa aag ata gaa gta cga gac      288
Thr Val Ala Thr Leu Tyr Cys Val His Glu Lys Ile Glu Val Arg Asp
                85                  90                  95

acc aag gaa gcc tta gat aag ata gag gaa gaa caa aac aaa tgt cag      336
Thr Lys Glu Ala Leu Asp Lys Ile Glu Glu Glu Gln Asn Lys Cys Gln
            100                 105                 110

caa aaa acg cag cag gca aaa gcg gct gac ggg aaa gtc agt caa aat      384
Gln Lys Thr Gln Gln Ala Lys Ala Ala Asp Gly Lys Val Ser Gln Asn
        115                 120                 125

tat cct ata gtg cag aat ctc caa ggg caa atg gta cat caa gcc ata      432
Tyr Pro Ile Val Gln Asn Leu Gln Gly Gln Met Val His Gln Ala Ile
    130                 135                 140

tca cct aga acc ttg aat gca tgg gta aaa gta ata gaa gaa aag gct      480
Ser Pro Arg Thr Leu Asn Ala Trp Val Lys Val Ile Glu Glu Lys Ala
145                 150                 155                 160

ttt agc cca gag gta ata ccc atg ttt aca gca tta tca gaa gga gcc      528
Phe Ser Pro Glu Val Ile Pro Met Phe Thr Ala Leu Ser Glu Gly Ala
                165                 170                 175

acc cca caa gat tta aac acc atg tta aat aca gtg ggg gga cac caa      576
Thr Pro Gln Asp Leu Asn Thr Met Leu Asn Thr Val Gly Gly His Gln
            180                 185                 190

gca gcc atg caa atg tta aaa gat act att aat gaa gag gct gca gaa      624
Ala Ala Met Gln Met Leu Lys Asp Thr Ile Asn Glu Glu Ala Ala Glu
        195                 200                 205
```

```
tgg gat aga tta cat cca gtc cat gcg ggg cct att gca cca ggc cag      672
Trp Asp Arg Leu His Pro Val His Ala Gly Pro Ile Ala Pro Gly Gln
    210                 215                 220

atg aga gaa cca agg gga agt gac ata gca gga act act agt acc ctt      720
Met Arg Glu Pro Arg Gly Ser Asp Ile Ala Gly Thr Thr Ser Thr Leu
225                 230                 235                 240

cag gaa caa ata gca tgg atg aca agt aac cca cct att cca gtg gga      768
Gln Glu Gln Ile Ala Trp Met Thr Ser Asn Pro Pro Ile Pro Val Gly
                245                 250                 255

gac atc tat aaa aga tgg ata att ctg ggg tta aat aaa ata gtg aga      816
Asp Ile Tyr Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys Ile Val Arg
            260                 265                 270

atg tat agc ccg gtc agc att ttg gac ata aga caa ggg cca aag gaa      864
Met Tyr Ser Pro Val Ser Ile Leu Asp Ile Arg Gln Gly Pro Lys Glu
        275                 280                 285

ccc ttt cga gac tat gta gat cgg ttc ttt aaa act tta aga gct gaa      912
Pro Phe Arg Asp Tyr Val Asp Arg Phe Phe Lys Thr Leu Arg Ala Glu
    290                 295                 300

caa gct aca caa gaa gta aaa aat tgg atg aca gac acc ttg tta gtc      960
Gln Ala Thr Gln Glu Val Lys Asn Trp Met Thr Asp Thr Leu Leu Val
305                 310                 315                 320

caa aat gcg aac cca gat tgt aag acc att ttg aga gca tta gga cca     1008
Gln Asn Ala Asn Pro Asp Cys Lys Thr Ile Leu Arg Ala Leu Gly Pro
                325                 330                 335

ggg gct aca tta gaa gaa atg atg aca gca tgt caa ggg gtg gga gga     1056
Gly Ala Thr Leu Glu Glu Met Met Thr Ala Cys Gln Gly Val Gly Gly
            340                 345                 350

cct ggc cac aaa gca aga gta ttg gct gag gca atg agt caa aca aac     1104
Pro Gly His Lys Ala Arg Val Leu Ala Glu Ala Met Ser Gln Thr Asn
        355                 360                 365

agt gga aac ata atg atg cag aga agc aat ttt aaa ggc cct aga aga     1152
Ser Gly Asn Ile Met Met Gln Arg Ser Asn Phe Lys Gly Pro Arg Arg
    370                 375                 380

att gtt aaa tgt ttt aac tgt ggc aag gaa ggg cac ata gcc aga aat     1200
Ile Val Lys Cys Phe Asn Cys Gly Lys Glu Gly His Ile Ala Arg Asn
385                 390                 395                 400

tgc aga gcc cct agg aaa aaa ggc tgt tgg aaa tgt gga aaa gaa gga     1248
Cys Arg Ala Pro Arg Lys Lys Gly Cys Trp Lys Cys Gly Lys Glu Gly
                405                 410                 415
cac caa atg aaa gac tgc act gag agg cag gct aat ttt tta ggg aaa     1296
His Gln Met Lys Asp Cys Thr Glu Arg Gln Ala Asn Phe Leu Gly Lys
            420                 425                 430
```

```
att tgg cct tcc cac aag ggg agg cca ggg aat ttc ctt cag aac aga     1344
Ile Trp Pro Ser His Lys Gly Arg Pro Gly Asn Phe Leu Gln Asn Arg
        435                 440                 445

cca gag cca aca gcc cca cca gca gag agc ttc agg ttc gaa gag aca     1392
Pro Glu Pro Thr Ala Pro Pro Ala Glu Ser Phe Arg Phe Glu Glu Thr
    450                 455                 460

acc ccc gct ccg aaa cag gag ccg ata gaa agg gaa ccc tta act tcc     1440
Thr Pro Ala Pro Lys Gln Glu Pro Ile Glu Arg Glu Pro Leu Thr Ser
465                 470                 475                 480

ctc aaa tca ctc ttt ggc agc gac ccc ttg tct caa                     1476
Leu Lys Ser Leu Phe Gly Ser Asp Pro Leu Ser Gln
                485                 490
```

<210> 5
<211> 492
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence; Note = synthetic construct

<400> 5

```
Met Ala Ala Arg Ala Ser Ile Leu Arg Gly Glu Lys Leu Asp Lys Trp
 1               5                  10                  15
Glu Lys Ile Arg Leu Arg Pro Gly Gly Lys Lys His Tyr Met Leu Lys
            20                  25                  30
His Ile Val Trp Ala Ser Arg Glu Leu Glu Arg Phe Ala Leu Asn Pro
        35                  40                  45
Gly Leu Leu Glu Thr Ser Glu Gly Cys Lys Gln Ile Met Lys Gln Leu
    50                  55                  60
Gln Pro Ala Leu Gln Thr Gly Thr Glu Glu Leu Lys Ser Leu Tyr Asn
65                  70                  75                  80
Thr Val Ala Thr Leu Tyr Cys Val His Glu Lys Ile Glu Val Arg Asp
                85                  90                  95
Thr Lys Glu Ala Leu Asp Lys Ile Glu Glu Glu Gln Asn Lys Cys Gln
            100                 105                 110
Gln Lys Thr Gln Gln Ala Lys Ala Ala Asp Gly Lys Val Ser Gln Asn
        115                 120                 125
Tyr Pro Ile Val Gln Asn Leu Gln Gly Gln Met Val His Gln Ala Ile
    130                 135                 140
Ser Pro Arg Thr Leu Asn Ala Trp Val Lys Val Ile Glu Glu Lys Ala
145                 150                 155                 160
Phe Ser Pro Glu Val Ile Pro Met Phe Thr Ala Leu Ser Glu Gly Ala
                165                 170                 175
Thr Pro Gln Asp Leu Asn Thr Met Leu Asn Thr Val Gly Gly His Gln
            180                 185                 190
Ala Ala Met Gln Met Leu Lys Asp Thr Ile Asn Glu Glu Ala Ala Glu
        195                 200                 205
```

```
Trp Asp Arg Leu His Pro Val His Ala Gly Pro Ile Ala Pro Gly Gln
    210                 215                 220
Met Arg Glu Pro Arg Gly Ser Asp Ile Ala Gly Thr Thr Ser Thr Leu
225                 230                 235                 240
Gln Glu Gln Ile Ala Trp Met Thr Ser Asn Pro Pro Ile Pro Val Gly
                245                 250                 255
Asp Ile Tyr Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys Ile Val Arg
            260                 265                 270
Met Tyr Ser Pro Val Ser Ile Leu Asp Ile Arg Gln Gly Pro Lys Glu
        275                 280                 285
Pro Phe Arg Asp Tyr Val Asp Arg Phe Phe Lys Thr Leu Arg Ala Glu
    290                 295                 300
Gln Ala Thr Gln Glu Val Lys Asn Trp Met Thr Asp Thr Leu Leu Val
305                 310                 315                 320
Gln Asn Ala Asn Pro Asp Cys Lys Thr Ile Leu Arg Ala Leu Gly Pro
                325                 330                 335
Gly Ala Thr Leu Glu Glu Met Met Thr Ala Cys Gln Gly Val Gly Gly
            340                 345                 350
Pro Gly His Lys Ala Arg Val Leu Ala Glu Ala Met Ser Gln Thr Asn
        355                 360                 365
Ser Gly Asn Ile Met Met Gln Arg Ser Asn Phe Lys Gly Pro Arg Arg
    370                 375                 380
Ile Val Lys Cys Phe Asn Cys Gly Lys Glu Gly His Ile Ala Arg Asn
385                 390                 395                 400
Cys Arg Ala Pro Arg Lys Lys Gly Cys Trp Lys Cys Gly Lys Glu Gly
                405                 410                 415
His Gln Met Lys Asp Cys Thr Glu Arg Gln Ala Asn Phe Leu Gly Lys
            420                 425                 430
Ile Trp Pro Ser His Lys Gly Arg Pro Gly Asn Phe Leu Gln Asn Arg
        435                 440                 445
Pro Glu Pro Thr Ala Pro Pro Ala Glu Ser Phe Arg Phe Glu Glu Thr
    450                 455                 460
Thr Pro Ala Pro Lys Gln Glu Pro Ile Glu Arg Glu Pro Leu Thr Ser
465                 470                 475                 480
Leu Lys Ser Leu Phe Gly Ser Asp Pro Leu Ser Gln
                485                 490
```

<210> 6
<211> 813
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence; Note =
synthetic construct

<221> CDS
<222> (1)...(813)

<400> 6

```
atg agc cat att caa cgg gaa acg tct tgc tcg agg ccg cga tta aat       48
Met Ser His Ile Gln Arg Glu Thr Ser Cys Ser Arg Pro Arg Leu Asn
 1               5                  10                  15
```

```
tcc aac atg gat gct gat tta tat ggg tat aaa tgg gct cgc gat aat       96
Ser Asn Met Asp Ala Asp Leu Tyr Gly Tyr Lys Trp Ala Arg Asp Asn
             20                  25                  30

gtc ggg caa tca ggt gcg aca atc tat cga ttg tat ggg aag ccc gat      144
Val Gly Gln Ser Gly Ala Thr Ile Tyr Arg Leu Tyr Gly Lys Pro Asp
         35                  40                  45

gcg cca gag ttg ttt ctg aaa cat ggc aaa ggt agc gtt gcc aat gat      192
Ala Pro Glu Leu Phe Leu Lys His Gly Lys Gly Ser Val Ala Asn Asp
     50                  55                  60

gtt aca gat gag atg gtc aga cta aac tgg ctg acg gaa ttt atg cct      240
Val Thr Asp Glu Met Val Arg Leu Asn Trp Leu Thr Glu Phe Met Pro
 65                  70                  75                  80

ctt ccg acc atc aag cat ttt atc cgt act cct gat gat gca tgg tta      288
Leu Pro Thr Ile Lys His Phe Ile Arg Thr Pro Asp Asp Ala Trp Leu
                 85                  90                  95

ctc acc act gcg atc ccc ggg aaa aca gca ttc cag gta tta gaa gaa      336
Leu Thr Thr Ala Ile Pro Gly Lys Thr Ala Phe Gln Val Leu Glu Glu
            100                 105                 110

tat cct gat tca ggt gaa aat att gtt gat gcg ctg gca gtg ttc ctg      384
Tyr Pro Asp Ser Gly Glu Asn Ile Val Asp Ala Leu Ala Val Phe Leu
        115                 120                 125

cgc cgg ttg cat tcg att cct gtt tgt aat tgt cct ttt aac agc gat      432
Arg Arg Leu His Ser Ile Pro Val Cys Asn Cys Pro Phe Asn Ser Asp
    130                 135                 140

cgc gta ttt cgt ctc gct cag gcg caa tca cga atg aat aac ggt ttg      480
Arg Val Phe Arg Leu Ala Gln Ala Gln Ser Arg Met Asn Asn Gly Leu
145                 150                 155                 160

gtt gat gcg agt gat ttt gat gac gag cgt aat ggc tgg cct gtt gaa      528
Val Asp Ala Ser Asp Phe Asp Asp Glu Arg Asn Gly Trp Pro Val Glu
                165                 170                 175

caa gtc tgg aaa gaa atg cat aag ctt ttg cca ttc tca ccg gat tca      576
Gln Val Trp Lys Glu Met His Lys Leu Leu Pro Phe Ser Pro Asp Ser
            180                 185                 190

gtc gtc act cat ggt gat ttc tca ctt gat aac ctt att ttt gac gag      624
Val Val Thr His Gly Asp Phe Ser Leu Asp Asn Leu Ile Phe Asp Glu
        195                 200                 205

ggg aaa tta ata ggt tgt att gat gtt gga cga gtc gga atc gca gac      672
Gly Lys Leu Ile Gly Cys Ile Asp Val Gly Arg Val Gly Ile Ala Asp
    210                 215                 220

cga tac cag gat ctt gcc atc cta tgg aac tgc ctc ggt gag ttt tct      720
Arg Tyr Gln Asp Leu Ala Ile Leu Trp Asn Cys Leu Gly Glu Phe Ser
225                 230                 235                 240
```

```
cct tca tta cag aaa cgg ctt ttt caa aaa tat ggt att gat aat cct      768
Pro Ser Leu Gln Lys Arg Leu Phe Gln Lys Tyr Gly Ile Asp Asn Pro
                245                 250                 255

gat atg aat aaa ttg cag ttt cat ttg atg ctc gat gag ttt ttc          813
Asp Met Asn Lys Leu Gln Phe His Leu Met Leu Asp Glu Phe Phe
            260                 265                 270
```

<210> 7
<211> 271
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence; Note =
synthetic construct

<400> 7

```
Met Ser His Ile Gln Arg Glu Thr Ser Cys Ser Arg Pro Arg Leu Asn
 1               5                  10                  15
Ser Asn Met Asp Ala Asp Leu Tyr Gly Tyr Lys Trp Ala Arg Asp Asn
            20                  25                  30
Val Gly Gln Ser Gly Ala Thr Ile Tyr Arg Leu Tyr Gly Lys Pro Asp
        35                  40                  45
Ala Pro Glu Leu Phe Leu Lys His Gly Lys Gly Ser Val Ala Asn Asp
    50                  55                  60
Val Thr Asp Glu Met Val Arg Leu Asn Trp Leu Thr Glu Phe Met Pro
65                  70                  75                  80
Leu Pro Thr Ile Lys His Phe Ile Arg Thr Pro Asp Asp Ala Trp Leu
                85                  90                  95
Leu Thr Thr Ala Ile Pro Gly Lys Thr Ala Phe Gln Val Leu Glu Glu
            100                 105                 110
Tyr Pro Asp Ser Gly Glu Asn Ile Val Asp Ala Leu Ala Val Phe Leu
        115                 120                 125
Arg Arg Leu His Ser Ile Pro Val Cys Asn Cys Pro Phe Asn Ser Asp
    130                 135                 140
Arg Val Phe Arg Leu Ala Gln Ala Gln Ser Arg Met Asn Asn Gly Leu
145                 150                 155                 160
Val Asp Ala Ser Asp Phe Asp Asp Glu Arg Asn Gly Trp Pro Val Glu
                165                 170                 175
Gln Val Trp Lys Glu Met His Lys Leu Leu Pro Phe Ser Pro Asp Ser
            180                 185                 190
Val Val Thr His Gly Asp Phe Ser Leu Asp Asn Leu Ile Phe Asp Glu
        195                 200                 205
Gly Lys Leu Ile Gly Cys Ile Asp Val Gly Arg Val Gly Ile Ala Asp
    210                 215                 220
Arg Tyr Gln Asp Leu Ala Ile Leu Trp Asn Cys Leu Gly Glu Phe Ser
225                 230                 235                 240
Pro Ser Leu Gln Lys Arg Leu Phe Gln Lys Tyr Gly Ile Asp Asn Pro
                245                 250                 255
Asp Met Asn Lys Leu Gln Phe His Leu Met Leu Asp Glu Phe Phe
            260                 265                 270
```

<210> 8
<211> 5076
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence; Note =
synthetic construct

<400> 8
ataggcggcg catgagagaa gcccagacca attacctacc caaaatggag aaagttcacg 60
ttgacatcga ggaagacagc ccattcctca gagctttgca gcggagcttc ccgcagtttg 120
aggtagaagc caagcaggtc actgataatg accatgctaa tgccagagcg ttttcgcatc 180
tggcttcaaa actgatcgaa acggaggtgg acccatccga cacgatcctt gacattggaa 240
gtgcgcccgc ccgcagaatg tattctaagc acaagtatca ttgtatctgt ccgatgagat 300
gtgcggaaga tccggacaga ttgtataagt atgcaactaa gctgaagaaa aactgtaagg 360
aaataactga taaggaattg gacaagaaaa tgaaggagct cgccgccgtc atgagcgacc 420
ctgacctgga aactgagact atgtgcctcc acgacgacga gtcgtgtcgc tacgaagggc 480
aagtcgctgt ttaccaggat gtatacgcgg ttgacggacc ctataactct ctacggctaa 540
cctgaatgga ctacgacata gtctagtccg ccaagatgtt cccgttccag ccaatgtatc 600
cgatgcagcc aatgccctat cgcaacccgt tcgcggcccc gcgcaggccc tggttcccca 660
gaaccgaccc ttttctggcg atgcaggtgc aggaattaac ccgctcgatg gctaacctga 720
cgttcaagca acgccgggac gcgccacctg aggggccatc cgctaagaaa ccgaagaagg 780
aggcctcgca aaaacagaaa gggggaggcc aagggaagaa gaagaagaac caagggaaga 840
agaaggctaa gacagggccg cctaatccga aggcacagaa tggaaacaag aagaagacca 900
acaagaaacc aggcaagaga cagcgcatgg tcatgaaatt ggaatctgac aagacgttcc 960
caatcatgtt ggaagggaag ataaacggct acgcttgtgt ggtcggaggg aagttattca 1020
ggccgatgca tgtggaaggc aagatcgaca acgacgttct ggccgcgctt aagacgaaga 1080
aagcatccaa atacgatctt gagtatgcag atgtgccaca gaacatgcgg gccgatacat 1140
tcaaatacac ccatgagaaa ccccaaggct attacagctg gcatcatgga gcagtccaat 1200
atgaaaatgg gcgtttcacg gtgccgaaag gagttggggc caagggagac agcggacgac 1260
ccattctgga taaccaggga cgggtggtcg ctattgtgct gggaggtgtg aatgaaggat 1320
ctaggacagc cctttcagtc gtcatgtgga acgagaaggg agttaccgtg aagtatactc 1380
cggagaactg cgagcaatgg tcactagtga ccaccatgtg tctgctcgcc aatgtgacgt 1440
tcccatgtgc tcaaccacca atttgctacg acagaaaacc agcagagact ttggccatgc 1500
tcagcgttaa catccctgct gggaggatca gccgtaatta ttataattgg cttggtgctg 1560
gctactattg tggccatgta cgtgctgacc aaccagaaac ataattgaat acagcagcaa 1620
ttggcaagct gcttacatag aactcgcggc gattggcatg ccgctttaaa atttttattt 1680
tatttttctt ttctttttccg aatcggattt tgtttttaat atttcaaaaa aaaaaaaaaa 1740
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa gggaagagcg cggccgcgcg ctgggctacg 1800
tcttgctggc gttcgcgacg cgaggctgga tggccttccc cattatgatt cttctcgctt 1860
ccggcggcat cgggatgccc gcgttgcagg ccatgctgtc caggcaggta gatgacgacc 1920
atcagggaca gcttcaagga tcgctcgcgg ctcttaccag cctaacttcg atcactggac 1980
cgctgatcgt cacggcgatt tatgccgcct cggcgagcac atggaacggg ttggcatgga 2040
ttgtaggcgc cgccctatac cttgtctgcc tccccgcgtt gcgtcgcggt gcatggagcc 2100
gggccacctc gacctgaatg gaagccggcg gcacctcgct aacggattca ccactccaag 2160
aattggagcc aatcaattct tgcggagaac tgtgaatgcg caaaccaacc cttggcagaa 2220
catatccatc gcgtccgcca tctccagcag ccgcacgcgg cgcatctcgg gcagcgttgg 2280
gtcctggcca cgggtgcgca tgatcgtgct cctgtcgttg aggacccggc taggctggcg 2340
gggttgcctt actggttagc agaatgaatc accgatacgc gagcgaacgt gaagcgactg 2400
ctgctgcaaa acgtctgcga cctgagcaac aacatgaatg gtcttcggtt tccgtgtttc 2460
gtaaagtctg gaaacgcgga agtcagcgcc ctgcaccatt atgttccgga tctgcatcgc 2520
aggatgctgc tggctaccct gtggaacacc tacatctgta ttaacgaagc gctggcattg 2580
accctgagtg atttttctct ggtcccgccg catccatacc gccagttgtt taccctcaca 2640
acgttccagt aaccgggcat gttcatcatc agtaacccgt atcgtgagca tcctctctcg 2700

tttcatcggt atcattaccc ccatgaacag aaatccccct tacacggagg catcagtgac 2760
caaacaggaa aaaaccgccc ttaacatggc ccgctttatc agaagccaga cattaacgct 2820
tctggagaaa ctcaacgagc tggacgcgga tgaacaggca gacatctgtg aatcgcttca 2880
cgaccacgct gatgagcttt accgcagctg cctcgcgcgt ttcggtgatg acggtgaaaa 2940
cctctgacac atgcagctcc cggagacggt cacagcttgt ctgtaagcgg atgccgggag 3000
cagacaagcc cgtcagggcg cgtcagcggg tgttggcggg tgtcggggcg cagccatgac 3060
ccagtcacgt agcgatagcg gagtgtatac tggcttaact atgcggcatc agagcagatt 3120
gtactgagag tgcaccatat atgcggtgtg aaataccgca cagatgcgta aggagaaaat 3180
accgcatcag gcgctcttcc gcttcctcgc tcactgactc gctgcgctcg gtcgttcggc 3240
tgcggcgagc ggtatcagct cactcaaagg cggtaatacg gttatccaca gaatcagggg 3300
ataacgcagg aaagaacatg tgagcaaaag gccagcaaaa ggccaggaac cgtaaaaagg 3360
ccgcgttgct ggcgtttttc cataggctcc gccccctga cgagcatcac aaaaatcgac 3420
gctcaagtca gaggtggcga aacccgacag gactataaag ataccaggcg tttccccctg 3480
gaagctccct cgtgcgctct cctgttccga ccctgccgct taccggatac ctgtccgcct 3540
ttctcccttc gggaagcgtg gcgctttctc atagctcacg ctgtaggtat ctcagttcgg 3600
tgtaggtcgt tcgctccaag ctgggctgtg tgcacgaacc ccccgttcag cccgaccgct 3660
gcgccttatc cggtaactat cgtcttgagt ccaacccggt aagacacgac ttatcgccac 3720
tggcagcagc cactggtaac aggattagca gagcgaggta tgtaggcggt gctacagagt 3780
tcttgaagtg gtggcctaac tacggctaca ctagaaggac agtatttggt atctgcgctc 3840
tgctgaagcc agttaccttc ggaaaaagag ttggtagctc ttgatccggc aaacaaacca 3900
ccgctggtag cggtggtttt tttgtttgca agcagcagat tacgcgcaga aaaaaaggat 3960
ctcaagaaga tcctttgatc ttttctacgg ggtctgacgc tcagtggaac gaaaactcac 4020
gttaagggat tttggtcatg aacaataaaa ctgtctgctt acataaacag taatacaagg 4080
ggtgttatga gccatattca acgggaaacg tcttgctcga ggccgcgatt aaattccaac 4140
atggatgctg atttatatgg gtataaatgg gctcgcgata atgtcgggca atcaggtgcg 4200
acaatctatc gattgtatgg gaagcccgat gcgccagagt tgtttctgaa acatggcaaa 4260
ggtagcgttg ccaatgatgt tacagatgag atggtcagac taaactggct gacggaattt 4320
atgcctcttc cgaccatcaa gcattttatc cgtactcctg atgatgcatg gttactcacc 4380
actgcgatcc ccgggaaaac agcattccag gtattagaag aatatcctga ttcaggtgaa 4440
aatattgttg atgcgctggc agtgttcctg cgccggttgc attcgattcc tgtttgtaat 4500
tgtccttta acagcgatcg cgtatttcgt ctcgctcagg cgcaatcacg aatgaataac 4560
ggtttggttg atgcgagtga ttttgatgac gagcgtaatg gctggcctgt tgaacaagtc 4620
tggaaagaaa tgcataagct tttgccattc tcaccggatt cagtcgtcac tcatggtgat 4680
ttctcacttg ataaccttat ttttgacgag gggaaattaa taggttgtat tgatgttgga 4740
cgagtcggaa tcgcagaccg ataccaggat cttgccatcc tatggaactg cctcggtgag 4800
ttttctcctt cattacagaa acggcttttt caaaaatatg gtattgataa tcctgatatg 4860
aataaattgc agtttcattt gatgctcgat gagtttttct aagaattctc atgtttgaca 4920
gcttatcatc gataagcttt aatgcggtag tttatcacag ttaaattgct aacgcagtca 4980
ggcaccgtgt atgaaatcta acaatgcgct catcgtcatc ctcggcaccg tcaccctgga 5040
tgctgtctag aggatcccta atacgactca ctatag 5076

<210> 9
<211> 1026
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence; Note =
synthetic construct

<221> CDS
<222> (1)...(1026)

<400> 9

```
atg ttc ccg ttc cag cca atg tat ccg atg cag cca atg ccc tat cgc       48
Met Phe Pro Phe Gln Pro Met Tyr Pro Met Gln Pro Met Pro Tyr Arg
 1               5                  10                  15

aac ccg ttc gcg gcc ccg cgc agg ccc tgg ttc ccc aga acc gac cct       96
Asn Pro Phe Ala Ala Pro Arg Arg Pro Trp Phe Pro Arg Thr Asp Pro
            20                  25                  30

ttt ctg gcg atg cag gtg cag gaa tta acc cgc tcg atg gct aac ctg      144
Phe Leu Ala Met Gln Val Gln Glu Leu Thr Arg Ser Met Ala Asn Leu
        35                  40                  45

acg ttc aag caa cgc cgg gac gcg cca cct gag ggg cca tcc gct aag      192
Thr Phe Lys Gln Arg Arg Asp Ala Pro Pro Glu Gly Pro Ser Ala Lys
    50                  55                  60

aaa ccg aag aag gag gcc tcg caa aaa cag aaa ggg gga ggc caa ggg      240
Lys Pro Lys Lys Glu Ala Ser Gln Lys Gln Lys Gly Gly Gly Gln Gly
65                  70                  75                  80

aag aag aag aag aac caa ggg aag aag aag gct aag aca ggg ccg cct      288
Lys Lys Lys Lys Asn Gln Gly Lys Lys Lys Ala Lys Thr Gly Pro Pro
                85                  90                  95

aat ccg aag gca cag aat gga aac aag aag aag acc aac aag aaa cca      336
Asn Pro Lys Ala Gln Asn Gly Asn Lys Lys Lys Thr Asn Lys Lys Pro
            100                 105                 110

ggc aag aga cag cgc atg gtc atg aaa ttg gaa tct gac aag acg ttc      384
Gly Lys Arg Gln Arg Met Val Met Lys Leu Glu Ser Asp Lys Thr Phe
        115                 120                 125

cca atc atg ttg gaa ggg aag ata aac ggc tac gct tgt gtg gtc gga      432
Pro Ile Met Leu Glu Gly Lys Ile Asn Gly Tyr Ala Cys Val Val Gly
    130                 135                 140

ggg aag tta ttc agg ccg atg cat gtg gaa ggc aag atc gac aac gac      480
Gly Lys Leu Phe Arg Pro Met His Val Glu Gly Lys Ile Asp Asn Asp
145                 150                 155                 160

gtt ctg gcc gcg ctt aag acg aag aaa gca tcc aaa tac gat ctt gag      528
Val Leu Ala Ala Leu Lys Thr Lys Lys Ala Ser Lys Tyr Asp Leu Glu
                165                 170                 175

tat gca gat gtg cca cag aac atg cgg gcc gat aca ttc aaa tac acc      576
Tyr Ala Asp Val Pro Gln Asn Met Arg Ala Asp Thr Phe Lys Tyr Thr
            180                 185                 190

cat gag aaa ccc caa ggc tat tac agc tgg cat cat gga gca gtc caa      624
His Glu Lys Pro Gln Gly Tyr Tyr Ser Trp His His Gly Ala Val Gln
        195                 200                 205
tat gaa aat ggg cgt ttc acg gtg ccg aaa gga gtt ggg gcc aag gga      672
Tyr Glu Asn Gly Arg Phe Thr Val Pro Lys Gly Val Gly Ala Lys Gly
    210                 215                 220
```

```
gac agc gga cga ccc att ctg gat aac cag gga cgg gtg gtc gct att      720
Asp Ser Gly Arg Pro Ile Leu Asp Asn Gln Gly Arg Val Val Ala Ile
225                 230                 235                 240

gtg ctg gga ggt gtg aat gaa gga tct agg aca gcc ctt tca gtc gtc      768
Val Leu Gly Gly Val Asn Glu Gly Ser Arg Thr Ala Leu Ser Val Val
                245                 250                 255

atg tgg aac gag aag gga gtt acc gtg aag tat act ccg gag aac tgc      816
Met Trp Asn Glu Lys Gly Val Thr Val Lys Tyr Thr Pro Glu Asn Cys
            260                 265                 270

gag caa tgg tca cta gtg acc acc atg tgt ctg ctc gcc aat gtg acg      864
Glu Gln Trp Ser Leu Val Thr Thr Met Cys Leu Leu Ala Asn Val Thr
        275                 280                 285

ttc cca tgt gct caa cca cca att tgc tac gac aga aaa cca gca gag      912
Phe Pro Cys Ala Gln Pro Pro Ile Cys Tyr Asp Arg Lys Pro Ala Glu
    290                 295                 300

act ttg gcc atg ctc agc gtt aac atc cct gct ggg agg atc agc cgt      960
Thr Leu Ala Met Leu Ser Val Asn Ile Pro Ala Gly Arg Ile Ser Arg
305                 310                 315                 320

aat tat tat aat tgg ctt ggt gct ggc tac tat tgt ggc cat gta cgt     1008
Asn Tyr Tyr Asn Trp Leu Gly Ala Gly Tyr Tyr Cys Gly His Val Arg
                325                 330                 335

gct gac caa cca gaa aca                                            1026
Ala Asp Gln Pro Glu Thr
            340
```

<210> 10
<211> 342
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence; Note =
synthetic construct

<400> 10

```
Met Phe Pro Phe Gln Pro Met Tyr Pro Met Gln Pro Met Pro Tyr Arg
 1               5                  10                  15
Asn Pro Phe Ala Ala Pro Arg Arg Pro Trp Phe Pro Arg Thr Asp Pro
            20                  25                  30
Phe Leu Ala Met Gln Val Gln Glu Leu Thr Arg Ser Met Ala Asn Leu
        35                  40                  45
Thr Phe Lys Gln Arg Arg Asp Ala Pro Pro Glu Gly Pro Ser Ala Lys
    50                  55                  60
Lys Pro Lys Lys Glu Ala Ser Gln Lys Gln Lys Gly Gly Gly Gln Gly
65                  70                  75                  80
```

```
Lys Lys Lys Lys Asn Gln Gly Lys Lys Lys Ala Lys Thr Gly Pro Pro
                85                  90                  95
Asn Pro Lys Ala Gln Asn Gly Asn Lys Lys Lys Thr Asn Lys Lys Pro
            100                 105                 110
Gly Lys Arg Gln Arg Met Val Met Lys Leu Glu Ser Asp Lys Thr Phe
        115                 120                 125
Pro Ile Met Leu Glu Gly Lys Ile Asn Gly Tyr Ala Cys Val Val Gly
    130                 135                 140
Gly Lys Leu Phe Arg Pro Met His Val Glu Gly Lys Ile Asp Asn Asp
145             150                 155                 160
Val Leu Ala Ala Leu Lys Thr Lys Lys Ala Ser Lys Tyr Asp Leu Glu
                165                 170                 175
Tyr Ala Asp Val Pro Gln Asn Met Arg Ala Asp Thr Phe Lys Tyr Thr
            180                 185                 190
His Glu Lys Pro Gln Gly Tyr Tyr Ser Trp His His Gly Ala Val Gln
        195                 200                 205
Tyr Glu Asn Gly Arg Phe Thr Val Pro Lys Gly Val Gly Ala Lys Gly
    210                 215                 220
Asp Ser Gly Arg Pro Ile Leu Asp Asn Gln Gly Arg Val Val Ala Ile
225                 230                 235                 240
Val Leu Gly Gly Val Asn Glu Gly Ser Arg Thr Ala Leu Ser Val Val
                245                 250                 255
Met Trp Asn Glu Lys Gly Val Thr Val Lys Tyr Thr Pro Glu Asn Cys
            260                 265                 270
Glu Gln Trp Ser Leu Val Thr Thr Met Cys Leu Leu Ala Asn Val Thr
        275                 280                 285
Phe Pro Cys Ala Gln Pro Pro Ile Cys Tyr Asp Arg Lys Pro Ala Glu
    290                 295                 300
Thr Leu Ala Met Leu Ser Val Asn Ile Pro Ala Gly Arg Ile Ser Arg
305                 310                 315                 320
Asn Tyr Tyr Asn Trp Leu Gly Ala Gly Tyr Tyr Cys Gly His Val Arg
                325                 330                 335
Ala Asp Gln Pro Glu Thr
            340
```

<210> 11
<211> 6989
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence; Note =
synthetic construct

<400> 11

```
ataggcggcg catgagagaa gcccagacca attacctacc caaaatggag aaagttcacg      60
ttgacatcga ggaagacagc ccattcctca gagctttgca gcggagcttc ccgcagtttg     120
aggtagaagc caagcaggtc actgataatg accatgctaa tgccagagcg ttttcgcatc     180
tggcttcaaa actgatcgaa acggaggtgg acccatccga cacgatcctt gacattggaa     240
gtgcgcccgc ccgcagaatg tattctaagc acaagtatca ttgtatctgt ccgatgagat     300
gtgcggaaga tccggacaga ttgtataagt atgcaactaa gctgaagaaa aactgtaagg     360
aaataactga taaggaattg gacaagaaaa tgaaggagct cgccgccgtc atgagcgacc     420
ctgacctgga aactgagact atgtgcctcc acgacgacga gtcgtgtcgc tacgaagggc     480
aagtcgctgt ttaccaggat gtatacgcgg ttgacggacc ctataactct ctacggctaa     540
cctgaatgga ctacgacata gtctagtccg ccaagatgtc actagtgacc accatgtgtc     600
```

tgctcgccaa tgtgacgttc ccatgtgctc aaccaccaat ttgctacgac agaaaaccag 660
cagagacttt ggccatgctc agcgttaacg ttgacaaccc gggctacgat gagctgctgg 720
aagcagctgt taagtgcccc ggaaggaaaa ggagatccac cgaggagctg tttaaggagt 780
ataagctaac gcgcccttac atggccagat gcatcagatg tgcagttggg agctgccata 840
gtccaatagc aatcgaggca gtaaagagcg acgggcacga cggttatgtt agacttcaga 900
cttcctcgca gtatggcctg gattcctccg gcaacttaaa gggcaggacc atgcggtatg 960
acatgcacgg gaccattaaa gagataccac tacatcaagt gtcactccat acatctcgcc 1020
cgtgtcacat tgtggatggg cacggttatt tcctgcttgc caggtgcccg gcaggggact 1080
ccatcaccat ggaatttaag aaagattccg tcacacactc ctgctcggtg ccgtatgaag 1140
tgaaatttaa tcctgtaggc agagaactct atactcatcc cccagaacac ggagtagagc 1200
aagcgtgcca agtctacgca catgatgcac agaacagagg agcttatgtc gagatgcacc 1260
tcccaggctc agaagtggac agcagtttgg tttccttgag cggcagttca gtcaccgtga 1320
cacctcctgt tgggactagc gccctggtgg aatgcgagtg tggcggcaca aagatctcca 1380
agaccatcaa caagacaaaa cagttcagcc agtgcacaaa gaaggagcag tgcagagcat 1440
atcggctgca gaacgataag tgggtgtata attctgacaa actgcccaaa gcagcgggag 1500
ccaccttaaa aggaaaactg catgtcccat tcttgctggc agacggcaaa tgcaccgtgc 1560
ctctagcacc agaacctatg ataaccttcg gtttcagatc agtgtcactg aaactgcacc 1620
ctaagaatcc cacatatcta accacccgcc aacttgctga tgagcctcac tacacgcatg 1680
agctcatatc tgaaccagct gttaggaatt ttaccgtcac cggaaaaggg tgggagtttg 1740
tatggggaaa ccacccgccg aaaaggtttt gggcacagga aacagcaccc ggaaatccac 1800
atgggctacc gcacgaggtg ataactcatt attaccacag ataccctatg tccaccatcc 1860
tgggtttgtc aatttgtgcc gccattgcaa ccgtttccgt tgcagcgtct acctggctgt 1920
tttgcagatc tagagttgcg tgcctaactc cttaccggct aacacctaac gctaggatac 1980
cattttgtct ggctgtgctt tgctgcgccc gcactgcccg ggccgagacc acctgggagt 2040
ccttggatca cctatggaac aataaccaac agatgttctg gattcaattg ctgatccctc 2100
tggccgcctt gatcgtagtg actcgcctgc tcaggtgcgt gtgctgtgtc gtgccttttt 2160
tagtcatggc cggcgccgca ggcgccggcg cctacgagca cgcgaccacg atgccgagcc 2220
aagcgggaat ctcgtataac actatagtca acagagcagg ctacgcacca ctccctatca 2280
gcataacacc aacaaagatc aagctgatac ctacagtgaa cttggagtac gtcacctgcc 2340
actacaaaac aggaatggat tcaccagcca tcaaatgctg cggatctcag gaatgcactc 2400
caacttacag gcctgatgaa cagtgcaaag tcttcacagg ggtttacccg ttcatgtggg 2460
gtggtgcata ttgcttttgc gacactgaga acacccaagt cagcaaggcc tacgtaatga 2520
aatctgacga ctgccttgcg gatcatgctg aagcatataa agcgcacaca gcctcagtgc 2580
aggcgttcct caacatcaca gtgggagaac actctattgt gactaccgtg tatgtgaatg 2640
gagaaactcc tgtgaatttc aatggggtca aattaactgc aggtccgctt tccacagctt 2700
ggacaccctt tgatcgcaaa atcgtgcagt atgccgggga gatctataat tatgattttc 2760
ctgagtatgg ggcaggacaa ccaggagcat ttggagatat acaatccaga acagtctcaa 2820
gctcagatct gtatgccaat accaacctag tgctgcagag acccaaagca ggagcgatcc 2880
acgtgccata cactcaggca ccttcgggtt ttgagcaatg gaagaaagat aaagctccat 2940
cattgaaatt taccgccccc ttcggatgcg aaatatatac aaaccccatt cgcgccgaaa 3000
actgtactgt agggtcaatt ccattagcct ttgacattcc cgacgccttg ttcaccaggg 3060
tgtcagaaac accgacactt tcagcggccg aatgcactct taacgagtgc gtgtattctt 3120
ccgactttgg tgggatcgcc acggtcaagt actcggccag caagtcaggc aagtgcgcag 3180
tccatgtgcc atcagggact gctaccctaa aagaagcagc agtcgagcta accgagcaag 3240
ggtcggcgac tatccatttc tcgaccgcaa atatccaccc ggagttcagg ctccaaatat 3300
gcacatcata tgttacgtgc aaaggtgatt gtcacccccc gaaagaccat attgtgacac 3360
accctcagta tcacgcccaa acatttacag ccgcggtgtc aaaaaccgcg tggacgtggt 3420
taacatccct gctgggagga tcagccgtaa ttattataat tggcttggtg ctggctacta 3480
ttgtggccat gtacgtgctg accaaccaga aacataattg aatacagcag caattggcaa 3540
gctgcttaca tagaactcgc ggcgattggc atgccgcttt aaaatttttа ttttatttt 3600
cttttctttt ccgaatcgga ttttgttttt aatatttcaa aaaaaaaaaa aaaaaaaaaa 3660
aaaaaaaaaa aaaaaaaaaa aaagggaaga gcgcggccgc gcgctgggct acgtcttgct 3720
ggcgttcgcg acgcgaggct ggatggcctt ccccattatg attcttctcg cttccggcgg 3780
catcgggatg cccgcgttgc aggccatgct gtccaggcag gtagatgacg accatcaggg 3840
acagcttcaa ggatcgctcg cggctcttac cagcctaact tcgatcactg gaccgctgat 3900

cgtcacggcg atttatgccg cctcggcgag cacatggaac gggttggcat ggattgtagg 3960
cgccgcccta taccttgtct gcctccccgc gttgcgtcgc ggtgcatgga gccgggccac 4020
ctcgacctga atggaagccg gcggcacctc gctaacggat tcaccactcc aagaattgga 4080
gccaatcaat tcttgcggag aactgtgaat gcgcaaacca acccttggca gaacatatcc 4140
atcgcgtccg ccatctccag cagccgcacg cggcgcatct cgggcagcgt tgggtcctgg 4200
ccacgggtgc gcatgatcgt gctcctgtcg ttgaggaccc ggctaggctg gcggggttgc 4260
cttactggtt agcagaatga atcaccgata cgcgagcgaa cgtgaagcga ctgctgctgc 4320
aaaacgtctg cgacctgagc aacaacatga atggtcttcg gtttccgtgt ttcgtaaagt 4380
ctggaaacgc ggaagtcagc gccctgcacc attatgttcc ggatctgcat cgcaggatgc 4440
tgctggctac cctgtggaac acctacatct gtattaacga agcgctggca ttgaccctga 4500
gtgatttttc tctggtcccg ccgcatccat accgccagtt gtttaccctc acaacgttcc 4560
agtaaccggg catgttcatc atcagtaacc cgtatcgtga gcatcctctc tcgtttcatc 4620
ggtatcatta cccccatgaa cagaaatccc ccttacacgg aggcatcagt gaccaaacag 4680
gaaaaaaccg cccttaacat ggcccgcttt atcagaagcc agacattaac gcttctggag 4740
aaactcaacg agctggacgc ggatgaacag gcagacatct gtgaatcgct tcacgaccac 4800
gctgatgagc tttaccgcag ctgcctcgcg cgtttcggtg atgacggtga aaacctctga 4860
cacatgcagc tcccggagac ggtcacagct tgtctgtaag cggatgccgg gagcagacaa 4920
gcccgtcagg gcgcgtcagc gggtgttggc gggtgtcggg gcgcagccat gacccagtca 4980
cgtagcgata gcggagtgta tactggctta actatgcggc atcagagcag attgtactga 5040
gagtgcacca tatatgcggt gtgaaatacc gcacagatgc gtaaggagaa aataccgcat 5100
caggcgctct tccgcttcct cgctcactga ctcgctgcgc tcggtcgttc ggctgcggcg 5160
agcggtatca gctcactcaa aggcggtaat acggttatcc acagaatcag gggataacgc 5220
aggaaagaac atgtgagcaa aaggccagca aaaggccagg aaccgtaaaa aggccgcgtt 5280
gctggcgttt ttccataggc tccgcccccc tgacgagcat cacaaaaatc gacgctcaag 5340
tcagaggtgg cgaaacccga caggactata aagataccag gcgtttcccc ctggaagctc 5400
cctcgtgcgc tctcctgttc cgaccctgcc gcttaccgga tacctgtccg cctttctccc 5460
ttcgggaagc gtggcgcttt ctcatagctc acgctgtagg tatctcagtt cggtgtaggt 5520
cgttcgctcc aagctgggct gtgtgcacga acccccccgtt cagcccgacc gctgcgcctt 5580
atccggtaac tatcgtcttg agtccaaccc ggtaagacac gacttatcgc cactggcagc 5640
agccactggt aacaggatta gcagagcgag gtatgtaggc ggtgctacag agttcttgaa 5700
gtggtggcct aactacggct acactagaag gacagtattt ggtatctgcg ctctgctgaa 5760
gccagttacc ttcggaaaaa gagttggtag ctcttgatcc ggcaaacaaa ccaccgctgg 5820
tagcggtggt ttttttgttt gcaagcagca gattacgcgc agaaaaaaag gatctcaaga 5880
agatcctttg atcttttcta cggggtctga cgctcagtgg aacgaaaact cacgttaagg 5940
gattttggtc atgaacaata aaactgtctg cttacataaa cagtaataca aggggtgtta 6000
tgagccatat tcaacgggaa acgtcttgct cgaggccgcg attaaattcc aacatggatg 6060
ctgatttata tgggtataaa tgggctcgcg ataatgtcgg gcaatcaggt gcgacaatct 6120
atcgattgta tgggaagccc gatgcgccag agttgtttct gaaacatggc aaaggtagcg 6180
ttgccaatga tgttacagat gagatggtca gactaaactg gctgacggaa tttatgcctc 6240
ttccgaccat caagcatttt atccgtactc ctgatgatgc atggttactc accactgcga 6300
tccccgggaa aacagcattc caggtattag aagaatatcc tgattcaggt gaaaatattg 6360
ttgatgcgct ggcagtgttc ctgcgccggt tgcattcgat tcctgtttgt aattgtcctt 6420
ttaacagcga tcgcgtattt cgtctcgctc aggcgcaatc acgaatgaat aacggtttgg 6480
ttgatgcgag tgattttgat gacgagcgta atggctggcc tgttgaacaa gtctggaaag 6540
aaatgcataa gcttttgcca ttctcaccgg attcagtcgt cactcatggt gatttctcac 6600
ttgataacct tatttttgac gaggggaaat taataggttg tattgatgtt ggacgagtcg 6660
gaatcgcaga ccgataccag gatcttgcca tcctatggaa ctgcctcggt gagttttctc 6720
cttcattaca gaaacggctt tttcaaaaat atggtattga taatcctgat atgaataaat 6780
tgcagtttca tttgatgctc gatgagtttt tctaagaatt ctcatgtttg acagcttatc 6840
atcgataagc tttaatgcgg tagtttatca cagttaaatt gctaacgcag tcaggcaccg 6900
tgtatgaaat ctaacaatgc gctcatcgtc atcctcggca ccgtcaccct ggatgctgtc 6960
tagaggatcc ctaatacgac tcactatag 6989

<210> 12
<211> 2943
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence; Note =
synthetic construct

<221> CDS
<222> (1)...(2943)

<400> 12

```
atg tca cta gtg acc acc atg tgt ctg ctc gcc aat gtg acg ttc cca       48
Met Ser Leu Val Thr Thr Met Cys Leu Leu Ala Asn Val Thr Phe Pro
 1               5                  10                  15

tgt gct caa cca cca att tgc tac gac aga aaa cca gca gag act ttg       96
Cys Ala Gln Pro Pro Ile Cys Tyr Asp Arg Lys Pro Ala Glu Thr Leu
            20                  25                  30

gcc atg ctc agc gtt aac gtt gac aac ccg ggc tac gat gag ctg ctg      144
Ala Met Leu Ser Val Asn Val Asp Asn Pro Gly Tyr Asp Glu Leu Leu
        35                  40                  45

gaa gca gct gtt aag tgc ccc gga agg aaa agg aga tcc acc gag gag      192
Glu Ala Ala Val Lys Cys Pro Gly Arg Lys Arg Arg Ser Thr Glu Glu
    50                  55                  60

ctg ttt aag gag tat aag cta acg cgc cct tac atg gcc aga tgc atc      240
Leu Phe Lys Glu Tyr Lys Leu Thr Arg Pro Tyr Met Ala Arg Cys Ile
65                  70                  75                  80

aga tgt gca gtt ggg agc tgc cat agt cca ata gca atc gag gca gta      288
Arg Cys Ala Val Gly Ser Cys His Ser Pro Ile Ala Ile Glu Ala Val
                85                  90                  95

aag agc gac ggg cac gac ggt tat gtt aga ctt cag act tcc tcg cag      336
Lys Ser Asp Gly His Asp Gly Tyr Val Arg Leu Gln Thr Ser Ser Gln
            100                 105                 110

tat ggc ctg gat tcc tcc ggc aac tta aag ggc agg acc atg cgg tat      384
Tyr Gly Leu Asp Ser Ser Gly Asn Leu Lys Gly Arg Thr Met Arg Tyr
        115                 120                 125

gac atg cac ggg acc att aaa gag ata cca cta cat caa gtg tca ctc      432
Asp Met His Gly Thr Ile Lys Glu Ile Pro Leu His Gln Val Ser Leu
    130                 135                 140

cat aca tct cgc ccg tgt cac att gtg gat ggg cac ggt tat ttc ctg      480
His Thr Ser Arg Pro Cys His Ile Val Asp Gly His Gly Tyr Phe Leu
145                 150                 155                 160
ctt gcc agg tgc ccg gca ggg gac tcc atc acc atg gaa ttt aag aaa      528
Leu Ala Arg Cys Pro Ala Gly Asp Ser Ile Thr Met Glu Phe Lys Lys
                165                 170                 175
```

```
gat tcc gtc aca cac tcc tgc tcg gtg ccg tat gaa gtg aaa ttt aat      576
Asp Ser Val Thr His Ser Cys Ser Val Pro Tyr Glu Val Lys Phe Asn
            180                 185                 190

cct gta ggc aga gaa ctc tat act cat ccc cca gaa cac gga gta gag      624
Pro Val Gly Arg Glu Leu Tyr Thr His Pro Pro Glu His Gly Val Glu
        195                 200                 205

caa gcg tgc caa gtc tac gca cat gat gca cag aac aga gga gct tat      672
Gln Ala Cys Gln Val Tyr Ala His Asp Ala Gln Asn Arg Gly Ala Tyr
    210                 215                 220

gtc gag atg cac ctc cca ggc tca gaa gtg gac agc agt ttg gtt tcc      720
Val Glu Met His Leu Pro Gly Ser Glu Val Asp Ser Ser Leu Val Ser
225                 230                 235                 240

ttg agc ggc agt tca gtc acc gtg aca cct cct gtt ggg act agc gcc      768
Leu Ser Gly Ser Ser Val Thr Val Thr Pro Pro Val Gly Thr Ser Ala
                245                 250                 255

ctg gtg gaa tgc gag tgt ggc ggc aca aag atc tcc aag acc atc aac      816
Leu Val Glu Cys Glu Cys Gly Gly Thr Lys Ile Ser Lys Thr Ile Asn
            260                 265                 270

aag aca aaa cag ttc agc cag tgc aca aag aag gag cag tgc aga gca      864
Lys Thr Lys Gln Phe Ser Gln Cys Thr Lys Lys Glu Gln Cys Arg Ala
        275                 280                 285

tat cgg ctg cag aac gat aag tgg gtg tat aat tct gac aaa ctg ccc      912
Tyr Arg Leu Gln Asn Asp Lys Trp Val Tyr Asn Ser Asp Lys Leu Pro
    290                 295                 300

aaa gca gcg gga gcc acc tta aaa gga aaa ctg cat gtc cca ttc ttg      960
Lys Ala Ala Gly Ala Thr Leu Lys Gly Lys Leu His Val Pro Phe Leu
305                 310                 315                 320

ctg gca gac ggc aaa tgc acc gtg cct cta gca cca gaa cct atg ata     1008
Leu Ala Asp Gly Lys Cys Thr Val Pro Leu Ala Pro Glu Pro Met Ile
                325                 330                 335

acc ttc ggt ttc aga tca gtg tca ctg aaa ctg cac cct aag aat ccc     1056
Thr Phe Gly Phe Arg Ser Val Ser Leu Lys Leu His Pro Lys Asn Pro
            340                 345                 350

aca tat cta acc acc cgc caa ctt gct gat gag cct cac tac acg cat     1104
Thr Tyr Leu Thr Thr Arg Gln Leu Ala Asp Glu Pro His Tyr Thr His
        355                 360                 365

gag ctc ata tct gaa cca gct gtt agg aat ttt acc gtc acc gga aaa     1152
Glu Leu Ile Ser Glu Pro Ala Val Arg Asn Phe Thr Val Thr Gly Lys
    370                 375                 380
ggg tgg gag ttt gta tgg gga aac cac ccg ccg aaa agg ttt tgg gca     1200
Gly Trp Glu Phe Val Trp Gly Asn His Pro Pro Lys Arg Phe Trp Ala
385                 390                 395                 400
```

```
cag gaa aca gca ccc gga aat cca cat ggg cta ccg cac gag gtg ata     1248
Gln Glu Thr Ala Pro Gly Asn Pro His Gly Leu Pro His Glu Val Ile
                405                 410                 415

act cat tat tac cac aga tac cct atg tcc acc atc ctg ggt ttg tca     1296
Thr His Tyr Tyr His Arg Tyr Pro Met Ser Thr Ile Leu Gly Leu Ser
            420                 425                 430

att tgt gcc gcc att gca acc gtt tcc gtt gca gcg tct acc tgg ctg     1344
Ile Cys Ala Ala Ile Ala Thr Val Ser Val Ala Ala Ser Thr Trp Leu
        435                 440                 445

ttt tgc aga tct aga gtt gcg tgc cta act cct tac cgg cta aca cct     1392
Phe Cys Arg Ser Arg Val Ala Cys Leu Thr Pro Tyr Arg Leu Thr Pro
    450                 455                 460

aac gct agg ata cca ttt tgt ctg gct gtg ctt tgc tgc gcc cgc act     1440
Asn Ala Arg Ile Pro Phe Cys Leu Ala Val Leu Cys Cys Ala Arg Thr
465                 470                 475                 480

gcc cgg gcc gag acc acc tgg gag tcc ttg gat cac cta tgg aac aat     1488
Ala Arg Ala Glu Thr Thr Trp Glu Ser Leu Asp His Leu Trp Asn Asn
                485                 490                 495

aac caa cag atg ttc tgg att caa ttg ctg atc cct ctg gcc gcc ttg     1536
Asn Gln Gln Met Phe Trp Ile Gln Leu Leu Ile Pro Leu Ala Ala Leu
            500                 505                 510

atc gta gtg act cgc ctg ctc agg tgc gtg tgc tgt gtc gtg cct ttt     1584
Ile Val Val Thr Arg Leu Leu Arg Cys Val Cys Cys Val Val Pro Phe
        515                 520                 525

tta gtc atg gcc ggc gcc gca ggc gcc ggc gcc tac gag cac gcg acc     1632
Leu Val Met Ala Gly Ala Ala Gly Ala Gly Ala Tyr Glu His Ala Thr
    530                 535                 540

acg atg ccg agc caa gcg gga atc tcg tat aac act ata gtc aac aga     1680
Thr Met Pro Ser Gln Ala Gly Ile Ser Tyr Asn Thr Ile Val Asn Arg
545                 550                 555                 560

gca ggc tac gca cca ctc cct atc agc ata aca cca aca aag atc aag     1728
Ala Gly Tyr Ala Pro Leu Pro Ile Ser Ile Thr Pro Thr Lys Ile Lys
                565                 570                 575

ctg ata cct aca gtg aac ttg gag tac gtc acc tgc cac tac aaa aca     1776
Leu Ile Pro Thr Val Asn Leu Glu Tyr Val Thr Cys His Tyr Lys Thr
            580                 585                 590

gga atg gat tca cca gcc atc aaa tgc tgc gga tct cag gaa tgc act     1824
Gly Met Asp Ser Pro Ala Ile Lys Cys Cys Gly Ser Gln Glu Cys Thr
        595                 600                 605
cca act tac agg cct gat gaa cag tgc aaa gtc ttc aca ggg gtt tac     1872
Pro Thr Tyr Arg Pro Asp Glu Gln Cys Lys Val Phe Thr Gly Val Tyr
    610                 615                 620
```

```
ccg ttc atg tgg ggt ggt gca tat tgc ttt tgc gac act gag aac acc     1920
Pro Phe Met Trp Gly Gly Ala Tyr Cys Phe Cys Asp Thr Glu Asn Thr
625                 630                 635                 640

caa gtc agc aag gcc tac gta atg aaa tct gac gac tgc ctt gcg gat     1968
Gln Val Ser Lys Ala Tyr Val Met Lys Ser Asp Asp Cys Leu Ala Asp
                645                 650                 655

cat gct gaa gca tat aaa gcg cac aca gcc tca gtg cag gcg ttc ctc     2016
His Ala Glu Ala Tyr Lys Ala His Thr Ala Ser Val Gln Ala Phe Leu
            660                 665                 670

aac atc aca gtg gga gaa cac tct att gtg act acc gtg tat gtg aat     2064
Asn Ile Thr Val Gly Glu His Ser Ile Val Thr Thr Val Tyr Val Asn
        675                 680                 685

gga gaa act cct gtg aat ttc aat ggg gtc aaa tta act gca ggt ccg     2112
Gly Glu Thr Pro Val Asn Phe Asn Gly Val Lys Leu Thr Ala Gly Pro
    690                 695                 700

ctt tcc aca gct tgg aca ccc ttt gat cgc aaa atc gtg cag tat gcc     2160
Leu Ser Thr Ala Trp Thr Pro Phe Asp Arg Lys Ile Val Gln Tyr Ala
705                 710                 715                 720

ggg gag atc tat aat tat gat ttt cct gag tat ggg gca gga caa cca     2208
Gly Glu Ile Tyr Asn Tyr Asp Phe Pro Glu Tyr Gly Ala Gly Gln Pro
                725                 730                 735

gga gca ttt gga gat ata caa tcc aga aca gtc tca agc tca gat ctg     2256
Gly Ala Phe Gly Asp Ile Gln Ser Arg Thr Val Ser Ser Ser Asp Leu
            740                 745                 750

tat gcc aat acc aac cta gtg ctg cag aga ccc aaa gca gga gcg atc     2304
Tyr Ala Asn Thr Asn Leu Val Leu Gln Arg Pro Lys Ala Gly Ala Ile
        755                 760                 765

cac gtg cca tac act cag gca cct tcg ggt ttt gag caa tgg aag aaa     2352
His Val Pro Tyr Thr Gln Ala Pro Ser Gly Phe Glu Gln Trp Lys Lys
    770                 775                 780

gat aaa gct cca tca ttg aaa ttt acc gcc cct ttc gga tgc gaa ata     2400
Asp Lys Ala Pro Ser Leu Lys Phe Thr Ala Pro Phe Gly Cys Glu Ile
785                 790                 795                 800

tat aca aac ccc att cgc gcc gaa aac tgt act gta ggg tca att cca     2448
Tyr Thr Asn Pro Ile Arg Ala Glu Asn Cys Thr Val Gly Ser Ile Pro
                805                 810                 815

tta gcc ttt gac att ccc gac gcc ttg ttc acc agg gtg tca gaa aca     2496
Leu Ala Phe Asp Ile Pro Asp Ala Leu Phe Thr Arg Val Ser Glu Thr
            820                 825                 830
ccg aca ctt tca gcg gcc gaa tgc act ctt aac gag tgc gtg tat tct     2544
Pro Thr Leu Ser Ala Ala Glu Cys Thr Leu Asn Glu Cys Val Tyr Ser
        835                 840                 845
```

```
tcc gac ttt ggt ggg atc gcc acg gtc aag tac tcg gcc agc aag tca     2592
Ser Asp Phe Gly Gly Ile Ala Thr Val Lys Tyr Ser Ala Ser Lys Ser
    850                 855                 860

ggc aag tgc gca gtc cat gtg cca tca ggg act gct acc cta aaa gaa     2640
Gly Lys Cys Ala Val His Val Pro Ser Gly Thr Ala Thr Leu Lys Glu
865                 870                 875                 880

gca gca gtc gag cta acc gag caa ggg tcg gcg act atc cat ttc tcg     2688
Ala Ala Val Glu Leu Thr Glu Gln Gly Ser Ala Thr Ile His Phe Ser
                885                 890                 895

acc gca aat atc cac ccg gag ttc agg ctc caa ata tgc aca tca tat     2736
Thr Ala Asn Ile His Pro Glu Phe Arg Leu Gln Ile Cys Thr Ser Tyr
            900                 905                 910

gtt acg tgc aaa ggt gat tgt cac ccc ccg aaa gac cat att gtg aca     2784
Val Thr Cys Lys Gly Asp Cys His Pro Pro Lys Asp His Ile Val Thr
        915                 920                 925

cac cct cag tat cac gcc caa aca ttt aca gcc gcg gtg tca aaa acc     2832
His Pro Gln Tyr His Ala Gln Thr Phe Thr Ala Ala Val Ser Lys Thr
    930                 935                 940

gcg tgg acg tgg tta aca tcc ctg ctg gga gga tca gcc gta att att     2880
Ala Trp Thr Trp Leu Thr Ser Leu Leu Gly Gly Ser Ala Val Ile Ile
945                 950                 955                 960

ata att ggc ttg gtg ctg gct act att gtg gcc atg tac gtg ctg acc     2928
Ile Ile Gly Leu Val Leu Ala Thr Ile Val Ala Met Tyr Val Leu Thr
                965                 970                 975

aac cag aaa cat aat                                                2943
Asn Gln Lys His Asn
            980
```

<210> 13
<211> 981
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence; Note =
synthetic construct

<400> 13

```
Met Ser Leu Val Thr Thr Met Cys Leu Leu Ala Asn Val Thr Phe Pro
 1               5                  10                  15
Cys Ala Gln Pro Pro Ile Cys Tyr Asp Arg Lys Pro Ala Glu Thr Leu
            20                  25                  30
Ala Met Leu Ser Val Asn Val Asp Asn Pro Gly Tyr Asp Glu Leu Leu
        35                  40                  45
```

```
Glu Ala Ala Val Lys Cys Pro Gly Arg Lys Arg Arg Ser Thr Glu Glu
    50                  55                  60
Leu Phe Lys Glu Tyr Lys Leu Thr Arg Pro Tyr Met Ala Arg Cys Ile
65                  70                  75                  80
Arg Cys Ala Val Gly Ser Cys His Ser Pro Ile Ala Ile Glu Ala Val
                85                  90                  95
Lys Ser Asp Gly His Asp Gly Tyr Val Arg Leu Gln Thr Ser Ser Gln
            100                 105                 110
Tyr Gly Leu Asp Ser Ser Gly Asn Leu Lys Gly Arg Thr Met Arg Tyr
        115                 120                 125
Asp Met His Gly Thr Ile Lys Glu Ile Pro Leu His Gln Val Ser Leu
    130                 135                 140
His Thr Ser Arg Pro Cys His Ile Val Asp Gly His Gly Tyr Phe Leu
145                 150                 155                 160
Leu Ala Arg Cys Pro Ala Gly Asp Ser Ile Thr Met Glu Phe Lys Lys
                165                 170                 175
Asp Ser Val Thr His Ser Cys Ser Val Pro Tyr Glu Val Lys Phe Asn
            180                 185                 190
Pro Val Gly Arg Glu Leu Tyr Thr His Pro Pro Glu His Gly Val Glu
        195                 200                 205
Gln Ala Cys Gln Val Tyr Ala His Asp Ala Gln Asn Arg Gly Ala Tyr
    210                 215                 220
Val Glu Met His Leu Pro Gly Ser Glu Val Asp Ser Ser Leu Val Ser
225                 230                 235                 240
Leu Ser Gly Ser Ser Val Thr Val Thr Pro Pro Val Gly Thr Ser Ala
                245                 250                 255
Leu Val Glu Cys Glu Cys Gly Gly Thr Lys Ile Ser Lys Thr Ile Asn
            260                 265                 270
Lys Thr Lys Gln Phe Ser Gln Cys Thr Lys Lys Glu Gln Cys Arg Ala
        275                 280                 285
Tyr Arg Leu Gln Asn Asp Lys Trp Val Tyr Asn Ser Asp Lys Leu Pro
    290                 295                 300
Lys Ala Ala Gly Ala Thr Leu Lys Gly Lys Leu His Val Pro Phe Leu
305                 310                 315                 320
Leu Ala Asp Gly Lys Cys Thr Val Pro Leu Ala Pro Glu Pro Met Ile
                325                 330                 335
Thr Phe Gly Phe Arg Ser Val Ser Leu Lys Leu His Pro Lys Asn Pro
            340                 345                 350
Thr Tyr Leu Thr Thr Arg Gln Leu Ala Asp Glu Pro His Tyr Thr His
        355                 360                 365
Glu Leu Ile Ser Glu Pro Ala Val Arg Asn Phe Thr Val Thr Gly Lys
    370                 375                 380
Gly Trp Glu Phe Val Trp Gly Asn His Pro Pro Lys Arg Phe Trp Ala
385                 390                 395                 400
Gln Glu Thr Ala Pro Gly Asn Pro His Gly Leu Pro His Glu Val Ile
                405                 410                 415
Thr His Tyr Tyr His Arg Tyr Pro Met Ser Thr Ile Leu Gly Leu Ser
            420                 425                 430
Ile Cys Ala Ala Ile Ala Thr Val Ser Val Ala Ala Ser Thr Trp Leu
        435                 440                 445
Phe Cys Arg Ser Arg Val Ala Cys Leu Thr Pro Tyr Arg Leu Thr Pro
    450                 455                 460
Asn Ala Arg Ile Pro Phe Cys Leu Ala Val Leu Cys Cys Ala Arg Thr
465                 470                 475                 480
```

```
Ala Arg Ala Glu Thr Thr Trp Glu Ser Leu Asp His Leu Trp Asn Asn
                485                 490                 495
Asn Gln Gln Met Phe Trp Ile Gln Leu Leu Ile Pro Leu Ala Ala Leu
            500                 505                 510
Ile Val Val Thr Arg Leu Leu Arg Cys Val Cys Cys Val Val Pro Phe
        515                 520                 525
Leu Val Met Ala Gly Ala Ala Gly Ala Gly Ala Tyr Glu His Ala Thr
    530                 535                 540
Thr Met Pro Ser Gln Ala Gly Ile Ser Tyr Asn Thr Ile Val Asn Arg
545                 550                 555                 560
Ala Gly Tyr Ala Pro Leu Pro Ile Ser Ile Thr Pro Thr Lys Ile Lys
                565                 570                 575
Leu Ile Pro Thr Val Asn Leu Glu Tyr Val Thr Cys His Tyr Lys Thr
            580                 585                 590
Gly Met Asp Ser Pro Ala Ile Lys Cys Cys Gly Ser Gln Glu Cys Thr
        595                 600                 605
Pro Thr Tyr Arg Pro Asp Glu Gln Cys Lys Val Phe Thr Gly Val Tyr
    610                 615                 620
Pro Phe Met Trp Gly Gly Ala Tyr Cys Phe Cys Asp Thr Glu Asn Thr
625                 630                 635                 640
Gln Val Ser Lys Ala Tyr Val Met Lys Ser Asp Asp Cys Leu Ala Asp
                645                 650                 655
His Ala Glu Ala Tyr Lys Ala His Thr Ala Ser Val Gln Ala Phe Leu
            660                 665                 670
Asn Ile Thr Val Gly Glu His Ser Ile Val Thr Thr Val Tyr Val Asn
        675                 680                 685
Gly Glu Thr Pro Val Asn Phe Asn Gly Val Lys Leu Thr Ala Gly Pro
    690                 695                 700
Leu Ser Thr Ala Trp Thr Pro Phe Asp Arg Lys Ile Val Gln Tyr Ala
705                 710                 715                 720
Gly Glu Ile Tyr Asn Tyr Asp Phe Pro Glu Tyr Gly Ala Gly Gln Pro
                725                 730                 735
Gly Ala Phe Gly Asp Ile Gln Ser Arg Thr Val Ser Ser Ser Asp Leu
            740                 745                 750
Tyr Ala Asn Thr Asn Leu Val Leu Gln Arg Pro Lys Ala Gly Ala Ile
        755                 760                 765
His Val Pro Tyr Thr Gln Ala Pro Ser Gly Phe Glu Gln Trp Lys Lys
    770                 775                 780
Asp Lys Ala Pro Ser Leu Lys Phe Thr Ala Pro Phe Gly Cys Glu Ile
785                 790                 795                 800
Tyr Thr Asn Pro Ile Arg Ala Glu Asn Cys Thr Val Gly Ser Ile Pro
                805                 810                 815
Leu Ala Phe Asp Ile Pro Asp Ala Leu Phe Thr Arg Val Ser Glu Thr
            820                 825                 830
Pro Thr Leu Ser Ala Ala Glu Cys Thr Leu Asn Glu Cys Val Tyr Ser
        835                 840                 845
Ser Asp Phe Gly Gly Ile Ala Thr Val Lys Tyr Ser Ala Ser Lys Ser
    850                 855                 860
Gly Lys Cys Ala Val His Val Pro Ser Gly Thr Ala Thr Leu Lys Glu
865                 870                 875                 880
Ala Ala Val Glu Leu Thr Glu Gln Gly Ser Ala Thr Ile His Phe Ser
                885                 890                 895
Thr Ala Asn Ile His Pro Glu Phe Arg Leu Gln Ile Cys Thr Ser Tyr
            900                 905                 910
```

Val Thr Cys Lys Gly Asp Cys His Pro Pro Lys Asp His Ile Val Thr
915 920 925
His Pro Gln Tyr His Ala Gln Thr Phe Thr Ala Ala Val Ser Lys Thr
930 935 940
Ala Trp Thr Trp Leu Thr Ser Leu Leu Gly Gly Ser Ala Val Ile Ile
945 950 955 960
Ile Ile Gly Leu Val Leu Ala Thr Ile Val Ala Met Tyr Val Leu Thr
965 970 975
Asn Gln Lys His Asn
980

<210> 14
<211> 12379
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence; Note =
synthetic construct

<400> 14
atgggcggcg catgagagaa gcccagacca attacctacc caaaatggag aaagttcacg 60
ttgacatcga ggaagacagc ccattcctca gagctttgca gcggagcttc ccgcagtttg 120
aggtagaagc caagcaggtc actgataatg accatgctaa tgccagagcg ttttcgcatc 180
tggcttcaaa actgatcgaa acggaggtgg acccatccga cacgatcctt gacattggaa 240
gtgcgcccgc ccgcagaatg tattctaagc acaagtatca ttgtatctgt ccgatgagat 300
gtgcggaaga tccggacaga ttgtataagt atgcaactaa gctgaagaaa aactgtaagg 360
aaataactga taaggaattg gacaagaaaa tgaaggagct cgccgccgtc atgagcgacc 420
ctgacctgga aactgagact atgtgcctcc acgacgacga gtcgtgtcgc tacgaagggc 480
aagtcgctgt ttaccaggat gtatacgcgg ttgacggacc gacaagtctc tatcaccaag 540
ccaataaggg agttagagtc gcctactgga taggctttga caccacccct tttatgttta 600
agaacttggc tggagcatat ccatcatact ctaccaactg ggccgacgaa accgtgttaa 660
cggctcgtaa cataggccta tgcagctctg acgttatgga gcggtcacgt agagggatgt 720
ccattcttag aaagaagtat ttgaaaccat ccaacaatgt tctattctct gttggctcga 780
ccatctacca cgagaagagg gacttactga ggagctggca cctgccgtct gtatttcact 840
tacgtggcaa gcaaaattac acatgtcggt gtgagactat agttagttgc gacgggtacg 900
tcgttaaaag aatagctatc agtccaggcc tgtatgggaa gccttcaggc tatgctgcta 960
cgatgcaccg cgagggattc ttgtgctgca aagtgacaga cacattcaac ggggagaggg 1020
tctcttttcc cgtgtgcacg tatgtgccag ctacattgtg tgaccaaatg actggcatac 1080
tggcaacaga tgtcagtgcg gacgacgcgc aaaaactgct ggttgggctc aaccagcgta 1140
tagtcgtcaa cggtcgcacc cagagaaaca ccaataccat gaaaaattac cttttgcccg 1200
tagtggccca ggcatttgct aggtgggcaa aggaatataa ggaagatcaa gaagatgaaa 1260
ggccactagg actacgagat agacagttag tcatggggtg ttgttgggct tttagaaggc 1320
acaagataac atctatttat aagcgcccgg atacccaaac catcatcaaa gtgaacagcg 1380
atttccactc attcgtgctg cccaggatag gcagtaacac attggagatc gggctgagaa 1440
caagaatcag gaaaatgtta gaggagcaca aggagccgtc acctctcatt accgccgagg 1500
acgtacaaga agctaagtgc gcagccgatg agcgtaagga ggtgcgtgaa gccgaggagt 1560
tgcgcgcagc tctaccacct ttggcagctg atgttgagga gcccactctg gaagccgatg 1620
tcgacttgat gttacaagag gctggggccg gctcagtgga gacacctcgt ggcttgataa 1680
aggttaccag ctacgatggc gaggacaaga tcggctctta cgctgtgctt tctccgcagg 1740
ctgtactcaa gagtgaaaaa ttatcttgca tccaccctct cgctgaacaa gtcatagtga 1800
taacacactc tggccgaaaa gggcgttatg ccgtggaacc ataccatggt aaagtagtgg 1860
tgccagaggg acatgcaata cccgtccagg actttcaagc tctgagtgaa agtgccacca 1920
ttgtgtacaa cgaacgtgag ttcgtaaaca ggtacctgca ccatattgcc acacatggag 1980
gagcgctgaa cactgatgaa gaatattaca aaactgtcaa gcccagcgag cacgacggcg 2040

aatacctgta cgacatcgac aggaaacagt gcgtcaagaa agaactagtc actgggctag 2100
ggctcacagg cgagctggtg gatcctccct tccatgaatt cgcctacgag agtctgagaa 2160
cacgaccagc cgctccttac caagtaccaa ccataggggt gtatggcgtg ccaggatcag 2220
gcaagtctgg catcattaaa agcgcagtca ccaaaaaaga tctagtggtg agcgccaaga 2280
aagaaaactg tgcagaaatt ataagggacg tcaagaaaat gaaagggctg gacgtcaatg 2340
ccagaactgt ggactcagtg ctcttgaatg gatgcaaaca ccccgtagag accctgtata 2400
ttgacgaagc ttttgcttgt catgcaggta ctctcagagc gctcatagcc attataagac 2460
ctaaaaaggc agtgctctgc ggggatccca aacagtgcgg ttttttaac atgatgtgcc 2520
tgaaagtgca ttttaaccac gagatttgca cacaagtctt ccacaaaagc atctctcgcc 2580
gttgcactaa atctgtgact tcggtcgtct caaccttgtt ttacgacaaa aaaatgagaa 2640
cgacgaatcc gaaagagact aagattgtga ttgacactac cggcagtacc aaacctaagc 2700
aggacgatct cattctcact tgtttcagag ggtgggtgaa gcagttgcaa atagattaca 2760
aaggcaacga aataatgacg gcagctgcct ctcaagggct gacccgtaaa ggtgtgtatg 2820
ccgttcggta caaggtgaat gaaaatcctc tgtacgcacc cacctcagaa catgtgaacg 2880
tcctactgac ccgcacggag gaccgcatcg tgtggaaaac actagccggc gacccatgga 2940
taaaaacact gactgccaag taccctggga atttcactgc cacgatagag gagtggcaag 3000
cagagcatga tgccatcatg aggcacatct tggagagacc ggaccctacc gacgtcttcc 3060
agaataaggc aaacgtgtgt tgggccaagg ctttagtgcc ggtgctgaag accgctggca 3120
tagacatgac cactgaacaa tggaacactg tggattattt tgaaacggac aaagctcact 3180
cagcagagat agtattgaac caactatgcg tgaggttctt tggactcgat ctggactccg 3240
gtctattttc tgcacccact gttccgttat ccattaggaa taatcactgg gataactccc 3300
cgtcgcctaa catgtacggg ctgaataaag aagtggtccg tcagctctct cgcaggtacc 3360
cacaactgcc tcgggcagtt gccactggaa gagtctatga catgaacact ggtacactgc 3420
gcaattatga tccgcgcata aacctagtac ctgtaaacag aagactgcct catgctttag 3480
tcctccacca taatgaacac ccacagagtg acttttcttc attcgtcagc aaattgaagg 3540
gcagaactgt cctggtggtc ggggaaaagt tgtccgtccc aggcaaaatg gttgactggt 3600
tgtcagaccg gcctgaggct accttcagag ctcggctgga tttaggcatc ccaggtgatg 3660
tgcccaaata tgacataata tttgttaatg tgaggacccc atataaatac catcactatc 3720
agcagtgtga agaccatgcc attaagctta gcatgttgac caagaaagct tgtctgcatc 3780
tgaatcccgg cggaacctgt gtcagcatag gttatggtta cgctgacagg gccagcgaaa 3840
gcatcattgg tgctatagcg cggcagttca agttttcccg ggtatgcaaa ccgaaatcct 3900
cacttgaaga gacggaagtt ctgtttgtat tcattgggta cgatcgcaag gcccgtacgc 3960
acaatcctta caagctttca tcaaccttga ccaacattta tacaggttcc agactccacg 4020
aagccggatg tgcaccctca tatcatgtgg tgcgagggga tattgccacg gccaccgaag 4080
gagtgattat aaatgctgct aacagcaaag gacaacctgg cggaggggtg tgcggagcgc 4140
tgtataagaa attcccggaa agcttcgatt tacagccgat cgaagtagga aaagcgcgac 4200
tggtcaaagg tgcagctaaa catatcattc atgccgtagg accaaacttc aacaaagttt 4260
cggaggttga aggtgacaaa cagttggcag aggcttatga gtccatcgct aagattgtca 4320
acgataacaa ttacaagtca gtagcgattc cactgttgtc caccggcatc ttttccggga 4380
acaaagatcg actaacccaa tcattgaacc atttgctgac agctttagac accactgatg 4440
cagatgtagc catatactgc agggacaaga aatgggaaat gactctcaag gaagcagtgg 4500
ctaggagaga agcagtggag gagatatgca tatccgacga ctcttcagtg acagaacctg 4560
atgcagagct ggtgagggtg catccgaaga gttctttggc tggaaggaag ggctacagca 4620
caagcgatgg caaaactttc tcatatttgg aagggaccaa gtttcaccag gcggccaagg 4680
atatagcaga aattaatgcc atgtggcccg ttgcaacgga ggccaatgag caggtatgca 4740
tgtatatcct cggagaaagc atgagcagta ttaggtcgaa atgccccgtc gaagagtcgg 4800
aagcctcctc accacctagc acgctgcctt gcttgtgcat ccatgccatg actccagaaa 4860
gagtacagcg cctaaaagcc tcacgtccag aacaaattac tgtgtgctca tcctttccat 4920
tgccgaagta tagaatcact ggtgtgcaga agatccaatg ctcccagcct atattgttct 4980
caccgaaagt gcctgcgtat attcatccaa ggaagtatct cgtggaaaca ccaccggtag 5040
acgagactcc ggagccatcg gcagagaacc aatccacaga ggggacacct gaacaaccac 5100
cacttataac cgaggatgag accaggacta gaacgcctga gccgatcatc atcgaagagg 5160
aagaagagga tagcataagt ttgctgtcag atggcccgac ccaccaggtg ctgcaagtcg 5220
aggcagacat tcacgggccg ccctctgtat ctagctcatc ctggtccatt cctcatgcat 5280
ccgactttga tgtggacagt ttatccatac ttgacaccct ggagggagct agcgtgacca 5340

gcggggcaac gtcagccgag actaactctt acttcgcaaa gagtatggag tttctggcgc 5400
gaccggtgcc tgcgcctcga acagtattca ggaaccctcc acatcccgct ccgcgcacaa 5460
gaacaccgtc acttgcaccc agcagggcct gctcgagaac cagcctagtt tccacccccgc 5520
caggcgtgaa tagggtgatc actagagagg agctcgaggc gcttaccccg tcacgcactc 5580
ctagcaggtc ggtctcgaga accagcctgg tctccaaccc gccaggcgta aatagggtga 5640
ttacaagaga ggagtttgag gcgttcgtag cacaacaaca atgacggttt gatgcgggtg 5700
catacatctt ttcctccgac accggtcaag ggcatttaca acaaaaatca gtaaggcaaa 5760
cggtgctatc cgaagtggtg ttggagagga ccgaattgga gatttcgtat gccccgcgcc 5820
tcgaccaaga aaaagaagaa ttactacgca agaaattaca gttaaatccc acacctgcta 5880
acagaagcag ataccagtcc aggaaggtgg agaacatgaa agccataaca gctagacgta 5940
ttctgcaagg cctagggcat tatttgaagg cagaaggaaa agtggagtgc taccgaaccc 6000
tgcatcctgt tcctttgtat tcatctagtg tgaaccgtgc cttttcaagc cccaaggtcg 6060
cagtggaagc ctgtaacgcc atgttgaaag agaactttcc gactgtggct tcttactgta 6120
ttattccaga gtacgatgcc tatttggaca tggttgacgg agcttcatgc tgcttagaca 6180
ctgccagttt ttgccctgca aagctgcgca gctttccaaa gaaacactcc tatttggaac 6240
ccacaatacg atcggcagtg ccttcagcga tccagaacac gctccagaac gtcctggcag 6300
ctgccacaaa aagaaattgc aatgtcacgc aaatgagaga attgcccgta ttggattcgg 6360
cggcctttaa tgtggaatgc ttcaagaaat atgcgtgtaa taatgaatat tgggaaacgt 6420
ttaaagaaaa ccccatcagg cttactgaag aaaacgtggt aaattacatt accaaattaa 6480
aaggaccaaa agctgctgct ctttttgcga agacacataa tttgaatatg ttgcaggaca 6540
taccaatgga caggtttgta atggacttaa agagagacgt gaaagtgact ccaggaacaa 6600
aacatactga agaacggccc aaggtacagg tgatccaggc tgccgatccg ctagcaacag 6660
cgtatctgtg cggaatccac cgagagctgg ttaggagatt aaatgcggtc ctgcttccga 6720
acattcatac actgtttgat atgtcggctg aagactttga cgctattata gccgagcact 6780
tccagcctgg ggattgtgtt ctggaaactg acatcgcgtc gtttgataaa agtgaggacg 6840
acgccatggc tctgaccgcg ttaatgattc tggaagactt aggtgtggac gcagagctgt 6900
tgacgctgat tgaggcggct ttcggcgaaa tttcatcaat acatttgccc actaaaacta 6960
aatttaaatt cggagccatg atgaaatctg gaatgttcct cacactgttt gtgaacacag 7020
tcattaacat tgtaatcgca agcagagtgt tgagagaacg gctaaccgga tcaccatgtg 7080
cagcattcat tggagatgac aatatcgtga aaggagtcaa atcggacaaa ttaatggcag 7140
acaggtgcgc cacctggttg aatatggaag tcaagattat agatgctgtg gtgggcgaga 7200
aagcgcctta tttctgtgga gggtttattt tgtgtgactc cgtgaccggc acagcgtgcc 7260
gtgtggcaga ccccctaaaa aggctgttta agcttggcaa acctctggca gcagacgatg 7320
aacatgatga tgacaggaga agggcattgc atgaagagtc aacacgctgg aaccgagtgg 7380
gtattctttc agagctgtgc aaggcagtag aatcaaggta tgaaaccgta ggaacttcca 7440
tcatagttat ggccatgact actctagcta gcagtgttaa atcattcagc tacctgagag 7500
gggcccctat aactctctac ggctaacctg aatggactac gacatagtct agtccgccaa 7560
gatgccaatc agtcccattg aaactgtacc agtaaaactg aagccaggaa tggatggccc 7620
aaaggttaaa caatggccgt taacagaagt gaaaataaaa gcattaacag caatttgtga 7680
agaaatggaa aaggaaggaa aaattacaaa aattgggcct gaaaatccat ataacactcc 7740
aatattcgcc ataaaaaagg aagacagcac taagtggaga aaattagtag atttcaggga 7800
actcaataaa agaactcaag acttttggga ggttcaatta ggaataccac acccagcagg 7860
gttaaaaaag aaaaaatcag tgacagtact ggatgtggga gatgcatatt tttcagttcc 7920
tttagatgaa ggcttcagga aatatactgc attcaccata cctagtataa acaatgaaac 7980
accagggatt agatatcaat ataatgtgct tccacaagga tggaaagggt caccagcaat 8040
attccaggct agcatgacaa aaatcctaga gcccttaga gctaaaaatc cagaaatagt 8100
catctatcaa catatggcgg cattgtatgt aggatctgac ttagaaatag ggcaacatag 8160
agcaaaaata gaagagttaa gagaacatct attaaagtgg ggatttacca caccagacaa 8220
aaaacatcag aaagaacccc catttctttg gatggggtat gaactccatc ctgacaaatg 8280
gacagtacag cctatacagc tgccagaaaa agatagctgg actgtcaatg acatacagaa 8340
gttagtggga aaattaaact ggacaagtca gatttaccca gggattaaag taaggcaact 8400
ttgtaagctc cttaggggga ccaaagcact aacagacata gtaccactaa ctgaagaagc 8460
agaattagaa ttggcagaga acagggaaat tctaaaagaa ccagtgcatg gagtatatta 8520
tgacccatca aaagacttga tagctgaaat acagaaacag ggggatgacc aatggacata 8580
tcaaatttac caagaaccat tcaaaaacct gaagacagga aagtatgcaa aaaggaggac 8640

tacccacact aatgatgtaa aacagttaac agaggcagtg caaaaaatat ccttggaaag 8700
catagtaaca tggggaaaga ctcctaaatt tagactaccc atccaaaaag aaacatggga 8760
aatatggtgg acagactatt ggcaagccac atggattcct gagtgggagt ttgttaatac 8820
ccctccccta gtaaaactat ggtaccagct agaaaaagaa cccatagcag gagcagaaac 8880
tttctgaagg ccggccttaa ttaagtaacg atacagcagc aattggcaag ctgcttacat 8940
agaactcgcg gcgattggca tgccgcttta aaatttttat tttatttttc ttttcttttc 9000
cgaatcggat tttgttttta atatttcaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 9060
aaaaaaaaaa aaagggaaga gcgcggccgc gcgctgggct acgtcttgct ggcgttcgcg 9120
acgcgaggct ggatggcctt ccccattatg attcttctcg cttccggcgg catcgggatg 9180
cccgcgttgc aggccatgct gtccaggcag gtagatgacg accatcaggg acagcttcaa 9240
ggatcgctcg cggctcttac cagcctaact tcgatcactg gaccgctgat cgtcacggcg 9300
atttatgccg cctcggcgag cacatggaac gggttggcat ggattgtagg cgccgcccta 9360
taccttgtct gcctccccgc gttgcgtcgc ggtgcatgga gccgggccac ctcgacctga 9420
atggaagccg gcggcacctc gctaacggat tcaccactcc aagaattgga gccaatcaat 9480
tcttgcggag aactgtgaat gcgcaaacca acccttggca gaacatatcc atcgcgtccg 9540
ccatctccag cagccgcacg cggcgcatct cgggcagcgt tgggtcctgg ccacgggtgc 9600
gcatgatcgt gctcctgtcg ttgaggaccc ggctaggctg gcggggttgc cttactggtt 9660
agcagaatga atcaccgata cgcgagcgaa cgtgaagcga ctgctgctgc aaaacgtctg 9720
cgacctgagc aacaacatga atggtcttcg gtttccgtgt ttcgtaaagt ctggaaacgc 9780
ggaagtcagc gccctgcacc attatgttcc ggatctgcat cgcaggatgc tgctggctac 9840
cctgtggaac acctacatct gtattaacga agcgctggca ttgaccctga gtgatttttc 9900
tctggtcccg ccgcatccat accgccagtt gtttaccctc acaacgttcc agtaaccggg 9960
catgttcatc atcagtaacc cgtatcgtga gcatcctctc tcgtttcatc ggtatcatta 10020
cccccatgaa cagaaatccc ccttacacgg aggcatcagt gaccaaacag gaaaaaaccg 10080
cccttaacat ggcccgcttt atcagaagcc agacattaac gcttctggag aaactcaacg 10140
agctggacgc ggatgaacag gcagacatct gtgaatcgct tcacgaccac gctgatgagc 10200
tttaccgcag ctgcctcgcg cgtttcggtg atgacggtga aaacctctga cacatgcagc 10260
tcccggagac ggtcacagct tgtctgtaag cggatgccgg gagcagacaa gcccgtcagg 10320
gcgcgtcagc gggtgttggc gggtgtcggg gcgcagccat gacccagtca cgtagcgata 10380
gcggagtgta tactggctta actatgcggc atcagagcag attgtactga gagtgcacca 10440
tatatgcggt gtgaaatacc gcacagatgc gtaaggagaa aataccgcat caggcgctct 10500
tccgcttcct cgctcactga ctcgctgcgc tcggtcgttc ggctgcggcg agcggtatca 10560
gctcactcaa aggcggtaat acggttatcc acagaatcag gggataacgc aggaaagaac 10620
atgtgagcaa aaggccagca aaaggccagg aaccgtaaaa aggccgcgtt gctggcgttt 10680
ttccataggc tccgcccccc tgacgagcat cacaaaaatc gacgctcaag tcagaggtgg 10740
cgaaacccga caggactata aagataccag gcgtttcccc ctggaagctc cctcgtgcgc 10800
tctcctgttc cgaccctgcc gcttaccgga tacctgtccg cctttctccc ttcgggaagc 10860
gtggcgcttt ctcatagctc acgctgtagg tatctcagtt cggtgtaggt cgttcgctcc 10920
aagctgggct gtgtgcacga acccccgttc agcccgacc gctgcgcctt atccggtaac 10980
tatcgtcttg agtccaaccc ggtaagacac gacttatcgc cactggcagc agccactggt 11040
aacaggatta gcagagcgag gtatgtaggc ggtgctacag agttcttgaa gtggtggcct 11100
aactacggct acactagaag gacagtattt ggtatctgcg ctctgctgaa gccagttacc 11160
ttcggaaaaa gagttggtag ctcttgatcc ggcaaacaaa ccaccgctgg tagcggtggt 11220
ttttttgttt gcaagcagca gattacgcgc agaaaaaaag gatctcaaga agatcctttg 11280
atcttttcta cggggtctga cgctcagtgg aacgaaaact cacgttaagg gattttggtc 11340
atgaacaata aaactgtctg cttacataaa cagtaataca aggggtgtta tgagccatat 11400
tcaacgggaa acgtcttgct cgaggccgcg attaaattcc aacatggatg ctgatttata 11460
tgggtataaa tgggctcgcg ataatgtcgg gcaatcaggt gcgacaatct atcgattgta 11520
tgggaagccc gatgcgccag agttgtttct gaaacatggc aaaggtagcg ttgccaatga 11580
tgttacagat gagatggtca gactaaactg gctgacggaa tttatgcctc ttccgaccat 11640
caagcatttt atccgtactc ctgatgatgc atggttactc accactgcga tccccgggaa 11700
aacagcattc caggtattag aagaatatcc tgattcaggt gaaaatattg ttgatgcgct 11760
ggcagtgttc ctgcgccggt tgcattcgat tcctgtttgt aattgtcctt ttaacagcga 11820
tcgcgtattt cgtctcgctc aggcgcaatc acgaatgaat aacggtttgg ttgatgcgag 11880
tgattttgat gacgagcgta atggctggcc tgttgaacaa gtctggaaag aaatgcataa 11940

gcttttgcca ttctcaccgg attcagtcgt cactcatggt gatttctcac ttgataacct 12000
tatttttgac gaggggaaat taataggttg tattgatgtt ggacgagtcg gaatcgcaga 12060
ccgataccag gatcttgcca tcctatggaa ctgcctcggt gagttttctc cttcattaca 12120
gaaacggctt tttcaaaaat atggtattga taatcctgat atgaataaat tgcagtttca 12180
tttgatgctc gatgagtttt tctaagaatt ctcatgtttg acagcttatc atcgataagc 12240
tttaatgcgg tagtttatca cagttaaatt gctaacgcag tcaggcaccg tgtatgaaat 12300
ctaacaatgc gctcatcgtc atcctcggca ccgtcaccct ggatgctgtc tagaggatcc 12360
ctaatacgac tcactatag 12379

<210> 15
<211> 1323
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence; Note =
synthetic construct

<221> CDS
<222> (1)...(1323)

<400> 15
atg cca atc agt ccc att gaa act gta cca gta aaa ctg aag cca gga 48
Met Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro Gly
1 5 10 15

atg gat ggc cca aag gtt aaa caa tgg ccg tta aca gaa gtg aaa ata 96
Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu Val Lys Ile
20 25 30

aaa gca tta aca gca att tgt gaa gaa atg gaa aag gaa gga aaa att 144
Lys Ala Leu Thr Ala Ile Cys Glu Glu Met Glu Lys Glu Gly Lys Ile
35 40 45

aca aaa att ggg cct gaa aat cca tat aac act cca ata ttc gcc ata 192
Thr Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Ile Phe Ala Ile
50 55 60

aaa aag gaa gac agc act aag tgg aga aaa tta gta gat ttc agg gaa 240
Lys Lys Glu Asp Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg Glu
65 70 75 80

ctc aat aaa aga act caa gac ttt tgg gag gtt caa tta gga ata cca 288
Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile Pro
85 90 95

cac cca gca ggg tta aaa aag aaa aaa tca gtg aca gta ctg gat gtg 336
His Pro Ala Gly Leu Lys Lys Lys Lys Ser Val Thr Val Leu Asp Val
100 105 110

gga gat gca tat ttt tca gtt cct tta gat gaa ggc ttc agg aaa tat 384
Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Gly Phe Arg Lys Tyr
115 120 125

```
act gca ttc acc ata cct agt ata aac aat gaa aca cca ggg att aga      432
Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg
    130                 135                 140

tat caa tat aat gtg ctt cca caa gga tgg aaa ggg tca cca gca ata      480
Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile
145                 150                 155                 160

ttc cag gct agc atg aca aaa atc cta gag ccc ttt aga gct aaa aat      528
Phe Gln Ala Ser Met Thr Lys Ile Leu Glu Pro Phe Arg Ala Lys Asn
                165                 170                 175

cca gaa ata gtc atc tat caa cat atg gcg gca ttg tat gta gga tct      576
Pro Glu Ile Val Ile Tyr Gln His Met Ala Ala Leu Tyr Val Gly Ser
            180                 185                 190

gac tta gaa ata ggg caa cat aga gca aaa ata gaa gag tta aga gaa      624
Asp Leu Glu Ile Gly Gln His Arg Ala Lys Ile Glu Glu Leu Arg Glu
        195                 200                 205

cat cta tta aag tgg gga ttt acc aca cca gac aaa aaa cat cag aaa      672
His Leu Leu Lys Trp Gly Phe Thr Thr Pro Asp Lys Lys His Gln Lys
    210                 215                 220

gaa ccc cca ttt ctt tgg atg ggg tat gaa ctc cat cct gac aaa tgg      720
Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys Trp
225                 230                 235                 240

aca gta cag cct ata cag ctg cca gaa aaa gat agc tgg act gtc aat      768
Thr Val Gln Pro Ile Gln Leu Pro Glu Lys Asp Ser Trp Thr Val Asn
                245                 250                 255

gac ata cag aag tta gtg gga aaa tta aac tgg aca agt cag att tac      816
Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Thr Ser Gln Ile Tyr
            260                 265                 270

cca ggg att aaa gta agg caa ctt tgt aag ctc ctt agg ggg acc aaa      864
Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys
        275                 280                 285

gca cta aca gac ata gta cca cta act gaa gaa gca gaa tta gaa ttg      912
Ala Leu Thr Asp Ile Val Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu
    290                 295                 300

gca gag aac agg gaa att cta aaa gaa cca gtg cat gga gta tat tat      960
Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr Tyr
305                 310                 315                 320

gac cca tca aaa gac ttg ata gct gaa ata cag aaa cag ggg gat gac     1008
Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Asp Asp
                325                 330                 335
caa tgg aca tat caa att tac caa gaa cca ttc aaa aac ctg aag aca     1056
Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr
            340                 345                 350
```

```
gga aag tat gca aaa agg agg act acc cac act aat gat gta aaa cag     1104
Gly Lys Tyr Ala Lys Arg Arg Thr Thr His Thr Asn Asp Val Lys Gln
        355                 360                 365

tta aca gag gca gtg caa aaa ata tcc ttg gaa agc ata gta aca tgg     1152
Leu Thr Glu Ala Val Gln Lys Ile Ser Leu Glu Ser Ile Val Thr Trp
    370                 375                 380

gga aag act cct aaa ttt aga cta ccc atc caa aaa gaa aca tgg gaa     1200
Gly Lys Thr Pro Lys Phe Arg Leu Pro Ile Gln Lys Glu Thr Trp Glu
385                 390                 395                 400

ata tgg tgg aca gac tat tgg caa gcc aca tgg att cct gag tgg gag     1248
Ile Trp Trp Thr Asp Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu
                405                 410                 415

ttt gtt aat acc cct ccc cta gta aaa cta tgg tac cag cta gaa aaa     1296
Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys
            420                 425                 430

gaa ccc ata gca gga gca gaa act ttc                                1323
Glu Pro Ile Ala Gly Ala Glu Thr Phe
        435                 440
```

<210> 16
<211> 441
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence; Note = synthetic construct

<400> 16

```
Met Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro Gly
 1               5                  10                  15
Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu Val Lys Ile
            20                  25                  30
Lys Ala Leu Thr Ala Ile Cys Glu Glu Met Glu Lys Glu Gly Lys Ile
        35                  40                  45
Thr Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Ile Phe Ala Ile
    50                  55                  60
Lys Lys Glu Asp Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg Glu
65                  70                  75                  80
Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile Pro
                85                  90                  95
His Pro Ala Gly Leu Lys Lys Lys Lys Ser Val Thr Val Leu Asp Val
            100                 105                 110
Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Gly Phe Arg Lys Tyr
        115                 120                 125
Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg
    130                 135                 140
```

```
Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile
145                 150                 155                 160
Phe Gln Ala Ser Met Thr Lys Ile Leu Glu Pro Phe Arg Ala Lys Asn
                165                 170                 175
Pro Glu Ile Val Ile Tyr Gln His Met Ala Ala Leu Tyr Val Gly Ser
            180                 185                 190
Asp Leu Glu Ile Gly Gln His Arg Ala Lys Ile Glu Glu Leu Arg Glu
        195                 200                 205
His Leu Leu Lys Trp Gly Phe Thr Thr Pro Asp Lys Lys His Gln Lys
    210                 215                 220
Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys Trp
225                 230                 235                 240
Thr Val Gln Pro Ile Gln Leu Pro Glu Lys Asp Ser Trp Thr Val Asn
                245                 250                 255
Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Thr Ser Gln Ile Tyr
            260                 265                 270
Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys
        275                 280                 285
Ala Leu Thr Asp Ile Val Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu
    290                 295                 300
Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr Tyr
305                 310                 315                 320
Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Asp Asp
                325                 330                 335
Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr
            340                 345                 350
Gly Lys Tyr Ala Lys Arg Arg Thr Thr His Thr Asn Asp Val Lys Gln
        355                 360                 365
Leu Thr Glu Ala Val Gln Lys Ile Ser Leu Glu Ser Ile Val Thr Trp
    370                 375                 380
Gly Lys Thr Pro Lys Phe Arg Leu Pro Ile Gln Lys Glu Thr Trp Glu
385                 390                 395                 400
Ile Trp Trp Thr Asp Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu
                405                 410                 415
Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys
            420                 425                 430
Glu Pro Ile Ala Gly Ala Glu Thr Phe
        435                 440
```

<210> 17
<211> 13584
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence; Note =
synthetic construct

<400> 17

```
atgggcggcg catgagagaa gcccagacca ttacctacc caaaatggag aaagttcacg      60
ttgacatcga ggaagacagc ccattcctca gagctttgca gcggagcttc ccgcagtttg     120
aggtagaagc caagcaggtc actgataatg accatgctaa tgccagagcg ttttcgcatc     180
tggcttcaaa actgatcgaa acggaggtgg acccatccga cacgatcctt gacattggaa     240
gtgcgcccgc ccgcagaatg tattctaagc acaagtatca ttgtatctgt ccgatgagat     300
gtgcggaaga tccggacaga ttgtataagt atgcaactaa gctgaagaaa aactgtaagg     360
```

aaataactga taaggaattg gacaagaaaa tgaaggagct cgccgccgtc atgagcgacc 420
ctgacctgga aactgagact atgtgcctcc acgacgacga gtcgtgtcgc tacgaagggc 480
aagtcgctgt ttaccaggat gtatacgcgg ttgacggacc gacaagtctc tatcaccaag 540
ccaataaggg agttagagtc gcctactgga taggctttga caccacccct tttatgttta 600
agaacttggc tggagcatat ccatcatact ctaccaactg ggccgacgaa accgtgttaa 660
cggctcgtaa cataggccta tgcagctctg acgttatgga gcggtcacgt agagggatgt 720
ccattcttag aaagaagtat ttgaaaccat ccaacaatgt tctattctct gttggctcga 780
ccatctacca cgagaagagg gacttactga ggagctggca cctgccgtct gtatttcact 840
tacgtggcaa gcaaaattac acatgtcggt gtgagactat agttagttgc gacgggtacg 900
tcgttaaaag aatagctatc agtccaggcc tgtatgggaa gccttcaggc tatgctgcta 960
cgatgcaccg cgagggattc ttgtgctgca aagtgacaga cacattcaac ggggagaggg 1020
tctcttttcc cgtgtgcacg tatgtgccag ctacattgtg tgaccaaatg actggcatac 1080
tggcaacaga tgtcagtgcg gacgacgcgc aaaaactgct ggttgggctc aaccagcgta 1140
tagtcgtcaa cggtcgcacc cagagaaaca ccaataccat gaaaaattac cttttgcccg 1200
tagtggccca ggcatttgct aggtgggcaa aggaatataa ggaagatcaa gaagatgaaa 1260
ggccactagg actacgagat agacagttag tcatggggtg ttgttgggct tttagaaggc 1320
acaagataac atctatttat aagcgcccgg atacccaaac catcatcaaa gtgaacagcg 1380
atttccactc attcgtgctg cccaggatag gcagtaacac attggagatc gggctgagaa 1440
caagaatcag gaaaatgtta gaggagcaca aggagccgtc acctctcatt accgccgagg 1500
acgtacaaga agctaagtgc gcagccgatg agcgtaagga ggtgcgtgaa gccgaggagt 1560
tgcgcgcagc tctaccacct ttggcagctg atgttgagga gcccactctg gaagccgatg 1620
tcgacttgat gttacaagag gctggggccg gctcagtgga gacacctcgt ggcttgataa 1680
aggttaccag ctacgatggc gaggacaaga tcggctctta cgctgtgctt tctccgcagg 1740
ctgtactcaa gagtgaaaaa ttatcttgca tccaccctct cgctgaacaa gtcatagtga 1800
taacacactc tggccgaaaa gggcgttatg ccgtggaacc ataccatggt aaagtagtgg 1860
tgccagaggg acatgcaata cccgtccagg actttcaagc tctgagtgaa agtgccacca 1920
ttgtgtacaa cgaacgtgag ttcgtaaaca ggtacctgca ccatattgcc acacatggag 1980
gagcgctgaa cactgatgaa gaatattaca aaactgtcaa gcccagcgag cacgacggcg 2040
aatacctgta cgacatcgac aggaaacagt gcgtcaagaa agaactagtc actgggctag 2100
ggctcacagg cgagctggtg gatcctccct tccatgaatt cgcctacgag agtctgagaa 2160
cacgaccagc cgctccttac caagtaccaa ccataggggt gtatggcgtg ccaggatcag 2220
gcaagtctgg catcattaaa agcgcagtca ccaaaaaaga tctagtggtg agcgccaaga 2280
aagaaaactg tgcagaaatt ataagggacg tcaagaaaat gaaagggctg gacgtcaatg 2340
ccagaactgt ggactcagtg ctcttgaatg gatgcaaaca ccccgtagag accctgtata 2400
ttgacgaagc ttttgcttgt catgcaggta ctctcagagc gctcatagcc attataagac 2460
ctaaaaaggc agtgctctgc ggggatccca aacagtgcgg ttttttaac atgatgtgcc 2520
tgaaagtgca ttttaaccac gagatttgca cacaagtctt ccacaaaagc atctctcgcc 2580
gttgcactaa atctgtgact tcggtcgtct caaccttgtt ttacgacaaa aaaatgagaa 2640
cgacgaatcc gaaagagact aagattgtga ttgacactac cggcagtacc aaacctaagc 2700
aggacgatct cattctcact tgtttcagag ggtgggtgaa gcagttgcaa atagattaca 2760
aaggcaacga aataatgacg gcagctgcct ctcaagggct gacccgtaaa ggtgtgtatg 2820
ccgttcggta caaggtgaat gaaaatcctc tgtacgcacc cacctcagaa catgtgaacg 2880
tcctactgac ccgcacggag gaccgcatcg tgtggaaaac actagccggc gacccatgga 2940
taaaaacact gactgccaag taccctggga atttcactgc cacgatagag gagtggcaag 3000
cagagcatga tgccatcatg aggcacatct tggagagacc ggaccctacc gacgtcttcc 3060
agaataaggc aaacgtgtgt tgggccaagg ctttagtgcc ggtgctgaag accgctggca 3120
tagacatgac cactgaacaa tggaacactg tggattattt tgaaacggac aaagctcact 3180
cagcagagat agtattgaac caactatgcg tgaggttctt tggactcgat ctggactccg 3240
gtctattttc tgcacccact gttccgttat ccattaggaa taatcactgg gataactccc 3300
cgtcgcctaa catgtacggg ctgaataaag aagtggtccg tcagctctct cgcaggtacc 3360
cacaactgcc tcgggcagtt gccactggaa gagtctatga catgaacact ggtacactgc 3420
gcaattatga tccgcgcata aacctagtac ctgtaaacag aagactgcct catgctttag 3480
tcctccacca taatgaacac ccacagagtg acttttcttc attcgtcagc aaattgaagg 3540
gcagaactgt cctggtggtc ggggaaaagt tgtccgtccc aggcaaaatg gttgactggt 3600
tgtcagaccg gcctgaggct accttcagag ctcggctgga tttaggcatc ccaggtgatg 3660

tgcccaaata tgacataata tttgttaatg tgaggacccc atataaatac catcactatc 3720
agcagtgtga agaccatgcc attaagctta gcatgttgac caagaaagct tgtctgcatc 3780
tgaatcccgg cggaacctgt gtcagcatag gttatggtta cgctgacagg gccagcgaaa 3840
gcatcattgg tgctatagcg cggcagttca agttttcccg ggtatgcaaa ccgaaatcct 3900
cacttgaaga gacggaagtt ctgtttgtat tcattgggta cgatcgcaag gcccgtacgc 3960
acaatcctta caagctttca tcaaccttga ccaacattta tacaggttcc agactccacg 4020
aagccggatg tgcaccctca tatcatgtgg tgcgagggga tattgccacg gccaccgaag 4080
gagtgattat aaatgctgct aacagcaaag gacaacctgg cggaggggtg tgcggagcgc 4140
tgtataagaa attcccggaa agcttcgatt tacagccgat cgaagtagga aaagcgcgac 4200
tggtcaaagg tgcagctaaa catatcattc atgccgtagg accaaacttc aacaaagttt 4260
cggaggttga aggtgacaaa cagttggcag aggcttatga gtccatcgct aagattgtca 4320
acgataacaa ttacaagtca gtagcgattc cactgttgtc caccggcatc ttttccggga 4380
acaaagatcg actaacccaa tcattgaacc atttgctgac agctttagac accactgatg 4440
cagatgtagc catatactgc agggacaaga aatgggaaat gactctcaag gaagcagtgg 4500
ctaggagaga agcagtggag gagatatgca tatccgacga ctcttcagtg acagaacctg 4560
atgcagagct ggtgagggtg catccgaaga gttctttggc tggaaggaag ggctacagca 4620
caagcgatgg caaaactttc tcatatttgg aagggaccaa gtttcaccag gcggccaagg 4680
atatagcaga aattaatgcc atgtggcccg ttgcaacgga ggccaatgag caggtatgca 4740
tgtatatcct cggagaaagc atgagcagta ttaggtcgaa atgccccgtc gaagagtcgg 4800
aagcctcctc accacctagc acgctgcctt gcttgtgcat ccatgccatg actccagaaa 4860
gagtacagcg cctaaaagcc tcacgtccag aacaaattac tgtgtgctca tcctttccat 4920
tgccgaagta tagaatcact ggtgtgcaga agatccaatg ctcccagcct atattgttct 4980
caccgaaagt gcctgcgtat attcatccaa ggaagtatct cgtggaaaca ccaccggtag 5040
acgagactcc ggagccatcg gcagagaacc aatccacaga ggggacacct gaacaaccac 5100
cacttataac cgaggatgag accaggacta gaacgcctga gccgatcatc atcgaagagg 5160
aagaagagga tagcataagt ttgctgtcag atggcccgac ccaccaggtg ctgcaagtcg 5220
aggcagacat tcacgggccg ccctctgtat ctagctcatc ctggtccatt cctcatgcat 5280
ccgactttga tgtggacagt ttatccatac ttgacaccct ggagggagct agcgtgacca 5340
gcggggcaac gtcagccgag actaactctt acttcgcaaa gagtatggag tttctggcgc 5400
gaccggtgcc tgcgcctcga acagtattca ggaaccctcc acatcccgct ccgcgcacaa 5460
gaacaccgtc acttgcaccc agcagggcct gctcgagaac cagcctagtt tccaccccgc 5520
caggcgtgaa tagggtgatc actagagagg agctcgaggc gcttaccccg tcacgcactc 5580
ctagcaggtc ggtctcgaga accagcctgg tctccaaccc gccaggcgta aatagggtga 5640
ttacaagaga ggagtttgag gcgttcgtag cacaacaaca atgacggttt gatgcgggtg 5700
catacatctt ttcctccgac accggtcaag ggcatttaca acaaaaatca gtaaggcaaa 5760
cggtgctatc cgaagtggtg ttggagagga ccgaattgga gatttcgtat gccccgcgcc 5820
tcgaccaaga aaaagaagaa ttactacgca agaaattaca gttaaatccc acacctgcta 5880
acagaagcag ataccagtcc aggaaggtgg agaacatgaa agccataaca gctagacgta 5940
ttctgcaagg cctagggcat tatttgaagg cagaaggaaa agtggagtgc taccgaaccc 6000
tgcatcctgt tcctttgtat tcatctagtg tgaaccgtgc cttttcaagc cccaaggtcg 6060
cagtggaagc ctgtaacgcc atgttgaaag agaactttcc gactgtggct tcttactgta 6120
ttattccaga gtacgatgcc tatttggaca tggttgacgg agcttcatgc tgcttagaca 6180
ctgccagttt ttgccctgca aagctgcgca gctttccaaa gaaacactcc tatttggaac 6240
ccacaatacg atcggcagtg ccttcagcga tccagaacac gctccagaac gtcctggcag 6300
ctgccacaaa aagaaattgc aatgtcacgc aaatgagaga attgcccgta ttggattcgg 6360
cggcctttaa tgtggaatgc ttcaagaaat atgcgtgtaa taatgaatat tgggaaacgt 6420
ttaaagaaaa ccccatcagg cttactgaag aaaacgtggt aaattacatt accaaattaa 6480
aaggaccaaa agctgctgct ctttttgcga agacacataa tttgaatatg ttgcaggaca 6540
taccaatgga caggtttgta atggacttaa agagagacgt gaaagtgact ccaggaacaa 6600
aacatactga agaacggccc aaggtacagg tgatccaggc tgccgatccg ctagcaacag 6660
cgtatctgtg cggaatccac cgagagctgg ttaggagatt aaatgcggtc ctgcttccga 6720
acattcatac actgtttgat atgtcggctg aagactttga cgctattata gccgagcact 6780
tccagcctgg ggattgtgtt ctggaaactg acatcgcgtc gtttgataaa agtgaggacg 6840
acgccatggc tctgaccgcg ttaatgattc tggaagactt aggtgtggac gcagagctgt 6900
tgacgctgat tgaggcggct ttcggcgaaa tttcatcaat acatttgccc actaaaacta 6960

aatttaaatt cggagccatg atgaaatctg gaatgttcct cacactgttt gtgaacacag 7020
tcattaacat tgtaatcgca agcagagtgt tgagagaacg gctaaccgga tcaccatgtg 7080
cagcattcat tggagatgac aatatcgtga aaggagtcaa atcggacaaa ttaatggcag 7140
acaggtgcgc cacctggttg aatatggaag tcaagattat agatgctgtg gtgggcgaga 7200
aagcgcctta tttctgtgga gggtttattt tgtgtgactc cgtgaccggc acagcgtgcc 7260
gtgtggcaga ccccctaaaa aggctgttta agcttggcaa acctctggca gcagacgatg 7320
aacatgatga tgacaggaga agggcattgc atgaagagtc aacacgctgg aaccgagtgg 7380
gtattctttc agagctgtgc aaggcagtag aatcaaggta tgaaaccgta ggaacttcca 7440
tcatagttat ggccatgact actctagcta gcagtgttaa atcattcagc tacctgagag 7500
gggcccctat aactctctac ggctaacctg aatggactac gacatagtct agtccgccaa 7560
gatgagagtg atggggatac agaggaattg gccacaatgg tggatatggg gcaccttagg 7620
cttttggatg ataataattt gtagggtggt ggggaacttg aacttgtggg tcacagtcta 7680
ttatggggta cctgtgtgga aagaagcaaa aactactcta ttctgtgcat cagatgctaa 7740
agcatatgat aaagaagtac ataatgtctg ggctacacat gcctgtgtac ccacagaccc 7800
caacccacga gaaatagttt tggaaaatgt aacagaaaat tttaacatgt ggaaaaatga 7860
catggtggat cagatgcatg aggatataat cagtttatgg gatcaaagcc taaaaccatg 7920
tgtaaagttg accccactct gtgtcacttt aaattgtaca aatgcacctg cctacaataa 7980
tagcatgcat ggagaaatga aaaattgctc tttcaataca accacagaga taagagatag 8040
gaaacagaaa gcgtatgcac ttttttataa acctgatgta gtgccactta ataggagaga 8100
agagaataat gggacaggag agtatatatt aataaattgc aattcctcaa ccataacaca 8160
agcctgtcca aaggtcactt ttgacccaat tcctatacat tattgtgctc cagctggtta 8220
tgcgattcta aagtgtaata ataagacatt caatgggaca ggaccatgca ataatgtcag 8280
cacagtacaa tgtacacatg gaattatgcc agtggtatca actcaattac tgttaaatgg 8340
tagcctagca gaagaagaga taataattag atctgaaaat ctgacaaaca atatcaaaac 8400
aataatagtc caccttaata aatctgtaga aattgtgtgt acaagaccca acaataatac 8460
aagaaaaagt ataaggatag gaccaggaca aacattctat gcaacaggtg aaataatagg 8520
aaacataaga gaagcacatt gtaacattag taaaagtaac tggaccagta ctttagaaca 8580
ggtaaagaaa aaattaaaag aacactacaa taagacaata gaatttaacc caccctcagg 8640
aggggatcta gaagttacaa cacatagctt taattgtaga ggagaatttt tctattgcaa 8700
tacaacaaaa ctgttttcaa acaacagtga ttcaaacaac gaaaccatca cactcccatg 8760
caagataaaa caaattataa acatgtggca gaaggtagga cgagcaatgt atgcccctcc 8820
cattgaagga aacataacat gtaaatcaaa tatcacagga ctactattga cacgtgatgg 8880
aggaaagaat acaacaaatg agatattcag accgggagga ggaaatatga aggacaattg 8940
gagaagtgaa ttatataaat ataaagtggt agaaattgag ccattgggag tagcacccac 9000
taaatcaaaa aggagagtgg tggagagaga aaaaagagca gtgggactag gagctgtact 9060
ccttgggttc ttgggagcag caggaagcac tatgggcgcg gcgtcaataa cgctgacggt 9120
acaggccaga caactgttgt ctggtatagt gcaacagcaa agcaatttgc tgagagctat 9180
agaggcgcaa cagcatatgt tgcaactcac ggtctggggc attaagcagc tccagacaag 9240
agtcttggct atagagagat acctaaagga tcaacagctc ctagggcttt ggggctgctc 9300
tggaaaaatc atctgcacca ctgctgtgcc ttggaactcc agttggagta ataaatctca 9360
agaagatatt tgggataaca tgacctggat gcagtgggat agagaaatta gtaattacac 9420
aggcacaata tataggttac ttgaagactc gcaaaaccag caggagaaaa atgaaaaaga 9480
tttattagca ttggacagtt ggaaaaactt gtggaattgg tttaacataa caaattggct 9540
gtggtatata aaaatattca tcatgatagt aggaggcttg ataggtttga gaataatttt 9600
tggtgtactc gctatagtga aaagagttag gcagggatac tcacctttgt cgtttcagac 9660
ccttacccca agcccgaggg gtcccgacag gctcggaaga atcgaagaag aaggtggaga 9720
gcaagacaaa gacagatcca ttcgattagt gagcggattc ttagcacttg cctgggacga 9780
tctgcggagc ctgtgcctct tcagctacca ccacttgaga gacttcatat tgattgcagc 9840
gagagcagcg gaacttctgg gacgcagcag tctcagggga ctgcagagag ggtgggaagc 9900
ccttaagtat ctgggaaatc ttgtgcagta tgggggtctg gagctaaaaa gaagtgctat 9960
taaactgttt gataccatag caatagcagt agctgaagga acagatagga ttcttgaagt 10020
aatacagaga atttgtagag ctatccgcca catacctata agaataagac agggctttga 10080
agcagctttg caataattaa ttaagtaacc gatacagcag caattggcaa gctgcttaca 10140
tagaactcgc ggcgattggc atgccgcctt aaaatttttа ttttatttt tcttttcttt 10200
tccgaatcgg attttgtttt taatatttca aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 10260

aaaaaaaaaa aaaaaaaaag gaagagcgcg gccgcgcgct gggctacgtc ttgctggcgt 10320
tcgcgacgcg aggctggatg gccttcccca ttatgattct tctcgcttcc ggcggcatcg 10380
ggatgcccgc gttgcaggcc atgctgtcca ggcaggtaga tgacgaccat cagggacagc 10440
ttcaaggatc gctcgcggct cttaccagcc taacttcgat cactggaccg ctgatcgtca 10500
cggcgattta tgccgcctcg gcgagcacat ggaacgggtt ggcatggatt gtaggcgccg 10560
ccctataccct tgtctgcctc cccgcgttgc gtcgcggtgc atggagccgg gccacctcga 10620
cctgaatgga agccggcggc acctcgctaa cggattcacc actccaagaa ttggagccaa 10680
tcaattcttg cggagaactg tgaatgcgca aaccaaccct tggcagaaca tatccatcgc 10740
gtccgccatc tccagcagcc gcacgcggcg catctcgggc agcgttgggt cctggccacg 10800
ggtgcgcatg atcgtgctcc tgtcgttgag gacccggcta ggctggcggg gttgccttac 10860
tggttagcag aatgaatcac cgatacgcga gcgaacgtga agcgactgct gctgcaaaac 10920
gtctgcgacc tgagcaacaa catgaatggt cttcggtttc cgtgtttcgt aaagtctgga 10980
aacgcggaag tcagcgccct gcaccattat gttccggatc tgcatcgcag gatgctgctg 11040
gctaccctgt ggaacaccta catctgtatt aacgaagcgc tggcattgac cctgagtgat 11100
ttttctctgg tcccgccgca tccataccgc cagttgttta ccctcacaac gttccagtaa 11160
ccgggcatgt tcatcatcag taacccgtat cgtgagcatc ctctctcgtt tcatcggtat 11220
cattaccccc atgaacagaa atcccccttа cacggaggca tcagtgacca aacaggaaaa 11280
aaccgccctt aacatggccc gctttatcag aagccagaca ttaacgcttc tggagaaact 11340
caacgagctg gacgcggatg aacaggcaga catctgtgaa tcgcttcacg accacgctga 11400
tgagctttac cgcagctgcc tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat 11460
gcagctcccg gagacggtca cagcttgtct gtaagcggat gccgggagca gacaagcccg 11520
tcagggcgcg tcagcgggtg ttggcgggtg tcggggcgca gccatgaccc agtcacgtag 11580
cgatagcgga gtgtatactg gcttaactat gcggcatcag agcagattgt actgagagtg 11640
caccatatat gcggtgtgaa ataccgcaca gatgcgtaag gagaaaatac cgcatcaggc 11700
gctcttccgc ttcctcgctc actgactcgc tgcgctcggt cgttcggctg cggcgagcgg 11760
tatcagctca ctcaaaggcg gtaatacggt tatccacaga atcaggggat aacgcaggaa 11820
agaacatgtg agcaaaaggc cagcaaaagg ccaggaaccg taaaaaggcc gcgttgctgg 11880
cgtttttcca taggctccgc ccccctgacg agcatcacaa aaatcgacgc tcaagtcaga 11940
ggtggcgaaa cccgacagga ctataaagat accaggcgtt tccccctgga agctccctcg 12000
tgcgctctcc tgttccgacc ctgccgctta ccggatacct gtccgccttt ctcccttcgg 12060
gaagcgtggc gctttctcat agctcacgct gtaggtatct cagttcggtg taggtcgttc 12120
gctccaagct gggctgtgtg cacgaacccc ccgttcagcc cgaccgctgc gccttatccg 12180
gtaactatcg tcttgagtcc aacccggtaa gacacgactt atcgccactg gcagcagcca 12240
ctggtaacag gattagcaga gcgaggtatg taggcggtgc tacagagttc ttgaagtggt 12300
ggcctaacta cggctacact agaaggacag tatttggtat ctgcgctctg ctgaagccag 12360
ttaccttcgg aaaaagagtt ggtagctctt gatccggcaa acaaaccacc gctggtagcg 12420
gtggtttttt tgtttgcaag cagcagatta cgcgcagaaa aaaaggatct caagaagatc 12480
ctttgatctt ttctacgggg tctgacgctc agtggaacga aaactcacgt taagggattt 12540
tggtcatgaa caataaaact gtctgcttac ataaacagta atacaagggg tgttatgagc 12600
catattcaac gggaaacgtc ttgctcgagg ccgcgattaa attccaacat ggatgctgat 12660
ttatatgggt ataaatgggc tcgcgataat gtcgggcaat caggtgcgac aatctatcga 12720
ttgtatggga agcccgatgc gccagagttg tttctgaaac atggcaaagg tagcgttgcc 12780
aatgatgtta cagatgagat ggtcagacta aactggctga cggaatttat gcctcttccg 12840
accatcaagc attttatccg tactcctgat gatgcatggt tactcaccac tgcgatcccc 12900
gggaaaacag cattccaggt attagaagaa tatcctgatt caggtgaaaa tattgttgat 12960
gcgctggcag tgttcctgcg ccggttgcat tcgattcctg tttgtaattg tccttttaac 13020
agcgatcgcg tatttcgtct cgctcaggcg caatcacgaa tgaataacgg tttggttgat 13080
gcgagtgatt ttgatgacga gcgtaatggc tggcctgttg aacaagtctg gaaagaaatg 13140
cataagcttt tgccattctc accggattca gtcgtcactc atggtgattt ctcacttgat 13200
aaccttattt ttgacgaggg gaaattaata ggttgtattg atgttggacg agtcggaatc 13260
gcagaccgat accaggatct tgccatccta tggaactgcc tcggtgagtt ttctccttca 13320
ttacagaaac ggctttttca aaaatatggt attgataatc ctgatatgaa taaattgcag 13380
tttcatttga tgctcgatga gtttttctaa gaattctcat gtttgacagc ttatcatcga 13440
taagctttaa tgcggtagtt tatcacagtt aaattgctaa cgcagtcagg caccgtgtat 13500
gaaatctaac aatgcgctca tcgtcatcct cggcaccgtc accctggatg ctgtctagag 13560

gatccctaat acgactcact atag 13584

<210> 18
<211> 2532
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence; Note =
synthetic construct

<221> CDS
<222> (1)...(2532)

<400> 18
atg aga gtg atg ggg ata cag agg aat tgg cca caa tgg tgg ata tgg 48
Met Arg Val Met Gly Ile Gln Arg Asn Trp Pro Gln Trp Trp Ile Trp
1 5 10 15

ggc acc tta ggc ttt tgg atg ata ata att tgt agg gtg gtg ggg aac 96
Gly Thr Leu Gly Phe Trp Met Ile Ile Ile Cys Arg Val Val Gly Asn
20 25 30

ttg aac ttg tgg gtc aca gtc tat tat ggg gta cct gtg tgg aaa gaa 144
Leu Asn Leu Trp Val Thr Val Tyr Tyr Gly Val Pro Val Trp Lys Glu
35 40 45

gca aaa act act cta ttc tgt gca tca gat gct aaa gca tat gat aaa 192
Ala Lys Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Asp Lys
50 55 60

gaa gta cat aat gtc tgg gct aca cat gcc tgt gta ccc aca gac ccc 240
Glu Val His Asn Val Trp Ala Thr His Ala Cys Val Pro Thr Asp Pro
65 70 75 80

aac cca cga gaa ata gtt ttg gaa aat gta aca gaa aat ttt aac atg 288
Asn Pro Arg Glu Ile Val Leu Glu Asn Val Thr Glu Asn Phe Asn Met
85 90 95

tgg aaa aat gac atg gtg gat cag atg cat gag gat ata atc agt tta 336
Trp Lys Asn Asp Met Val Asp Gln Met His Glu Asp Ile Ile Ser Leu
100 105 110

tgg gat caa agc cta aaa cca tgt gta aag ttg acc cca ctc tgt gtc 384
Trp Asp Gln Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu Cys Val
115 120 125

act tta aat tgt aca aat gca cct gcc tac aat aat agc atg cat gga 432
Thr Leu Asn Cys Thr Asn Ala Pro Ala Tyr Asn Asn Ser Met His Gly
130 135 140
gaa atg aaa aat tgc tct ttc aat aca acc aca gag ata aga gat agg 480
Glu Met Lys Asn Cys Ser Phe Asn Thr Thr Thr Glu Ile Arg Asp Arg
145 150 155 160

```
aaa cag aaa gcg tat gca ctt ttt tat aaa cct gat gta gtg cca ctt      528
Lys Gln Lys Ala Tyr Ala Leu Phe Tyr Lys Pro Asp Val Val Pro Leu
                165                 170                 175

aat agg aga gaa gag aat aat ggg aca gga gag tat ata tta ata aat      576
Asn Arg Arg Glu Glu Asn Asn Gly Thr Gly Glu Tyr Ile Leu Ile Asn
            180                 185                 190

tgc aat tcc tca acc ata aca caa gcc tgt cca aag gtc act ttt gac      624
Cys Asn Ser Ser Thr Ile Thr Gln Ala Cys Pro Lys Val Thr Phe Asp
        195                 200                 205

cca att cct ata cat tat tgt gct cca gct ggt tat gcg att cta aag      672
Pro Ile Pro Ile His Tyr Cys Ala Pro Ala Gly Tyr Ala Ile Leu Lys
    210                 215                 220

tgt aat aat aag aca ttc aat ggg aca gga cca tgc aat aat gtc agc      720
Cys Asn Asn Lys Thr Phe Asn Gly Thr Gly Pro Cys Asn Asn Val Ser
225                 230                 235                 240

aca gta caa tgt aca cat gga att atg cca gtg gta tca act caa tta      768
Thr Val Gln Cys Thr His Gly Ile Met Pro Val Val Ser Thr Gln Leu
                245                 250                 255

ctg tta aat ggt agc cta gca gaa gaa gag ata ata att aga tct gaa      816
Leu Leu Asn Gly Ser Leu Ala Glu Glu Glu Ile Ile Ile Arg Ser Glu
            260                 265                 270

aat ctg aca aac aat atc aaa aca ata ata gtc cac ctt aat aaa tct      864
Asn Leu Thr Asn Asn Ile Lys Thr Ile Ile Val His Leu Asn Lys Ser
        275                 280                 285

gta gaa att gtg tgt aca aga ccc aac aat aat aca aga aaa agt ata      912
Val Glu Ile Val Cys Thr Arg Pro Asn Asn Asn Thr Arg Lys Ser Ile
    290                 295                 300

agg ata gga cca gga caa aca ttc tat gca aca ggt gaa ata ata gga      960
Arg Ile Gly Pro Gly Gln Thr Phe Tyr Ala Thr Gly Glu Ile Ile Gly
305                 310                 315                 320

aac ata aga gaa gca cat tgt aac att agt aaa agt aac tgg acc agt     1008
Asn Ile Arg Glu Ala His Cys Asn Ile Ser Lys Ser Asn Trp Thr Ser
                325                 330                 335

act tta gaa cag gta aag aaa aaa tta aaa gaa cac tac aat aag aca     1056
Thr Leu Glu Gln Val Lys Lys Lys Leu Lys Glu His Tyr Asn Lys Thr
            340                 345                 350

ata gaa ttt aac cca ccc tca gga ggg gat cta gaa gtt aca aca cat     1104
Ile Glu Phe Asn Pro Pro Ser Gly Gly Asp Leu Glu Val Thr Thr His
        355                 360                 365
agc ttt aat tgt aga gga gaa ttt ttc tat tgc aat aca aca aaa ctg     1152
Ser Phe Asn Cys Arg Gly Glu Phe Phe Tyr Cys Asn Thr Thr Lys Leu
    370                 375                 380
```

```
ttt tca aac aac agt gat tca aac aac gaa acc atc aca ctc cca tgc     1200
Phe Ser Asn Asn Ser Asp Ser Asn Asn Glu Thr Ile Thr Leu Pro Cys
385                 390                 395                 400

aag ata aaa caa att ata aac atg tgg cag aag gta gga cga gca atg     1248
Lys Ile Lys Gln Ile Ile Asn Met Trp Gln Lys Val Gly Arg Ala Met
                405                 410                 415

tat gcc cct ccc att gaa gga aac ata aca tgt aaa tca aat atc aca     1296
Tyr Ala Pro Pro Ile Glu Gly Asn Ile Thr Cys Lys Ser Asn Ile Thr
            420                 425                 430

gga cta cta ttg aca cgt gat gga gga aag aat aca aca aat gag ata     1344
Gly Leu Leu Leu Thr Arg Asp Gly Gly Lys Asn Thr Thr Asn Glu Ile
        435                 440                 445

ttc aga ccg gga gga gga aat atg aag gac aat tgg aga agt gaa tta     1392
Phe Arg Pro Gly Gly Gly Asn Met Lys Asp Asn Trp Arg Ser Glu Leu
    450                 455                 460

tat aaa tat aaa gtg gta gaa att gag cca ttg gga gta gca ccc act     1440
Tyr Lys Tyr Lys Val Val Glu Ile Glu Pro Leu Gly Val Ala Pro Thr
465                 470                 475                 480

aaa tca aaa agg aga gtg gtg gag aga gaa aaa aga gca gtg gga cta     1488
Lys Ser Lys Arg Arg Val Val Glu Arg Glu Lys Arg Ala Val Gly Leu
                485                 490                 495

gga gct gta ctc ctt ggg ttc ttg gga gca gca gga agc act atg ggc     1536
Gly Ala Val Leu Leu Gly Phe Leu Gly Ala Ala Gly Ser Thr Met Gly
            500                 505                 510

gcg gcg tca ata acg ctg acg gta cag gcc aga caa ctg ttg tct ggt     1584
Ala Ala Ser Ile Thr Leu Thr Val Gln Ala Arg Gln Leu Leu Ser Gly
        515                 520                 525

ata gtg caa cag caa agc aat ttg ctg aga gct ata gag gcg caa cag     1632
Ile Val Gln Gln Gln Ser Asn Leu Leu Arg Ala Ile Glu Ala Gln Gln
    530                 535                 540

cat atg ttg caa ctc acg gtc tgg ggc att aag cag ctc cag aca aga     1680
His Met Leu Gln Leu Thr Val Trp Gly Ile Lys Gln Leu Gln Thr Arg
545                 550                 555                 560

gtc ttg gct ata gag aga tac cta aag gat caa cag ctc cta ggg ctt     1728
Val Leu Ala Ile Glu Arg Tyr Leu Lys Asp Gln Gln Leu Leu Gly Leu
                565                 570                 575

tgg ggc tgc tct gga aaa atc atc tgc acc act gct gtg cct tgg aac     1776
Trp Gly Cys Ser Gly Lys Ile Ile Cys Thr Thr Ala Val Pro Trp Asn
            580                 585                 590
tcc agt tgg agt aat aaa tct caa gaa gat att tgg gat aac atg acc     1824
Ser Ser Trp Ser Asn Lys Ser Gln Glu Asp Ile Trp Asp Asn Met Thr
        595                 600                 605
```

```
tgg atg cag tgg gat aga gaa att agt aat tac aca ggc aca ata tat     1872
Trp Met Gln Trp Asp Arg Glu Ile Ser Asn Tyr Thr Gly Thr Ile Tyr
    610                 615                 620

agg tta ctt gaa gac tcg caa aac cag cag gag aaa aat gaa aaa gat     1920
Arg Leu Leu Glu Asp Ser Gln Asn Gln Gln Glu Lys Asn Glu Lys Asp
625                 630                 635                 640

tta tta gca ttg gac agt tgg aaa aac ttg tgg aat tgg ttt aac ata     1968
Leu Leu Ala Leu Asp Ser Trp Lys Asn Leu Trp Asn Trp Phe Asn Ile
                645                 650                 655

aca aat tgg ctg tgg tat ata aaa ata ttc atc atg ata gta gga ggc     2016
Thr Asn Trp Leu Trp Tyr Ile Lys Ile Phe Ile Met Ile Val Gly Gly
            660                 665                 670

ttg ata ggt ttg aga ata att ttt ggt gta ctc gct ata gtg aaa aga     2064
Leu Ile Gly Leu Arg Ile Ile Phe Gly Val Leu Ala Ile Val Lys Arg
        675                 680                 685

gtt agg cag gga tac tca cct ttg tcg ttt cag acc ctt acc cca agc     2112
Val Arg Gln Gly Tyr Ser Pro Leu Ser Phe Gln Thr Leu Thr Pro Ser
    690                 695                 700

ccg agg ggt ccc gac agg ctc gga aga atc gaa gaa gaa ggt gga gag     2160
Pro Arg Gly Pro Asp Arg Leu Gly Arg Ile Glu Glu Glu Gly Gly Glu
705                 710                 715                 720

caa gac aaa gac aga tcc att cga tta gtg agc gga ttc tta gca ctt     2208
Gln Asp Lys Asp Arg Ser Ile Arg Leu Val Ser Gly Phe Leu Ala Leu
                725                 730                 735

gcc tgg gac gat ctg cgg agc ctg tgc ctc ttc agc tac cac cac ttg     2256
Ala Trp Asp Asp Leu Arg Ser Leu Cys Leu Phe Ser Tyr His His Leu
            740                 745                 750

aga gac ttc ata ttg att gca gcg aga gca gcg gaa ctt ctg gga cgc     2304
Arg Asp Phe Ile Leu Ile Ala Ala Arg Ala Ala Glu Leu Leu Gly Arg
        755                 760                 765

agc agt ctc agg gga ctg cag aga ggg tgg gaa gcc ctt aag tat ctg     2352
Ser Ser Leu Arg Gly Leu Gln Arg Gly Trp Glu Ala Leu Lys Tyr Leu
    770                 775                 780

gga aat ctt gtg cag tat ggg ggt ctg gag cta aaa aga agt gct att     2400
Gly Asn Leu Val Gln Tyr Gly Gly Leu Glu Leu Lys Arg Ser Ala Ile
785                 790                 795                 800

aaa ctg ttt gat acc ata gca ata gca gta gct gaa gga aca gat agg     2448
Lys Leu Phe Asp Thr Ile Ala Ile Ala Val Ala Glu Gly Thr Asp Arg
                805                 810                 815
att ctt gaa gta ata cag aga att tgt aga gct atc cgc cac ata cct     2496
Ile Leu Glu Val Ile Gln Arg Ile Cys Arg Ala Ile Arg His Ile Pro
            820                 825                 830
```

ata aga ata aga cag ggc ttt gaa gca gct ttg caa 2532
Ile Arg Ile Arg Gln Gly Phe Glu Ala Ala Leu Gln
835 840

<210> 19
<211> 844
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence; Note =
synthetic construct

<400> 19
Met Arg Val Met Gly Ile Gln Arg Asn Trp Pro Gln Trp Trp Ile Trp
1 5 10 15
Gly Thr Leu Gly Phe Trp Met Ile Ile Ile Cys Arg Val Val Gly Asn
20 25 30
Leu Asn Leu Trp Val Thr Val Tyr Tyr Gly Val Pro Val Trp Lys Glu
35 40 45
Ala Lys Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Asp Lys
50 55 60
Glu Val His Asn Val Trp Ala Thr His Ala Cys Val Pro Thr Asp Pro
65 70 75 80
Asn Pro Arg Glu Ile Val Leu Glu Asn Val Thr Glu Asn Phe Asn Met
85 90 95
Trp Lys Asn Asp Met Val Asp Gln Met His Glu Asp Ile Ile Ser Leu
100 105 110
Trp Asp Gln Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu Cys Val
115 120 125
Thr Leu Asn Cys Thr Asn Ala Pro Ala Tyr Asn Asn Ser Met His Gly
130 135 140
Glu Met Lys Asn Cys Ser Phe Asn Thr Thr Thr Glu Ile Arg Asp Arg
145 150 155 160
Lys Gln Lys Ala Tyr Ala Leu Phe Tyr Lys Pro Asp Val Val Pro Leu
165 170 175
Asn Arg Arg Glu Glu Asn Asn Gly Thr Gly Glu Tyr Ile Leu Ile Asn
180 185 190
Cys Asn Ser Ser Thr Ile Thr Gln Ala Cys Pro Lys Val Thr Phe Asp
195 200 205
Pro Ile Pro Ile His Tyr Cys Ala Pro Ala Gly Tyr Ala Ile Leu Lys
210 215 220
Cys Asn Asn Lys Thr Phe Asn Gly Thr Gly Pro Cys Asn Asn Val Ser
225 230 235 240
Thr Val Gln Cys Thr His Gly Ile Met Pro Val Val Ser Thr Gln Leu
245 250 255
Leu Leu Asn Gly Ser Leu Ala Glu Glu Glu Ile Ile Ile Arg Ser Glu
260 265 270
Asn Leu Thr Asn Asn Ile Lys Thr Ile Ile Val His Leu Asn Lys Ser
275 280 285
Val Glu Ile Val Cys Thr Arg Pro Asn Asn Asn Thr Arg Lys Ser Ile
290 295 300

```
Arg Ile Gly Pro Gly Gln Thr Phe Tyr Ala Thr Gly Glu Ile Ile Gly
305                 310                 315                 320
Asn Ile Arg Glu Ala His Cys Asn Ile Ser Lys Ser Asn Trp Thr Ser
                325                 330                 335
Thr Leu Glu Gln Val Lys Lys Lys Leu Lys Glu His Tyr Asn Lys Thr
            340                 345                 350
Ile Glu Phe Asn Pro Pro Ser Gly Gly Asp Leu Glu Val Thr Thr His
        355                 360                 365
Ser Phe Asn Cys Arg Gly Glu Phe Phe Tyr Cys Asn Thr Thr Lys Leu
    370                 375                 380
Phe Ser Asn Asn Ser Asp Ser Asn Asn Glu Thr Ile Thr Leu Pro Cys
385                 390                 395                 400
Lys Ile Lys Gln Ile Ile Asn Met Trp Gln Lys Val Gly Arg Ala Met
                405                 410                 415
Tyr Ala Pro Pro Ile Glu Gly Asn Ile Thr Cys Lys Ser Asn Ile Thr
            420                 425                 430
Gly Leu Leu Leu Thr Arg Asp Gly Gly Lys Asn Thr Thr Asn Glu Ile
        435                 440                 445
Phe Arg Pro Gly Gly Gly Asn Met Lys Asp Asn Trp Arg Ser Glu Leu
    450                 455                 460
Tyr Lys Tyr Lys Val Val Glu Ile Glu Pro Leu Gly Val Ala Pro Thr
465                 470                 475                 480
Lys Ser Lys Arg Arg Val Val Glu Arg Glu Lys Arg Ala Val Gly Leu
                485                 490                 495
Gly Ala Val Leu Leu Gly Phe Leu Gly Ala Ala Gly Ser Thr Met Gly
            500                 505                 510
Ala Ala Ser Ile Thr Leu Thr Val Gln Ala Arg Gln Leu Leu Ser Gly
        515                 520                 525
Ile Val Gln Gln Gln Ser Asn Leu Leu Arg Ala Ile Glu Ala Gln Gln
    530                 535                 540
His Met Leu Gln Leu Thr Val Trp Gly Ile Lys Gln Leu Gln Thr Arg
545                 550                 555                 560
Val Leu Ala Ile Glu Arg Tyr Leu Lys Asp Gln Gln Leu Leu Gly Leu
                565                 570                 575
Trp Gly Cys Ser Gly Lys Ile Ile Cys Thr Thr Ala Val Pro Trp Asn
            580                 585                 590
Ser Ser Trp Ser Asn Lys Ser Gln Glu Asp Ile Trp Asp Asn Met Thr
        595                 600                 605
Trp Met Gln Trp Asp Arg Glu Ile Ser Asn Tyr Thr Gly Thr Ile Tyr
    610                 615                 620
Arg Leu Leu Glu Asp Ser Gln Asn Gln Gln Glu Lys Asn Glu Lys Asp
625                 630                 635                 640
Leu Leu Ala Leu Asp Ser Trp Lys Asn Leu Trp Asn Trp Phe Asn Ile
                645                 650                 655
Thr Asn Trp Leu Trp Tyr Ile Lys Ile Phe Ile Met Ile Val Gly Gly
            660                 665                 670
Leu Ile Gly Leu Arg Ile Ile Phe Gly Val Leu Ala Ile Val Lys Arg
        675                 680                 685
Val Arg Gln Gly Tyr Ser Pro Leu Ser Phe Gln Thr Leu Thr Pro Ser
    690                 695                 700
Pro Arg Gly Pro Asp Arg Leu Gly Arg Ile Glu Glu Glu Gly Gly Glu
705                 710                 715                 720
Gln Asp Lys Asp Arg Ser Ile Arg Leu Val Ser Gly Phe Leu Ala Leu
                725                 730                 735
```

```
Ala Trp Asp Asp Leu Arg Ser Leu Cys Leu Phe Ser Tyr His His Leu
            740                 745                 750
Arg Asp Phe Ile Leu Ile Ala Ala Arg Ala Ala Glu Leu Leu Gly Arg
        755                 760                 765
Ser Ser Leu Arg Gly Leu Gln Arg Gly Trp Glu Ala Leu Lys Tyr Leu
    770                 775                 780
Gly Asn Leu Val Gln Tyr Gly Gly Leu Glu Leu Lys Arg Ser Ala Ile
785                 790                 795                 800
Lys Leu Phe Asp Thr Ile Ala Ile Ala Val Ala Glu Gly Thr Asp Arg
                805                 810                 815
Ile Leu Glu Val Ile Gln Arg Ile Cys Arg Ala Ile Arg His Ile Pro
            820                 825                 830
Ile Arg Ile Arg Gln Gly Phe Glu Ala Ala Leu Gln
        835                 840
```

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 January 2002 (17.01.2002)

PCT

(10) International Publication Number
WO 02/003917 A3

(51) International Patent Classification[7]: A61K 39/12

(21) International Application Number: PCT/US01/21701

(22) International Filing Date: 9 July 2001 (09.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/216,995 7 July 2000 (07.07.2000) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 60/216,995 (CIP)
Filed on 7 July 2000 (07.07.2000)

(71) Applicants *(for all designated States except US)*: **ALPHAVAX, INC.** [US/US]; P.O. Box 110307, 2 Triangle Drive, Research Triangle Park, NC 27709-0307 (US). **UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL** [US/US]; 308 Bynum Hall, Campus Box 4105, Chapel Hill, NC 27599-4105 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **OLMSTED, Robert** [US/US]; 420 Bayberry Drive, Chapel Hill, NC 27514 (US). **KEITH, Paula** [US/US]; 5004 Sadelia Place, Holly Springs, NC 27540 (US). **DRYGA, Sergey** [RU/US]; 211 Bonsail Place, Chapel Hill, NC 27514 (US). **CALEY, Ian** [GB/US]; 314 Marist Court, Durham, NC 27713 (US). **MAUGHAN, Maureen** [US/US]; 2532 Wrightwood Avenue, Durham, NC 27705 (US). **JOHNSTON, Robert** [US/US]; 101 Marin Place, Chapel Hill, NC 27516 (US). **DAVIS, Nancy** [US/US]; 132 New Castle Drive, Chapel Hill, NC 27514 (US). **SWANSTROM, Ronald** [US/US]; 7021 Knotty Pine Drive, Chapel Hill, NC 27514-8659 (US).

(74) Agents: **MILLER, Mary, L.** et al.; Needle & Rosenberg, P.C., 127 Peachtree Street, N.E., Suite 1200, Atlanta, GA 30303-1811 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(88) Date of publication of the international search report:
29 August 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/003917 A3

(54) Title: ALPHAVIRUS VECTORS AND VIROSOMES WITH MODIFIED HIV GENES FOR USE AS VACCINES

(57) Abstract: The present invention provides methods and compositions comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit integrase, Rnase H and/or reverse transcriptase activity, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/21701

A. CLASSIFICATION OF SUBJECT MATTER
IPC(7) : A61K 39/12
US CL : 424/199.1
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 424/ 93.2; 435/69.1, 173.3, 199.1, 235.1, 236, 239, 320.1, 325; 536/23.72

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	BAROUCH et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proceedings of the National Academy of Science, April 2000, Vol. 97, No. 8, pp. 4192-4197, see figure 1.	1, 21 --- 2, 3, 22, 23
X --- Y	US 5,792,462 A (JOHNSTON et al.) 11 Aug. 1998 (11.08.1998), column 2 lines 14-38 and examples 1-4.	41, 42 --- 2, 3, 22, 23, 44, 70, 71, 74
Y	SYKES et al. Genetic Live Vaccines Mimic the Antigenicity But Not Pathogenicity of Live Viruses. DNA and Cell Biology, 1999, Vol. 18, No. 7, pp. 521-531, see	1, 2, 3, 21, 22, 23
X --- Y	US 6,156,558 A (JOHNSTON et al.) 5 Dec. 2000 (05.12.2000), see claims.	41, 42 --- 2, 3, 22, 23, 44, 70, 71, 74
A	FEYZI et al. Stuctural Reqirement of Heparin Sulfate for Interaction with Herpes Simplex Virus Type 1 Virions and Isolated Glycoprotein C*. The Journal of Biological Chemistry, 1997, Vol. 272, No. 40, pp. 24850-24857, see methods.	55, 57

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
02 November 2001 (02.11.2001)	12 JUN 2002
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230	Authorized officer Felicia D. Roberts for Ulrike Winkler, Ph.D. Telephone No. 703-308-0196

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/21701

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	US 6,146,874 A (ZOLOTUKHIN et al.) 14 Nov. 2000 (14.11.2000), see figure 1.	55, 57

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/21701

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: 1-3,21-23,41,42,44,55,57,70,71 and 74

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest
☒ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/21701

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group 1, claim(s) 1, 21, drawn to a nucleic acid composition comprising two or more HIV nucleic acids.

Group 2, claim(s) 2, 3, 22 and 23 drawn to an alphavirus replicon particle.

Group 3 claim(s) 4-10, 24-30 drawn to a method of making the alphavirus replicon particle.

Group 4, claim(s) 11, 31, drawn to a method of inducing an HIV immune response using nucleic acids.

Group 5, claim(s) 12-15 and 32-35 drawn to a method of inducing an HIV immune response using an alphavirus particle.

Group 6, claim(s) 16, 36 drawn to a method of treatment or prevention of HIV using a nucleic acid composition.

Group 7, claim(s) 17-20 and 37-40 drawn to a method of treatment or prevention of HIV using a alphavirus particle.

Group 8, claim(s) 41, 42, and 44, drawn to an alphavirus replicon virosome.

Group 9, claim(s) 43, drawn to method of producing an alphavirus virosome.

Group 10, claim(s) 45, drawn to method inducing an immune response using a virosome.

Group 11, claim(s) 46, drawn to a method treating or preventing HIV infection using a virosome.

Group 12, claim(s) 47 and 48, drawn to a composition comprising an alphavirus replicon virosome comprising HIV genes.

Group 13 claim(s) 49 and 50 drawn to a method of making the alphavirus replicon particle comprising HIV genes.

Group 14 claim(s) 51 and 52 drawn to a method of eliciting an immune response to HIV utilizing an alphavirus virosome.

Group 15 claim(s) 53 and 54 drawn to a method preventing or treating HIV infection using an alphavirus virosome.

Group 16 claim(s) 55 and 57 drawn to a composition comprising a heparin affinity purified alpha virus replicon particle.

Group 17 claim(s) 56 drawn to a method of making the alphavirus replicon particle utilizing heparin affinity chromatography.

Group 18 claim(s) 58-60 drawn to a method of making VRP for a vaccine.

Group 19 claim(s) 61-64 drawn to an isolated *pol* gene product.

Group 20 claim(s) 65, 68 and 69 drawn to an alphavirus particle comprising a *pol* gene product.

Group 21 claim(s) 66 and 67 drawn to a method of making the alphavirus replicon particle comprising the *pol* gene product.

Group 22 claim(s) 70, 71 and 74 drawn to a method of inducing an immune response with the alphavirus replicon particle comprising the *pol* gene product.

Group 23 claim(s) 72, 73 and 75 drawn to a method of treating or preventing disease with the alphavirus replicon particle comprising the *pol* gene product.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/21701

The inventions listed as Groups 1-23 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The technical feature linking groups 1-23 appears to be the nucleic acid composition set out in claim 1. The nucleic acid composition requires two or more isolated nucleic acid comprising either *env*, *gag* or *pol* gene products. Barouch et al. (PNAS April 2000) disclose the immunization of mice using a composition of two plasmids encoding *gag* and *env* genes (see figure 1). This composition is injected into mice and the immune response is measured after several weeks indicating that the gene products encode immunogenic fragments. Therefore, the technical feature linking the inventions of groups 1-23 does not constitute a special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over the prior art.

The special technical feature of group 1 is considered to be the nucleic acid composition.

The special technical feature of group 2 is considered to be an alphavirus replicon particle.

The special technical feature of group 3 is considered to be a method of making an alphavirus replicon particle.

The special technical feature of group 4 is a method of inducing an immune response to HIV using nucleic acids.

The special technical feature of group 5 is considered to be a method of inducing an immune response to HIV using an alphavirus replicon particle.

The special technical feature of group 6 is considered to be a method of treating or preventing HIV using nucleic acids.

The special technical feature of group 7 is considered to be a method of treating or preventing HIV using an alphavirus replicon particle.

The special technical feature of group 8 is considered to be an alphavirus replicon virosome.

The special technical feature of group 9 is considered to be a method of making an alphavirus replicon virosome.

The special technical feature of group 10 is considered to be a method inducing an immune respose utilizing a virosome.

The special technical feature of group 11 is considered to be a method of treating or preventing HIV using a virosome.

The special technical feature of group 12 is considered to be a composition comprising an alphovirus replicon virosome comprising HIV genes.

The special technical feature of group 13 is considered to be a method of making alphavirus replicon virosome comprising HIV genes.

The special technical feature of group 14 is considered to be a method of eliciting an immune resposne to HIV using an alphavirus replicon virosome.

The special technical feature of group 15 is considered to be a method of treating or preventing HIV using an alphavirus replicon virosome.

The special technical feature of group 16 is considered to be a composition comprising a heparin affinity purified alpha virus replicon particle.

The special technical feature of group 17 is considered to be a method of making a heparin affintiy purified alphavirus replicon particle.

The special technical feature of group 18 is considered to be a method of making VRP for a vaccine.

The special technical feature of group 19 is considered to be a the isolated *pol* gene product.

The special technical feature of group 20 is considered to be an alphavirus particle comprising the *pol* gene product.

The special technical feature of group 21 is considered to be a method of making the alphavirus particle comprising the *pol* gene product.

The special technical feature of group 22 is considered to be a method of inducing an immue reaspose with an alphavirus replicon particle comprising the pol gene product.

The special technical feature of group 23 is considered to be a method of treating or preventing disease with an alphavirus replicon particle comprising the pol gene product.

Accordingly, groups 1-23 are not so linked by the same or corresponding technical feature as to form a single general inventive concept.

Continuation of B. FIELDS SEARCHED Item 3:
WEST 2.0, DERWENT, MEDLINE, STN-BIOSIS
Togaviridae, alphavirus, flavivirus, Venezuelan equine encephalitis virus, VEE, replicon, purification, heparin, heparin affinity